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1 INTRODUCTION 
 
INTRODUCTION TO AMYOTROPHIC LATERAL SCLEROSIS  (ALS) 
 
Jean-Martin Charcot born in Paris (1825-1893) was a French neurologist and professor 
of anatomical pathology, and was the one who first described the amyotrophic lateral 
sclerosis (ALS) profile. He was the first attributing the progressive and acute muscular 
atrophy to a progressive lesion of the anterior horns of the spinal cord and he correlated 
locomotor ataxia to the posterior horn and spinal cord. Charcot’s understanding of ALS 
was based on amazingly few patients (Goetz, 2000; Pearce, 2002). At the time of 
Charcot’s descriptions of ALS, primarily 1850 to 1874 the clinical diagnosis was 
rudimentary and the distinction between upper and lower motoneurons (MNs), which 
is the different form of motoneuron disease (MND) detected later, had not yet been 
made, and there was no understanding of the role of the corticospinal tract which 
mostly contains motor axons that travel between the cerebral cortex and the spinal cord 
(Goetz et al., 1995). The earliest description of ALS (1865) refer to a young woman 
whose deficit was restricted to the lower MNs. Autopsy showed the presence of 
sclerotic changes limited to the lateral column of the spinal cord (Charcot 1865). Four 
years later (1869) Charcot reported cases where the lesions were restricted to the 
anterior horn cells (Charcot and Joffroy 1869 a,b,c). Further clinical studies revealed a 
combination of upper and lower motor neuron signs, which led Charcot to coin the 
term “amyotrophic lateral sclerosis” (Charcot, 1874, 1880). Nowadays ALS is a term 
used to cover the spectrum of neurodegenerative syndromes characterized by 
progressive degeneration of MNs, however, it is also the commonest term used in 
modern clinical practice to indicate the disease also known as Lou Gerig’s disease. 
This disease can be defined as a neurodegenerative disorder characterized by 
progressive muscular paralysis, which reflects the degeneration of MNs in the primary 
motor cortex, brain steam and spinal cord. In fact “Amyotrophy” refers to the atrophy 
of muscles fibres, which are de-nervated as their corresponding anterior horn cells 
degenerate, leading to weakness of affected muscles and evident fasciculation. “Lateral 
sclerosis” refers to hardening of the anterior and lateral cortico-spinal tracts as MNs in 
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these area degenerate and are replaced by glial scar (gliosis, Rowland et al., 2001). 
ALS is, in reality, a member of a group of heterogeneous disorders separated in 
different groups depending on which area of the body is initially involved in the 
paralysis. In the last decades, numerous potential mechanisms, responsible for the 
selective killing of upper and lower MNs have been put forward. However, when a 
patient presents the first symptoms, to achieve a clear diagnosis is not straightforward. 
Other syndromes related to this spectrum of disorders include: progressive bulbar palsy 
(PBP), progressive muscular atrophy (PMA), primary arm sclerosis (PLS), flail leg 
syndromes (Vulpian Bernhardt syndromes), flail leg syndromes (Pseudopolyneuritic 
form) and ALS with multy-system involvement. Lord Russel proposed the term Motor 
Neuron Disease (MND) to incorporate these conditions into a single spectrum of 
disorders (Brain et al., 1969). 
 
AETIOLOGY 
 
ALS research has undergone exciting progress in the past decades, with an increasing 
amount of evidence indicating that the injury could be caused by free radicals, 
exogenous neurotoxic agents or excitotoxins. Alternatively, a cumulative effect of all 
these factors may play an important role in the pathogenesis of ALS. Thus, the 
majority of current epidemiologic studies has emphasized the investigation of these 
potential risk factors. The causes of ALS/MND are unknown, but the interplay between 
endogenous (genetic, metabolic) and exogenous (environmental, lifestyle) factors is 
believed to be involved in the development of the disease (Goodall and Morrison 2006; 
Rothstein 2009). Excessive physical activity has been suggested as a risk factor for 
developing ALS. Theoretically, physical activity fits the main hypothesis regarding the 
pathogenesis of ALS: increased oxidative stress and glutamate excitotoxicity. Physical 
activity can alter the balance between free radicals formation and scavenger systems, 
leading to oxidative stress. (Sjodin et al., 1990), and over-stimulation of motor neuron 
(excitotoxicity) can enhances motor neuron death (Longstreth et al., 1991) nevertheless 
there is no association between physical activity and the risk of developing ALS 
(Veldink et al., 2005). Most authors favour the hypothesis of complex 
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genetic/environmental interactions as the causal factors for MNs degeneration (Shaw, 
2005; Cozzolino, 2008). Some epidemiological studies have shown an increased 
incidence of ALS in rural population. A strong association was found between 
agricultural activity and ALS, and these results suggest a potential role of exposure to 
agricultural chemicals or contact with animals linked to agricultural work, (Furby et al., 
2009) but there is no a priori reason to ascribe a single environmental agent as 
responsible for triggering ALS. However, a cause-effect implicating specific toxic 
agents including contamination of drinking water and poisoning by heavy metals (lead, 
arsenic, aluminium etc.) in ALS has never been proven. Even so, it is interesting to 
note that aluminium pre-treatment impairs the ability of astrocytes to protect neurons, 
maintained in tissue cultures, from glutamate-mediated toxicity (Sass et al., 1993). 
Loss of glial and/or neuronal glutamate transporters could play a relevant role, and 
chronic selective inhibition of glutamate uptake can induce a model of slow 
neurotoxicity (Rothstein et al., 1993). 
 
Figure 1. Hiroshi et al., 2005 
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EPIDEMIOLOGY 
 
The incidence of sporadic amyotrophic lateral sclerosis (sALS) in the 1990’s was 
reported to be between 1,5 and 2,7 per 100,000 population/year in Europe and North 
America (Worms, 2001) with uniform incidence across the countries. A consistent 
finding in these studies is that males are affected slightly more than females, with a 
M:F ratio about 1.5:1, although more recent data suggest that the gender ratio is, in 
reality, approaching equality. (Worms 2001; Abhinav et al., 2007; Zoccollela et al., 
2008 & Logroscino et al., 2008). Nonetheless, explanation for this “male excess” has 
been related to the possible protective role of hormonal factors in women, together 
with an increased likelihood of males for being exposed to environmental risk factors 
(Armon, 2003 & Nelsom et al., 2000). 
 
Figure 2. (Traynor et al., 2000) 
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The mean age of onset for sALS varies between 55-65 years with a median age of 
onset of 64 years (Leigh 2007; Haverkamp et al., 1995). Only 5% of cases have an 
onset before the age of 30 years old (Haverkamp et al., 1995), although juvenile 
sporadic onset cases are being increasingly recognized (Gouveia et al., 2007). Bulbar 
onset is commoner in women and in older age groups, with 43% of patients over the 
age of 70 presenting with bulbar symptoms compared to 15% below the age of 30 
(Beghi et al., 2007; Forbes et al., 2004). Although most cases of ALS are sporadic, 
about 5% of cases have a family history of ALS (also called familial ALS or fALS) 
(Anderson, 2003; Collette. Hand et al., 2002) There is an often Mendelian inheritance 
and high penetrance, with most cases having autosomal dominant pattern of 
inheritance, although autosomal recessive pedigrees have been reported. The ages of 
onset of fALS are about a decade earlier than sporadic cases, affects male and female 
equally, and have a shorter survival (Anderson, 2003; Li et al., 1988). Age of onset in 
fALS display a normal Gaussian distribution, whereas sALS has an age dependant 
incidence (Strong et al., 1991). Juvenile onset ALS (jALS) is a term used when age of 
onset is less than 25 years old (Ben Hamida et al., 1990). The disease is transmitted in 
an autosomal dominant fashion in most cases and is rarely autosomal recessive. Most 
cases are autosomal recessive although dominant inheritance linked to chromosome 
9q34 (ALS4, senataxin) has been reported (Chance et al., 1998). Recessive forms have 
been mapped to chromosome regions 2q33 (ALS2, alsin), and 15q12-21 (Hentati et al., 
1994; Hentati et al., 1998). Although the majority of sporadic and familial ALS cases 
are clinically identical, some minor features distinguish the two classes (Camu et al., 
1999). No genetic anticipation has been observed in sALS. The male:female ratio is 1:1 
in fALS (Camu et al., 1999) and 1.7:1 in sALS, although this value decreases with 
increasing age at presentation, approaching 1:1 after 70 years of age (Haverkamp et al., 
1995). 
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CLINICAL FEATURES 
 
Approximately two thirds of typical ALS patients display the spinal form of the disease 
(classical “Charcot ALS”). They present symptoms related to focal muscle weakness 
usually appearing either distally or proximally in the upper limbs and lower limbs. 
Rarely, patients may notice focal muscle wasting before onset of weakness, and some 
patients may present with spastic paraphrases. Patients may have noticed fasciculation 
(involuntary muscle twitching) or cramps preceding the onset of weakness or wasting 
for some months or years. The weakness is usually of insidious onset, and patients may 
notice that symptoms are exacerbated by cold weather. Although it is usually 
asymmetrical at onset, the controlateral  limbs develop weakness and wasting sooner or 
later, and, in most patients, there is the development of bulbar symptoms and 
eventually respiratory symptoms. Gradually, spasticity may develop in the weakened 
atrophic limbs, affecting manually dexterity and gait. During the later stages of the 
disease, patients may develop flexor spasm, which are involuntary spasms occurring 
due to excess activation of the flexor arc in a spastic limb. Patients with bulbar onset of 
ALS, usually present speech disorders such as dysarthria, which may initially be 
exacerbated by ingestion of small amounts of alcohol. Rarely, patients may present 
dysphagia for solid or liquids before the appearance of speech disturbances. About 5% 
of ALS cases present respiratory weakness, which are not preceded by significant limb 
or bulbar symptoms (de Carvalho et al., 1996). 
At closer usually reveals focal muscle atrophy, in the limb-onset disease, especially 
involving the muscles in the lower limbs. Fasciculations are rarely isolated phenomena, 
rather they are usually visible in more muscle groups. Spasticity is evident in the upper 
limbs by increased tone and a supinator catch, and in lower limbs with patellar catch 
and clonus together with hypertonia. In ALS patients, tendon reflexes are 
pathologically brisk in a symmetrical manner, including the finger jerks in the upper 
limb and positive crossed adductor reflex in the lower limb. On examining the cranial 
nerves, the jaw jerk may be brisk, especially in bulbar-onset disease. An upper motor 
neurone type facial weakness affects the lower half of the face causing difficulty with 
lip seal and blowing cheeks, but often varying degrees of upper motor neuron (UMN) 
and lower motor neuron (LMN) facial weakness coexist. The gag reflex generally is 
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preserved and is often brisk while the soft palate may be weak. Patients develop 
fasciculation and wasting of the tongue, and the tongue movements are slowed due to 
spasticity. The rest of cranial nerves remain intact (Okuda. et al., 1992; Kobayashi et 
al., 1999). Sensory examination is almost always unremarkable. As disease progresses, 
ALS patients develop the characteristic picture of the combination of upper motor 
neurons and lower motor neurons signs coexisting within the same central nervous 
system region, affecting the bulbar, cervical, thoracic and lumbar territories. 
Respiratory failure and other pulmonary complications are the usual causes of death, in 
ALS. However, patients who are kept alive by tracheostomy-assisted ventilation are 
found to eventually develop a profound state motor paralysis termed the totally locked-
in state (TLS), were there is paralysis of all voluntary muscles and varying degree of 
oculomotor impairment (Hayashy et al., 1989). 
Variants of motor neuron disease (MND) may display different clinical features, rate of 
progression and prognosis. Such variabilities, have raised the question whether these 
syndromes should be classed as separate entities from ALS, despite the evidence that 
these diseases may share a common molecular pathology. The syndrome of progressive 
muscular atrophy (PMA) accounts for 5-10% of patients with MND, and indicates a 
pure lower motor neurone syndrome without accompanying upper motor neurone signs 
(Norris et al., 1992). It is almost always of limb onset, but patients may eventually 
develop swallowing difficulties.  It is reported that up to 50% of patients may develop 
UMN sign and go on to develop typical ALS picture (Traynor et al., 2000). 
 
 
PATHOGENESIS OF MOTONEURONE DEGENERATION 
 
ALS affects about 1 of 100,000 people. The causes of ALS are still not known, as well 
as the molecular pathway(s) ultimately leading to MNs degeneration. ALS is a very 
complex disease and, in a fashion similar to other neurodegenerative diseases, is likely 
due to a complex interplay between multiple pathogenic mechanisms that may not be 
mutually exclusive (Shaw, 2005; Cozzolino et al., 2008). It is particularly difficult to 
establish when the disease process begins and it is possible that the different 
manifestations of ALS (e.g., fast versus slow progression, bulbar versus limb onset, 
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young versus older age onset) basically represent different disorders. Presently, there 
are no evidences supporting this hypothesis, therefore, although with different clinical 
features, all forms of ALS are considered variations of the same disorder. Early 
detection would help efficacious neuron protective therapy. Once ALS is clinically 
overt it is likely that a final cascade of events has been initiated running an average 
course of about three to five years. Several pathogenic mechanisms can be taken into 
consideration. In this introduction a brief summary of the main hypothesis for motor 
neuron pathogenesis is provided. Each suggested mechanism is separately accounted 
for, in the following order: 
 
- Genetic factors  
- Excitotoxicity  
- Oxidative stress  
- Mitochondrial dysfunction  
- Impaired axonal transport 
- Deficit in neurotrofic factors and dysfunction  
- Neurofilament aggregation 
- Protein aggregation 
- Inflammatory dysfunction and contribution of non – neuronal cells  
- Activation of apoptotic molecular pathways  
- Interactions between motor neuron and microglia 
 
GENETIC FACTORS 
 
Only 5% to 10% of patients have one or more first-degree relatives with ALS (Brooks, 
et al., 2000; McDonald, et al., 1993; Sasaki, et al., 1993; Yoshida, et al., 1995; 
Okamoto, et al., 1991). Some ALS patients have a Mendelian pattern of disease in their 
family, but the large majority of fALS patients do not display a clear cut Mendelian 
inheritance pattern. fALS may be inherited in either an autosomal dominant, autosomal 
recessive, or X-linked recessive pattern (Rowland 1998; Mitsumoto 2001). In the 
autosomal dominant cases, the gender ratio is close 1:1. The most common form of 
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inheritance is autosomal dominant (Pullen et al., 1995; Takahashi et al., 1991) and in 
only rare instances is in the form of autosomal recessive (Iwanaga et al., 1997). 
Recessive fALS cases, often have juvenile onset and slow progression. Genetic link-
age analysis in fALS cases is not easy due to the late (2th – 5th decade) onset together 
with the fast disease progression.  
Mutations in the SOD1 gene on chromosome 21 account for 20% of familial cases and, 
such forms of fALS, are usually inherited as autosomal dominant; with, at the 
moment,>100 SOD1 mutations were identified (Pullen et al., 1995). Additional 
chromosomes implicated in autosomal recessive ALS4 for senataxin gene are 
chromosome 15 (Nakano I et al., 1990) which encodes a 302,8 kDA protein of 
unknown function that shows a wide tissue distribution including brain and spinal cord. 
Chromosome 2 for ALS2/alsin gene (Takahashi et al., 1991), which is gene that 
encodes two mRNA transcripts that are widely expressed in human tissue, including 
the brain and spinal cord (Hadano et al., 2001) but the precise  function of alsin is not 
known, as well as an X linked gene (Takahashi et al., 1992) where the males appear to 
be more susceptible to ALS than females with approximate ratio 2:1, suggesting that 
there may be a sex-linked factor involved (Garofalo et al., 1993). Regardless the age at 
onset, dominant fALS is usually clinically and pathologically indistinguishable from 
sALS (Cudkowicz et al., 1997; Camu et al., 1999). Similar to mutation carriers in other 
genetic diseases, not all carriers of SOD1 will develop ALS, suggesting that other 
unknown factors must be contributing to the penetrance of the SOD1 mutations itself.  
The fact that the large majority (90%) of ALS cases are sporadic forms, ALS has been 
considered basically a non-genetic disease. However, due to the recent technological 
advancements in our ability to detect genetic components in diseases applying 
techniques which has allowed  to localize and amplify the different genetic mutations, 
it became possible to address the genetic contribution in different familial subgroups of 
largely sporadic disorders and therefore localize the presence of any kind of genetic 
mutation which could be responsible for appearing of ALS disease considered until 
now sporadic.  As already mentioned above, the majority of fALS cases displays a 
Mendelian pattern of inheritance, this was shown in 20% of fALS families exhibiting 
mutations in the SOD1 gene as the cause of disease (Deng et al., 1993; Rosen et al., 
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1993), despite this, many familial cases have been linked to several other distinct loci 
in the human genome which may contribute to the appearing of MND (Table 1.) 
 
Table 1. Reported authopsy pathology of patients with Motor Neuronpathy of suspected 
autoimmune etiology. (Hiroshi et al., 2005) 
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The genes responsible for ALS disease have been identified for some of these loci, 
giving insights into disease pathogenesis. Nevertheless there are other genes that have 
also been identified that by themselves do not cause disease, but are considered as 
potential risk factors. The diversity of genes involved in FALS illustrates the 
complexity of the disease and, elucidating the role of such genes, holds the potential to 
substantially improve our knowledge of the disease mechanisms and may provide 
useful information towards the future development of novel therapeutic strategies. The 
localization of all genetic factors that may be involved in the ALS disease may give us 
a clearer description of the general molecular mechanisms involved in these 
neurodegenerative diseases. Below are listed the genetic factors that have been 
identified in different ALS patients. The identification of molecular mechanisms might 
help also the developing of new therapeutic strategies. 
 
 
ALS 1: Copper Zn/Cu SOD1 
 
A major breakthrough in ALS research came with the identification that mutation in 
copper, zinc superoxide dismutase 1 (SOD1) account for ∼20% of fALS (Rosen et al., 
1993). More than 100 different SOD1 mutations leading to ALS have been identified 
and these mutations are spread throughout all five exons, as well as a small number in 
un-translated regions (Orrell 2000). The majority of these mutations are mis-sense 
mutations, where one amino acid is substituted for another, in addition there might be 
also a small number of insertions or deletions which can shift the reading frame and 
consequently change the downstream amino acid sequences. A particularly intriguing 
mutation is the D90A mutation, found in the periphery of the SOD1 molecules, which 
was originally reported as a recessive mutation (Andersen et al., 1995, 1996), but has 
subsequently been shown to be dominantly inherited in other genetic pedigrees (or 
genetic tree), which was a tools for studying genetic transmission of mutation that may 
lead to the onset of ALS disease (Robberecht et al., 1996; Andersen et al., 1997). This 
led to a worldwide study of A90D pedigrees, which showed that all the twenty 
recessive D90A pedigrees studied shared a common ancestor, whereas the eight 
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dominant D90A families arose from several unrelated ancestors (Al-Chalabi et al., 
1998). These findings  suggest that A90D is a dominant mutation but in the recessive 
pedigrees there is a tightly linked protective factor that reduces the toxicity of the 
mutation itself. Mutations in SOD1 are also responsible for a small proportion of 
apparently sALS cases (Jones et al., 1993; Jackson et al., 1997), although sometimes 
the mutation may have low penetrance and may appear to skip several generations, 
making the diagnosis of  fALS extremely difficult, if not impossible trough the 
pedigree study (Orrell et al., 1996). Although SOD1 mutations are only responsible for 
∼2% of all ALS cases, these mutations have received extensive attention because they 
allowed the development of animal models of the disease. Transgenic mice over 
expressing a variety of human SOD1 mutations develop MNs degeneration that is 
clinically and pathologically similar to human ALS (Gurney et al., 1994; Ripps et al., 
1995; Wong et al., 1995; Bruijn et al., 1997). 
 
ALS 2: Alsin 
 
A rare recessively inherited juvenile onset form of ALS with slow disease progression 
has been shown to be caused by mutations in the ALS2/alsin gene, located on 
chromosome 2 (Hadano et al., 2001; Yang et al., 2001). In addition, mutations in ALS2 
also cause juvenile onset forms of primary lateral sclerosis and hereditary spastic 
paraplegia (Yang et al., 2001). In this form a non sense mutation was identified, that 
induces a premature stop codon, resulting in the production of a truncated form of the 
protein (Devon et al., 2003) and this truncated proteins are rapidly degraded by the 
proteosome (Yamanaka et al., 2003), suggesting that ultimately the disease is caused 
by alsin function loss. The precise function of alsin is not known, although evidence is 
growing suggesting its role in endosomal trafficking (Otomo et al., 2003; Topp et al., 
2004). How the loss of functional alsin may lead to the development of MND in 
general and ALS in particular, is not understood, but several hypotheses have been 
proposed. The majority of these have focussed on two mechanisms: the disruption of 
actin dynamics and that of the endosomal trafficking. For example, if alsin is involved 
in glutamate receptor endocytosis, a loss of alsin activity could led to a glutamate 
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excitotoxicity due to  extracellular glutamate accumulation (Topp et al., 2004). Another 
general mechanism of disease could involve the astocytes. Astrocytes play important 
roles in inter-cellular communication, clearance of extracellular glutamate, 
maintenance of extracellular ion concentrations and fluid balance and since alsin has 
been implicated in endocytosis (Otomo et al., 2003; Topp et al., 2004; Devon et al., 
2006) and membrane trafficking (Topp et al., 2004)  mutation in alsin protein could 
compromise all these mechanisms determining, directly or indirectly, an higher MNs 
vulnerability to both excitotoxc and oxidative stress (Jacquier et al., 2009). 
 
 
ALS 4: Senataxin 
 
A juvenile onset autosomal dominant form of ALS that affects upper and lower MNs 
but has a slow rate of progression and does not affect lifespan, has been designated as 
ALS4. Genetic linkage analysis of a single large pedigree found that ALS4 mapped on 
locus to chromosome 9q34  (chromosome 9 locus q34; (Chance et al., 1998) and was 
subsequently found to be caused by mutations in the Senataxin gene, SETX (Chen et 
al., 2004). Since little is known about the function of SETX, it is difficult to predict 
how these mutations are causally linked to the disease. 
 
 
ALS 5 (RFALS Type 1) 
 
The most prevalent form of recessive FALS, initially named recessive familial ALS 
type 1 (RFALS Type 1) was mapped on locus to chromosomes 15q15.1-q21.1 in four 
families and the locus has been named ALS5. Three of four 15q-linked families 
showed juvenile onset and slow progression of symptoms. Genetic heterogeneity at 
ALS5 locus suggests that there may be more than one mutation, so the differences in 
disease progression may be due to different mutations.  ALS5 have not yet been 
identified, although candidate genes within the genetic locus include microtubule 
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associated protein 1A (MAP1A) and 1,4,5-triphosphate 3-kinase A (Hentati et al., 
1998). 
 
ALS 8: Vesicle-associated membrane protein/synaptobrevin-associated 
membrane protein B 
 
Nishimura et al., (2004a) mapped this new locus of ALS subtype, ALS8, to 20q13.3. 
Subsequent analysis of a further six families, which are believed to share a common 
ancestor, showed the same mutation but presented different clinical features, ranging 
from typical rapid progressing ALS, to atypical ALS and late onset spinal muscular 
atrophy (SMA) (Nishimura et al., 2004a). This heterogeneity suggests that other 
factor(s), either environmental or genetic, are involved in dictating the clinical 
progression of the disease. The mutation was identified as substitution of proline for 
serine at codon 56 (P56S) of vesicle-associated membrane protein/synaptobrevin-
associated membrane protein B (VAPB). The VAPB has been shown to act during 
endoplasmic reticulum (ER) to Golgi transport and secretion (Soussan et al., 1999; 
Foster et al., 2000). This mutation (P56S) is predicted to remove a link between two 
regions of the β-strand thus disrupting the H bonding pattern between the β-sheets and 
leading to a more flexible protein, capable of forming a new conformation. A point 
mutation (P56S or substitution of the proline for a serine at codon 56) in the P56S-
VAPB gene could interfere with stability of a VAPB, thus, the mutant VAPB protein 
may compromise intracellular membrane transport and secretion, which may 
subsequently lead to loss of extracellular trophic signals or to disruption of intracellular 
processes that ultimately result in the loss of motor neurons. VAPB protein was found 
in intracellular aggregates (Nishimura et al., 2004a).  
 
 
OTHER AUTOSOMAL DOMINANT FALS LOCI 
 
After linkage of a subset of fALS with mutation described until now, there has been 
much effort in screening adult onset autosomal dominant FALS. Consequently other 
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genes were screened to identify additional mutations linked to ALS. These studies 
revealed additional loci, associated to the ALS disease, within chromosomes 16, 18 and 
20. Three separate studies have linked three adult onset autosomal dominant fALS 
pedigrees to 16q12 (ALS6) (Abalkhail et al., 2003; Ruddy et al., 2003; Sapp et al., 
2003).  Another adult onset autosomal dominant fALS pedigree has been linked to 
20ptel-p13 (ALS7) (Sapp et al., 2003). A deletion in the intermediate filament protein 
pheripherin, leading to production of a truncated form of the protein that disrupts 
neurofilament assembly has recently been identified in one sALS patient (Gros-Louis 
et al., 2004). 
 
ALS RELATED TO OTHER NEURODEGENERATIVE DISEASE 
 
In a small proportion of cases, ALS can occur in conjunction with other 
neurodegenerative features, such as dementia and Parkinsonism, in fact it was found 
that ALS, dementia and Parkinson disease (PD) occur together within families more 
frequently than expected by chance, suggesting a genetic component (Majoor-Krakauer 
et al., 1994). ALS with fronto-temporal dementia (ALS-FTD), characterized by 
behavioural abnormalities and personality changes that precede dementia, in addition 
to the motor symptoms, has been linked to 9q21-q22 (Hosler et al., 2000, but see also 
TDP-43, Bodansky et al., 2010; Wils Hans et al., 2010; Wegorzewska et al., 2009). 
 
 
X-LINKED ALS 
 
The fact that males appear to be more susceptible to sALS than females, with an 
approximate ratio 2:1, suggesting that there may be a sex-linked factor involved 
(Garofalo et al., 1993). Usually the sex-linked factor are represented by genetic 
mutations linked to the cromopsome X (Garofalo et al., 1993) but also the hormonal 
factors may be involved in MND. 
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DYNACTIN 
 
Dynactin is a large, multi-subunit protein complex that includes the p150Glued, 
dynamitin, and Arp1 subunits responsible for minus-end-directed movement along the 
microtubule and plays an important role in fast retrograde-related axonal transport 
which is required for cellular maintenance. Dynein and dynactin mediate the transport 
of mis-folded and aggregated proteins to the cell centre for efficient degradation via the 
lysosomial and autophagic pathways (Ravikumar et al., 2005) required for most of the 
cellular functions. However, retrograde transport is also critical mediator of 
intracellular signalling pathways, such as neurotrophic factor signalling (Heerssen et 
al., 2004) and injury response signalling pathways (Perlson et al., 2005). The 
hypothesis that disruption of retrograde axonal transport is sufficient to induce MNs 
degeneration was first tested in a transgenic mouse with a targeted inhibition of 
dynein/dynactin function. Overexpression of the dynactin subunit dynamitin in motor 
neurons led to the disruption of dynein/dynactin function and to subsequent inhibition 
of retrograde transport (LaMonte et al., 2002). Tgdynamitin mouse (with a targeted 
inhibition of dynein/dynactin function) displays late onset, slowly progressive 
degeneration of MNs. An early onset, slow progressing form of MND that affects 
lower MNs only, has been linked to a mutation in the p150 subunit of the transporter 
protein dynactin (Puls et al., 2003). Dynactin is also involved in dynein-mediated 
retrograde transport of vesicles and organelles along microtubules. The mutation is a 
single base change causing an amino acid substitution from glycine to serine at position 
59 (G59S) of the p150 subunit and this mutation can disrupt the normal assembling 
structures.  A subsequent study, which screened the p150 subunit of dynactin, revealed 
three mis-sense mutations in ALS patients which are absent in controls (Munch et al., 
2004). These ALS patients all showed upper MNs involvement and differ in the 
disease progression. Inactivation of the dynactin complex by overexpression of the 
dynamitin (p150) subunits was previously shown to inhibit retrograde axonal transport 
and caused late onset MNs degeneration in transgenic mice (LaMonte et al., 2002). 
Initial studies in mouse models of fALS expressing mutant SOD1, which exhibit rapid 
and dramatic loss of MNs (Gurney et al., 1994), led to the suggestion that axonal 
aggregates of mutant SOD1 might physically block transport. While retrograde axonal 
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transport represents one key role for dynein and dynactin in the neuron, an additional 
cellular function of dynein and dynactin may also be critical to the health and function 
of MNs. Studies in Drosophila have shown that dynactin is essential to maintain the 
integrity of neuromuscular junctions (NMJs) (Eaton et al., 2002). Disruption of 
dynactin or expression of a mutant form of p150Glued leads to local disruption of the 
microtubule cytoskeleton in presynaptic MNsnerve terminals, followed by synapse 
retraction. This observation is particularly intriguing, given the MNJ degeneration in 
mice expressing the G59S mutant form of dynactin (Lai et al., 2007 Laird et al., 2008; 
Chevalier-Larsen et al., 2008), as well as the early and progressive loss of NMJs in the 
mSOD1 model for fALS (Fischer et al., 2004). Further work will be required to 
determine if this axonal die-back is a downstream consequence of an additional 
function for dynactin in maintaining junctional integrity. Additional mutation in 
dynactin have been identified in patients with either fALS and sALS (Munch et al., 
2004), although these have not yet been casually linked to the disease. 
 
 
TDP-43 
 
TDP-43 or transactive response (TAR) DNA-binding protein 43 is a 414-amino acid 
nuclear protein. It is a highly conserved protein expressed in non CNS tissue as well. It 
contains 2 RNA recognition motifs as well as glycine-rich C terminal sequence (Ayala 
et al., 2006; Buratti et al., 2001). TDP-43 is encoded by the TDP (TAR-DBP) gene on 
chromosome 1. Mutation in this gene has been linked to ALS, interestingly in both 
sALS and fALS (Sreedharan et al., 2008; Gitcho et al., 2008). Recently, TDP-43 
nuclear protein has been involved in other neurodegenerative diseases, such as the 
fronto-temporal lobar degeneration and ALS. This represents an entirely novel 
aetiopathogenesis factor in ALS and was achieved via the discovery that the TAR-
DNA-43 is one of the major constituents of the characteristic ubiquitinated inclusions 
found in neuronal and glial cells in ALS. TDP-43 is a multifunctional RNA binding 
protein that plays a role in a great variety of cellular processes such as transcription, 
pre-mRNA splicing, RNA stability, transport, and translation (Buratti and Baralle 
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2008). Recent results show that human TDP-43 is normally localized in the nucleus 
but, upon over-expression, this protein can contribute to the development of 
cytoplasmic, highly toxic, inclusions (Johnson et al., 2008). In keeping with these 
results, Tatom and collaborators (2009) have expressed human TDP-43 in the 
cytoplasm’s of rat neurons successfully reproducing several features of FTD disease 
including gliosis, apoptosis, ubiquitination resulting in the development of motor 
impairments (Tatom et al., 2009). In a rather distant species such as the Drosophila, it 
has been shown that TDP-43 loss of function in the MNsleads to a paralytic phenotype 
(Feiguin et al., 2009). Interestingly, two studies performed on different SOD1 mice 
genetic lineages showed that there was no evidence of TDP-43 inclusions or mis-
location in MNs analysed from different SOD1 ALS mice models (Robertso et al., 
2007; Turner et al., 2008). In fact, this result is in keeping with expectations based on 
human patient’s analyses, were a lack of TDP-43 pathology was documented in fALS 
cases linked to SOD1 mutations (Mackenzie et al., 2007; Tan et al., 2007). This is 
highly relevant, since it suggests for the first time that the mechanisms of SOD1 
mediated neurodegeneration may be functionally distinct from those mediated by TDP-
43. The TDP-43 mutations are found in 2-3% of ALS patients displaying TDP-43 
aggregates. Recently, the TDP-43 has been identified as the major component of 
neuronal ceroid lipofuscinosis NCIs (or excessive accumulation of lipopigments made 
up of fats and proteins) in sALS and superoxide dismutase 1 (SOD1)-negative fALS, 
as well as sporadic and familial frontotemporal lobar dementia (FTLD) (Sreedharan, et 
al., 2008; Gitcho, et al., 2008). More recently, it has been suggested that in ALS animal 
models the TDP-43 pathology, characteristic of human sALS, is not a core component 
of the neurodegenerative mechanisms caused by SOD1 mutation (Turner et al., 2008 
BMC neuroscience). 
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 EXCITOTOXCICITY 
 
EXTRACELLULAR GLUTAMATE INCREASE 
Excitotoxicity, a term coined by Dr. John Olney (1979), is the process by which high 
levels of glutamate and its analogues excite neurons and bring about their demise 
(Onley et al., 1979; Choi, 1988) involving also glial cells expressing functional 
AMPA/kainate glutamate receptors (Matute et al., 2006). Ca2+ influx mediates 
excitotoxicity with a cascade of events involving free radical generation, mitochondrial 
dysfunction, and the activation of many enzymes. About 40% of central nervous 
system synapse use glutamate as the neurotransmitter (Cotman et al., 1987). It acts 
trough ionotropic (NMDA and AMPA/kainate suntypes) and metabotropic types of 
glutamate receptors and plays crucial roles in developmental synaptogenesis, plasticity, 
long term potentiation. Over-stimulation of glutamate receptors produces neuronal 
injury or death by a mechanism called excitotoxicity. Excitotoxicity is closely 
associated with neurochemical and neuropathological changes involved in acute neural 
trauma (stroke, spinal cord trauma and other types of injury) and neurodegenerative 
disease such Alzheimer disease (AD), PD, Huntington disease (HD), Creutzfeld-Jakob 
disease (CJD), Multiple sclerosis (MS) and ALS. 
As mentionated, the hyperexcitability is mediated by high levels of ambient glutamate 
neurotransmitter. Glutamate is released from presynaptic terminals in response to 
depolarization and crosses the synaptic cleft to activate postsynaptic receptors. The 
excitatory signal is terminated by the active removal of glutamate from the synaptic 
cleft by several types of glutamate reuptake transporter proteins that are located on 
both neurons and astrocytes (Doble, 1999). In fact the excitotoxicity occuring in MNs 
or in other types of neurons is usually due to increased extracellular levels of glutamate 
(>1 µM, Danbolt, 1994,  to 3-4 µM; Farooqui and Horrock 1991) that lead to an 
excessive signalling through ionotropic AMPA/NMDA receptors, leading to sustained 
depolarization of membrane potential. The sustained membrane depolarization cause 
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the large and uncontrolled influx of Ca2+ that stresses the Ca2+-buffering systems of the 
cell, in particular the mitochondria. When the mitochondria are overly stressed by 
cytosolic Ca2+ levels, an apoptotic cascade can be activated concomitant with increased 
reactive oxygen species (ROS) production. The stressed mithocondria are not capable 
of maintaining proper electron activity and ROS escape into the cytoplasm ( Emilly 
Foran Trotti, 2009, Heath and Shaw 2002). In MNS, excitotoxicity is usually prevented 
by removal of glutamate from the synaptic and extrasynaptic space by neuronal and 
glial glutamate transporters, predominately EAAT2 (Rothstein et al., 1996). However, 
in a subset of ALS patients there appear to be defects in glutamate handing, resulting in 
elevated levels of glutamate in cerebrospinal fluid (CSF) that from extrasynaptic or 
extracellular space flow trough plasma and blood’s vassal (Rothstein et al., 1990,1991; 
Shaw et al., 1995a; Spreux-Varoquaux et al., 2002). In addition, CSF sampled from 
ALS patients was shown to preserve toxicity when administered to cultured neurones 
(Couratier et al., 1993; Roisen FJ et al., 1982; Wolfgram, Myers L 1973). This toxicity 
was apparently mediated by non-NMDA glutamate receptors, suggesting that the toxic 
product is a non-NMDA receptor agonist, though no direct evidence has emerged to 
implicate glutamate itself as the toxic factor (Couratier et al., 1994). This concept is 
supported by the evidence that the glutamate-release inhibitor, riluzole, is 
neuroprotective in this paradigm. A further study (Tikka et al., 2002) examined the 
toxicity of CSF from five individuals homozygous for the G90A SOD1 mutation, five 
other fALS cases, and 16 sALS compared to 24 non-neurodegenerative controls. These 
authors (Tikka et al., 2002) demonstrated that the CSF from all the ALS cases was 
toxic to rat embryo spinal cord cultures compared to the control CSF. The toxicity was 
associated with a decline in neuronal numbers in the cultures. Administration of 
NMDA (MK-801) or AMPA (CNQX) antagonist prevented the toxicity of the CSF. 
Several studies have shown a consistent decrease in glutamate levels in various regions 
of postmortem CNS tissue in ALS patients in comparison with controls (Heath and 
Shaw, 2002) The overriding impression from these studies is the presence of a 
multiple, underlying disturbance in glutamate metabolism or transport in ALS. The 
failure to properly regulate glutamate metabolism or transport in ALS may result in 
raised extracellular levels of glutamate and reduced levels within CNS tissue.   
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The detection of raised glutamate concentrations in sALS patients’ CSF was thought to 
imply that glutamate excitotoxicity contributed to neurodegeneration in ALS although 
other reports could not confirm these observations (Perry et al., 1990; Camu et al., 
1993). However, the mechanisms leading to altered glutamatergic signalling in ALS 
are not fully understood. Expression of glutamate transporter EAAT2 is reduced 
(Rothstein et al., 1995; Fray et al., 1998) and a decrease in glutamate uptake in the 
motor cortex and in the spinal cord has been described in ALS patients (Rothstein et 
al., 1992; Shaw et al., 1994). Similar alterations were described in transgenic SOD1 
rodent (see below), a widely studied ALS animal model (Bruijn et al., 1997a,b; 
Bendotti et al., 2001; Howland et al., 2002). Several authors put forward the hypothesis 
that glutamate toxicity in motor neurons is primarily mediated via AMPA receptors 
(Rothstein et al., 1993; Carriedo et al., 1996; Van Den Bosch et al., 2000). This is 
further sustained by the observation that exogenous AMPA receptor antagonists 
treatment in different motor neuron disease-models (Mennini et al. 1999;Canton et al., 
2001, Van Damme et al., 2003) significantly reduced symptoms and increased survival 
times in these rodents. A further study (Tikka TM et al., 2002) examined the toxicity of 
CSF from five individuals homozygous for the D90A SOD1 mutation, five other fALS 
cases, and 16 sALS cases compared to 24 non-neurodegenerative controls. These 
works provided evidences supporting that CSF sampled from all ALS patients were 
toxic when tested on cultured spinal neurons, isolated from the rat embryos, while the 
same neurons were not affected by control CSF sampled from non affected ALS 
patients. These authors observed a decline in cultured neuronal density accompanied 
by a marked increase in microglia. Administration of NMDA (MK-801) or AMPA 
(CNQX) antagonists prevented CSF toxicity, but did not prevent the microglia 
proliferation (Shaw 2002; Iwasaki et al., 1994). This study is important because it 
highlights a possible role of microglia in excitotoxic cell death of motor neurons. In 
fact several mechanisms have been suggested for the role of glial cells in excitotoxic 
cell death: (i) astocytes can release glutamate in the vicinity of neurons by a calcium 
dependent mechanism, (ii) activated microglia could secrete TNFα which has been 
shown to mediate AMPA mediated excitotoxicity, and (iii) activated microglia release 
matrix metalloproteinases (MMP) a family of proteolitic enzymes whose catalytic 
mechanism involves a metal like active site (Shaw et al., 2002). At least one laboratory 
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has not been able to confirm the neuronal toxicity of ALS CSF (Iwasaki et al., 1995). 
Additional work by Spreus-Varoquaux et al. (2002) describes two groups of ALS 
patients. The first one, shows CSF with normal glutamate levels, the second group, 
characterized by spinal onset of the disease, shows a significantly higher CSF 
glutamate concentration. The results were in conflict with other studies, in that they 
documented significant changes in CSF glutamate when sampled from ALS patients, 
regardless the CSF ability to display toxicity in cultured primary motor neurons (Tikka 
et al., 2002). On this complex matter we have to add the evidences reporting a 
significant reduction in glutamate levels in various regions of postmortem CNS tissue 
(spinal cord and motor cortex) in ALS patients, when compared to non-
neurodegenerative ost mortem controls  (Perry et al., 1987; Tsai et al., 1991).  
 
GLUTAMATE REUPTAKE TRANSPORTERS 
 
One of the hypothesis put forward to explain the accumulation of extracellular 
glutamate was a malfunction of glutamate transporters (EAAT). There are five 
different types of EAAT which were cloned, and they show a high degree of homology 
between different species (O’Shea, 2002). The human versions have been named 
EAAT one to five. The role of these transporters is to regulate the concentration of 
extracellular glutamate by its reuptake, and hence maintain a concentration in the 
synaptic cleft  between 1 and 3 µM (Trotti et al., 1998). This process of glutamate 
Clarence is electrogenic, being coupled to the transport of two or three sodium ions and 
one proton from extracellular space and the counter-transport of K+(Grewer and Rauen 
2005).  
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Figure 3.  (Hiroshi et al., 2005) 
 
EAAT1, EAAT2 and EAAT3 are found throughout brain.  EAAT1 is the most 
abundant in the cerebellum and expressed by both glia and neurons (Furuta et al., 
1997). EAAT2 is the major glutamate transporters and is localised exclusively in glia. 
It is widely expressed in human CNS, representing approximately 1% of total brain 
protein amounts (Furuta et al., 1997). The expression of EAAT2 by glia makes this 
transporters of particular interest in terms of glutamate clearance at synapses and 
potential involvement in excitotoxicity. The high importance of the transporter in 
glutamate clearance was confirmed by reducing the expression of GLT1 (the rat 
homologue of EAAT2) using antisense oligonucleotides which caused a dramatic 
elevation of extracellular glutamate and neuronal injury in specific region of the CNS 
(Rothstein, 1995), and since we have seen that in patients with ALS there is an excess 
of extracellular glutamate it has been proposed that the expression and function of 
glutamate reuptake transport system may be abnormal in ALS. Such a defect could 
potentially contribute to an elevation of extracellular glutamate levels, which may 
predispose to excitotoxic neuronal injury. An initial study by Rothstein et al., (1992) 
examined high-affinity Na+-dependent glutamate transport in synaptosomes derived 
from postmortem brain and spinal cord tissue of ALS patients. These authors reported 
 29 
that the synaptosomes from ALS patients showed a selective decrease in maximum 
glutamate transport velocity, but not affinity, when compared to control ones. This 
transport defect appeared to be localized to areas of the brain and spinal cord 
pathologically damaged in ALS. Further evidence for this hypothesis comes  from 
experiments on spinal cord explant in which model of chronic glutamatergic toxicity 
was developed by pharmacological inhibition of glutamate uptake using threohydroxy-
aspartate (THC) which is a potent non-transportable blocker for the excitatory amino 
acid transporters (Rothstein 1993) that caused a slow and selective degeneration and 
loss of MNs over a period of weeks. The MNs toxicity was selectively prevented by 
non-NMDA antagonist and not by NMDA antagonist.  From these observations we can 
deduce that excitotoxicity may be caused at least in part by a malfunction of glutamate 
transporter EAAT localized on neuron or on glial cells.  As results of this failure of 
reuptake of glutamate the neurotranmitter start to stagnates in extrasynaptic space 
which may induce excitotoxicity trough activation of non-NMDA receptors thus 
causing further release of other glutamate and selective loss of MNs like in ALS 
disease. The discovery of the excitotoxic mechanism has led to the development of 
several anti-glutamate based drugs (e.g., riluzole, gabapentin, and NBQX) which 
demonstrate to possess some neuroprotective effects on anterior horn cell degeneration 
in animal models of ALS (Louvel et al., 1997; Ludolph et al., 2000; Van Damme et al., 
2003). Two large clinical trials have demonstrated that riluzole has a modest effect in 
prolonging survival in patients with ALS (Bensimon et al., 1994; Lacomblez et al., 
1996). Gabapentin, although showing a positive effect in animal models, does not 
appear to produce robust benefits in human ALS cases (Miller et al., 1996; Miller et al., 
2001). The low effectiveness of treatment against glutamate could be the 
demonstration that this the mechanism of aberrant glutamate transport may not be the 
only mechanism involved in ALS disease. Other mechanisms were proposed to explain 
the excitotoxicity in ALS disease and the selective MNs degeneration. 
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AMPA RECEPTORS PERMEABILITY 
 
Other mechanisms postulated as the cause of excitotoxicity are the anomalous 
permeability or glutamatergic AMPA receptors, that may induce an excessive influx of 
ions trough the receptors. The increased receptors permeability to the positive charge 
may lead to excessive neuronal excitation and depolarization which could lead to the 
excessive glutamate release. The AMPA glutamate receptors Glu1-4 are proteins of 95 
to 163 kDa and have three transmembrane domains or  four potential transmembrane 
domain which creates a loop into the cytoplasmatic side of the membrane (Dingledine 
et al., 1999). The protein subunits are considerably important for the regulation of ion 
selectivity to Ca2+,N+ and K+. The GluR2 subunit is of particular functional importance 
as it plays a key role in determining the calcium ion permeability of the assembled 
AMPA receptors (Dingledine et al., 1999). The presence of the GluR2 subunit in a 
heteromeric receptor confers the property of low permeability to Ca2+, whereas AMPA 
lacking GluR2 are permeable to calcium, so the loss of GluR2 subunits may cause an 
excessive calcium influx into the cell and thus cause an excessive neuronal excitability. 
There are works showing an increase Ca2+ permeability trough AMPA receptors 
(Vandenberghe et al., 2000; Tateno et al., 2004; Grosskreutz et al., 2010) that 
determine the intracellular Ca2+ dis-regulation suggested to play a central role in ALS 
pathophysiology  (Grosskreutz et al., 2010; Kawamata and Manfredi, 2010). Other 
studies have shown however that AMPA receptor properties are not crucial to Ca2+ 
permeability. It was observed in SOD1 transgenic animal model for ALS d, an 
increased Na+ and K+ influx through voltage gated Ca2+ channels (Pieri et al 2003) 
which may alternatively be responsible for the increased neuronal sensitivity to  other 
excitotoxic stimuli. 
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GLUTAMATE METABOLISM 
 
Synaptic glutamate that has been taken up by perisynaptic astroglial cells is converted 
into glutamine by the enzyme glutamine synthetase (GS) and then the glutamine is 
shuttled back to the neuronal terminal, where glutaminase converts it back into 
glutamate (Laake et al., 1995). Any type of abnormal activation of glutamate receptors 
is an important final common pathway to neuronal death, and several 
neurodegenerative diseases have been linked to glutamate deregulation during synaptic 
transmission. Several pieces of evidence have suggested that there is an underlying 
defect in glutamate metabolism in ALS. Astroglia were fond to be a major site of 
uptake of synaptically released glutamate and its conversion to glutamine based on GS 
being astrocytes-specific (Martinez-Hernandes et al., 1977).  
 
 
OXIDATIVE STRESS 
 
Another widely accepted mechanism involved in neurodegeneration and neuronal 
damage in general is the so called oxidative stress. Reactive oxygen species (ROS), 
such as superoxide anions (O2-°), hydroxil radicals (OH°), hydrogen peroxide (H2O2), 
and peroxinitrite (ONOO-), are generated as by-products of aerobic metabolism. If 
allowed to persist, these molecules will disrupt the normal reducing conditions within 
the cell, causing oxidative damage to proteins, lipids and DNA. This damage is 
collectively called oxidative stress (Coyle et al., 1993). The cellular concentration of 
ROS may influence several physiological processes in fact the increased oxidative 
stress can play a role in ischemic, epileptic, and degenerative neural death. However, 
the role of oxidative stress in ALS and neurodegeneration in general needs to be 
explored in more depth. Nevertheless, increased free nitrotyrosine staining has indeed 
been reported in spinal motor neurons of sALS patients (Abe et al., 1995; Beal et al., 
1998; Chou et al., 1996) and 4-Hydroxynonenal (a well known marker for lipid 
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peroxidation (Yasukazu and, Etsuo, 2006), was found to be increased in CSF samples 
of sALS patients (Kamelija Zarkovic, 2003). Immunohistochemistry and 
immunoblotting experiments showed that in the spinal cord of sALS patients, the 
content of protein modified by 4-hydroxynoneal was increased (Pedersen et al., 1998). 
It has been suggested that one of the targets of this oxidation be the glial glutamate 
transporter EAAT2 (Pedersen et al., 1998).  Multiple pathological studies reported an 
increase in oxidative stress in ALS post-mortem tissue samples when compared to 
controls. In fact, elevated protein charbonyl levels have been shown in the spinal cord 
(Shaw et al., 1995) and motor cortex (Ferrante et al., 1997) from sALS patients, and 
increased 3-nitrotyrosine levels, a marker for peroxynitrite-mediated damage, were 
found within spinal cord motor neurons in both SOD1-fALS and sALS patients (Abe et 
al., 1995 and Beal et al., 1997).  Immunoreactivity to the brain and endothelial forms of 
NOS, but not inducible forms, was also elevated in ALS motor neuron relative to 
controls (Abe et al., 1997), supporting an alteration in reactive nitrogen species 
production as well as in ROS generation. Lipid oxidation markers, usually absent in 
control spinal cords, were also detected in spinal tissue samples from sALS patients 
(Shibata et al., 2001). Levels of 8-hydroxy-2’deoxyguanosine (8-OHdG), a marker of 
oxidized DNA, were measured, and were significantly elevated in the cervical spinal 
cord of ALS patients, notably, such increases were most prominent within the ventral 
horn (Ferrante et al., 1997; Fitzsmaurice et al., 1996). Similar analysis in transgenic 
mouse models of ALS overexpressing (see below) human ALS linked SOD1 
mutations, support the findings of these studies in humans and show an increase 
oxidative damage of proteins, lipids and DNA (Ferrante et al., 1997; Andrus et al., 
1998; Liu et al., 1998, 1999). The increased levels of oxidative stress observed in ALS 
patients suggest the presence of mitochondrial DNA (mDNA) damage. Swerdlow et al. 
(1998) have shown that the oxidation of mitochondrial DNA can determine the 
reduction electron transport chain (ETC) activity, further increased ROS production, 
and decrease calcium-buffering capacity in mitochondria from ALS patients. Although 
this result was not directly replicated, several other studies confirmed the increased 
mitochondrial DNA mutation in ALS patients.  Vielhaber et al., (2000) found a 
reduced mDNA content and increase in the frequency of mitochondrial DNA mutation.  
Dhaliwal and Grewal (2000)  found that in ALS patients, the frequency of mDNA 
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mutation was much higher in the motor cortex than in the temporal cortex, difference 
which was not found in control cases and suggests that oxidative damage affects 
preferably the motor region, in agreement with the selective death of MN. However, 
oxidative stress affects indiscriminately also other cellular portion like lipids, or 
proteina, as observed in tissue of both human ALS and SOD1 mice (rewieved in 
Brown and Robberecht, 2001; Rowland and Shneider, 2001). The high levels of 
extracellular glutamate, observed in greater concentration in patients with ALS (see 
excitotoxicity), can interfere with cysteine uptake through the cysteine/glutamate 
antiporter, which normally transports cysteine into cells at the expense of the outflow 
of glutamate. This is the mechanism that modulates glutathione supply, relevant to 
achieve neuroprotection from oxidative stress. In fact this reduction in cystein uptake 
decreases intracellular levels of glutathione, a cystine-containing tripeptide whose 
deficiency causes oxidative stress-mediated cell death. This mechanism of cell death is 
named oxidative glutamate toxicity. Also the excessive Ca2+ influx can generate free 
radicals and ROS, and consequently can reduce the levels of gluthatione (Farooqui and 
Horrock, 1991, 1994). ROS also play a critical role in initiation of apoptosis through 
changes in mitochondrial permeability (Warner et al., 2004). The superoxide oxide 
radical interacts with nitric oxide to produce peroxynitrite  at three times faster rate 
than that required to superoxide dismutase (Beckman, 1994). Peroxynitrite is capable 
of diffusing to distant places in neural cells where it induces lipid peroxidation and 
may be involved in synaptosomal and myelin damage (Van der Veen and Roberts, 
1999). After protonation and decomposition, peroxynitrite produces more hydroxyl 
radicals. This mechanism of  hydroxyl radical generation is not dependent on redox 
active metal ions and may be involved in initiating lipid and protein peroxidation in 
vivo (Warner et al., 2004). Several pathologic mechanisms can trigger different 
pathways which could lead to a ROS species production. One of the mechanisms that 
can lead to the production of several reactive species is the mutation on superoxide 
dismutase enzyme (SOD), the enzyme used for cell protection of free radical and 
oxidative species. While increasing data implicate oxidative stress and excitotoxic 
mechanisms in the pathogenesis of MNs degeneration in ALS disease (Inna. Kruman, 
1999), their specific roles in the neurodegenerative process are unknown. The existence 
of both sporadic and inherited forms of ALS, which manifest similar pathological and 
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clinical phenotype, suggests that different initiating causes lead to a mechanistically 
similar neurodegenerative cascade. Many cases of autosomal dominant fALS result 
from mis-sence mutation in Cu/Zn–superoxide dismutase (Cu/Zn-SOD) (Inna Kruman, 
1999). SOD enzyme catalizes the dismutation of superoxide radical anion (O2-°) to 
hydrogen peroxide and can also act as peroxidase resulting in generation of hydroxyl 
radical upon interaction of enzyme-associated Cu+ with hydrogen peroxide (Inna. 
Kruman, 1999). Several observations suggest that the pathogenic action of Cu/Zn-SOD 
mutations in fALS does not result from a loss of dismutase function of the enzyme but 
instead results from gain of adverse property of the mutant protein. Although 
transgenic mice results in progressive MN degeneration and ALS-like deficits in motor 
function there is no correlation between enzyme activity and disease severity (Inna 
Kruman, 1999).  
 
 
SUPEROXIDE DISMUTASE INVOLVED IN OXIDATIVE STRESS  
 
There are now ample evidence demonstrating the relationship between oxidative stress 
and ALS pathogenesis. The initial discovery of genetic linkage to the SOD1 locus was 
therefore exciting, since the primary role of SOD1 is in antioxidant defense. The 
superoxide dismutase are a group of three isoenzymes that play a key role in reducing 
free-radical-induced cellular damage. They scavenge the superoxide (O2-) free radical 
produced as a by product of oxidative respiration. 
 
 
 
SOD1 is primarily a cytosolic enzyme (Fridovich, 1975), but is also present in small 
amounts in mitochondrial and other organelles (Okado-Matsumoto, Fridovich, 2002; 
Okado-Matsumoto A, Fridovich, 2001).  There are three types of SOD. The SOD2 is 
present in mitochondria (Boukaftane et al., 1998), SOD3 which is present in 
extracellular space (Boukaftane et al., 1998) and SOD1 present in intracellular space. 
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No mutations have been described in SOD2 or SOD3 in ALS patients.  Despite the 
discovery of mutation in the SOD enzymes and the direct relationship between the 
mutation and the ALS pathologies the mechanisms by which mutation in SOD1 cause 
fALS are yet not understood.  Transgenic mice or rats Transgenic mice and rats over-
expressing ALS associated mutant SOD1 develop an ALS-like phenotype, while 
transgenic mice over-expressing wild type SOD1 (wtSOD1) remain unaffected, 
furthermore, increasing or decreasing levels of wild-type SOD1 have no effect on 
mutant SOD1 related ALS (Bruijn et al., 1998) and the SOD1 knockout mice show 
axonal damage with no evidence of MNs degeneration (Gurney et al., 1994; Wong et 
al., 1995; Ripps et al., 1995; Reaume, et al., 1996; Bruijn et al., 1997; Ho et al., 1998; 
Nagai et al., 2001) or ALS (Reaume et al., 1996). These data suggest that SOD1-linked 
fALS is not simply related to a loss of normal SOD1 activity, rather the emerging 
hypothesis is that the mutated SOD1 enzyme gains a toxic function. A gain in toxic 
function can in principle be related to a more open conformation of the mutated SOD 
protein, such a different conformation may allow other aberrant substrates to enter the 
active site and react with the copper ion.  
 
Figure 4. Describe the different way with which the SOD1 mutation can lead to a intracellular 
pathological condition (http://www.english.als-
charite.de/VM/ALS/Cause/FamilialALS/tabid/1247/Default.aspx). 
 
Due to the structural alterations of the mutated SOD1 the central copper and zinc atoms 
are presented more strongly on the surface of the molecule. Chemical reaction 
activated by copper/zinc can therefore be catalised in an uncontrolled manner 
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(copper/zinc mediated toxicity). The mutated SOD1 (mSOD1) molecules also have a 
tendency to form aggregates and lead to a harmful accumulation of SOD1 protein in 
the MNs. Furthemore, mSOD1 protein seems to be preferentially associated with brain 
and spinal cord mitochondria isolated from postmortem patients. The mSOD1 has 
altered properties, which lead to an increase in the production of free radicals. Copper 
chaperone, which is a class of protein that assist the non-covalent folding or unfolding 
and the assembly or disassembly of other macromolecular structures like SOD 
enzymes, for superoxide dismutase (CCS) colocalizes with SOD1 in hyaline inclusion 
in the spinal cord of five SOD1-fALS although CCS does not appear  to be a consistent 
partner to ubiquitin in sALS (Kato et al., 2001; Watanabe et al., 2001). Nonetheless, in 
the majority of cases there is not the direct involvement of the mSOD1 enzyme, 
therefore the oxidative stress involves different mechanisms and pathways. It is 
interesting to note, that the oxidative damage is not specific of ALS, as mentioned at 
the beginning of this paragraph, it is observed and it is certainly involved in a variety of 
neurodegenerative diseases or other nerve tissue damage/lesions. This lack of 
specificity does not necessarily mean that it is pathogenically irrelevant. One of the 
current hypothesis states that the casual factor of the degenerative disease, either 
genetic or environmental in nature, may affect the cell’s metabolism trough the 
induction of energetic failure and thus gradually induce oxidative stress; alternatively 
the oxidative stress is a consequence of other insults occurring earlier and able to 
trigger the synthesis of ROS. The documented presence of oxidative damage in all 
forms of ALS, familial and sporadic, suggests its involvement in motor neuron 
degeneration, independently of the primary aetiology. For this reason it is highly 
relevant to further investigate and understand whether and how the oxidative stress-
mediating pathways represent the initiating cause or an epiphenomenon of motor 
neuron death. Note that the neurodegenerative mechanisms such as oxidative stress, 
wrong protein conformation and compromises of the intracellular transport are often 
accompanied by an anomalous protein aggregates. The protein accumulation 
mechanism will be discussed further in a section below. 
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MITOCHONDRIAL DYSFUNCTIONS 
 
The high energy yield of oxidative glucose utilization is closely linked to 
mitochondrial respiration. Electrons are passed along a series of respiratory enzymes – 
the electron transport chain - located at the mitochondrial inner membrane, and the 
energy released by this transfer is used to pump protons across  the membrane. The 
resultant electrochemical gradient is used by ATP synthase to phosphorylate ADP to 
ATP at a rate which accounts to more than 80 % of the  cellular ATP turnover, 
rendering the brain particularly sensitive to any mitochondrial dysfunction. However, 
the importance of the mitochondria in brain pathophysiology goes beyond their critical 
role for the generation of energy. As the primary intracellular source of free radicals, 
their involvement in the regulation of calcium homeostasis and the association with 
apoptosis-promoting pathways, dysfunction of mitochondria is a central mediator of 
cellular injury. An important cause of mitochondrial dysfunction is the pathological 
rise of the intracellular calcium activity, as induced by toxic levels of glutamate or 
other excitatory neurotransmitters (Fiskum, 2000). Mitochondria are not only 
responsible for ATP synthesis, but are also the major site for the intracellular 
generation of important by products of cellular metabolism, namely ROS such as free 
radicals, which are known to induce cell damage and to increase cellular vulnerability 
to secondary excitotoxicity which may occur as a secondary process triggered by some 
other primary pathological event, if the initial insult compromises the neuronal energy 
status leading to a loss of normal resting membrane potential. In these circumstances 
the voltage-dependent magnesium block of NMDA receptor channels is lost, which 
results in excessive activation of the receptor in the presence of normal levels of 
extracellular glutamate. An additional relevant role of mitochondria is related to their 
ability in acting as potent calcium buffer/stores. Mitochondria are also involved in the 
initiation of apoptotic pathways. All these roles are considered important in ALS 
pathogenesis. (Menzies et al., 2002a,c; Heath et al., 2002; , Atlante, et al., 2001; Shaw 
et al. 1997). Morphologically abnormal mitochondria have been described in motor 
neurons isolated in human ALS (Nakano et al., 1987; Siklos et al., 1996; Sasaki and 
Iwata 1999), together with a reported decrease in cytochrome C oxidase activity in the 
spinal ventral horn in general and in individual motor neurons, in particular (Borthwick 
 38 
et al., 1999; Menzies et al., 2002a,c). It is relevant to note that excessive glutamate 
receptor activation, free radical generation and mitochondrial energy metabolism are 
considered as interconnected systems via the common intracellular Ca2+ messenger 
(Shaw et al. 1997). The excessive activation of neuronal glutamate receptors caused  
extreme calcium influx (Stout et al., 1998). An important cause of mitochondrial 
dysfunction is the pathological rise of the intracellular calcium activity, as induced by 
toxic levels of glutamate or other excitatory neurotransmitters. In the attempt to reverse 
this increase, mitochondria actively accumulate calcium via the Ca2+ uniporter located 
in the mitochondrial inner membrane. Consequently the mitochondria dysfunction 
improve an higher neuronal vulnerability to glutamate toxicity (Ikonomidou, Turski. 
1996; Bittigau, Ikonomidou, 1997) in particular MNs. In fact, these cells, in respect to 
other spinal neurons, are known to display a higher sensitivity to AMPA induced 
excitotoxicity (Carriedo et al., 2000). The high AMPA receptor density (Vandenberghe 
et al., 2000), together with the propensity of MN mitochondria to overload the 
intracellular cytoplasma with Ca2+ during cell excitation (Carriedo et al., 2000), and the 
tendency of MN mitochondria to generate high levels of ROS upon excitatory stimuli 
(Rao et al. 2003; Sullivan et al., 2004) can represent a network of weaknesses that 
allow for the selective loss of MNs. Such hypothesis is strengthened by several 
observations in ALS patients mitochondria, such as the reduced activity in the ETC the 
concomitant increase in ROS production, together with a marked decrease in calcium 
buffering capacity of these organelles (Swerdlow et al., 1998; Jung et al., 2002; 
Mattiazzi et al., 2002; Menzies et al., 2002a; Wiedemann et al., 2002). Wiedmann and 
colleges (2002) analyzed the mitochondrial DNA isolated from the spinal cord of ALS 
patients, these authors  detected a significant increase in mitochondrial mutations (see 
also Ro LS et al., 2003). Interestingly, several pro-apoptotic molecules are increased in 
the spinal cord of ALS patients as well as in transgenic mice ALS models, which over-
express the mutant SOD1 (Pasinelli et al., 2000; Li et al.,2000). Elevated levels of ROS 
are suggested to induce increased frequency in mitochondrial DNA mutations in the 
motor cortex and spinal cord of ALS patients (Dhaliwal and Grewl, 2000; Wiedemann 
et al 2002). One atypical MND case was found to carry a mitochondrial DNA mutation 
resulting in the production of a truncate cytochrome c oxidase subunit (Comi et al., 
1998). SOD1, mostly considered a cytosolic protein, has been recently described in 
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mitochondria, in the form of a pool of enzymatically active SOD1 in the inter-
membrane space (Okado-Matsumoto and Fridovich, 2001; Sturtz et al., 2001, Higgins 
et al., 2002; Mattiazzi et al., 2002). Since mitochondria are the major site of ROS 
generation, via incomplete reduction of O2 during respiration (Lenaz 1998; Swerdlow 
et al., 1998). Moreover, calcium increases the generation of ROS which interfere with 
energy metabolism in a dual way: directly by inhibiting complex I of the ETC, or 
indirectly by producing oxidative membrane alterations that result in further increase of 
intracellular calcium (Fiskum 2000). Cytochrome C is a member of the mitochondrial 
ETC required for the generation of ATP. In addition to its role in bioenergetics, 
Cytochrome c is an important trigger of caspase cascade and a key member of the 
mitochondrial apoptotic cascade. Cytochrome  C-mediated activation of cell death 
occurs if cytochrome c is released from mitochondria into the cytoplasm. Several 
studies have shown increased translocation of cytochrome c from mitochondria into 
cytoplasm, during disease progression in SOD1 mice (Guegan et al., 2001; Zhu et al., 
2002). The tetracycline derivative minocycline, which inhibits cytochrome c release 
from the mitochondria, has been shown to delay disease onset and to extend survival in 
SOD1 mice (Zhu et al., 2002). Human trials of minocycline in ALS are still in progress 
(Tikka et al., 2002). Several studies have measured the function of mitochondrial 
respiratory chain, which is controlled by the nuclear and the mitochondrial genomes. 
The large majority of the mitochondrial proteins are encoded by mitochondrial DNA, 
therefore mutations of the mitochondrial DNA (mDNA) are potentially associated to 
impairments in the ETC function, or deregulation of calcium homeostasis. Deficits in 
ETC complex activities  were described in the skeletal muscles and in the spinal cord 
of sALS patients (Wiedemann et al., 1998; Veilhaber et al., 2000; Borthwick et al., 
1999; Comi et al., 1998; Sverdlow et al., 1998). Compelling evidence suggests that 
mitochondria play a crucial role in the pathogenesis of MNs death in ALS in fact 
dramatic morphological abnormalities in mitochondria are found in human ALS cases 
and in mutant SOD1 transgenic mice. In the transgenic mice, these abnormalities peak 
at early stages, before the onset of the disease and probably exacerbated further by  
mDNA damage and mutations. Mitochondrial abnormalities may cause motor neuron 
degeneration also by sensitizing MNs to excitotoxicity, by increasing generation of 
ROS, and by releasing mitochondrial death factors. However the mechanisms by which 
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the mitochondria are damaged in ALS are not clear but one of the most important step 
may be to understand how SOD1 mutations damage mitochondria. 
 
 
CYTOSCHELETAL DYSFUNCTIONS AND IMPAIRED 
INTRACELLULAR TRANSPORT  
 
The cytoscheletal proteins are synthesized in the neuronal cell body and transported 
down the axon toward the nerve endings. Recently, many studies showed that defects 
in the microtubule-based transport machinery may provoke MND. Axonal and cell 
body accumulation of organelles and other proteins are hallmarks of pathology in 
several different human neurodegenerative diseases (Mark Head et al., 2003; Uversky 
et al., 2003; Hoozemans et al., 2007; Christopher Ross and Michelle Poirier 2004). 
Accordingly, also in ALS patients neurofilament accumulations have been described 
(Qi Wang et al., 2008; Kabashi Edor et al., 2009;), and, more recently, TDP-43 which 
is an RNA/DNA binding protein, implicated in regulation of alternative splicing of 
messenger RNA, RNA stability, and transcriptional control (Buratti and Baralle 2008), 
and its accumulations have been observed in ALS and in the FTLD (Neumann et al 
2006). Axonal transport relies on the kinesin (anterograde) and dyneine (retrograde) 
motors. Due to the length of their axons motor neurones are likely to be especially 
vulnerable to any change that might affect intracellular transport, that is also relevant to 
neurotrophic factor signalling  (Salehi et al., 2003; Delcroix et al., 2003). Neurotrophic 
factors released from cells to their targets diffuse , bind, and activate their specific 
receptors, and the complexes thus formed are internalized and are essential for the 
survival and the differentiation of developing neurons and for the maintenance of 
proper function and plasticity of mature ones (Sofroniewet al., 2001). Neurofilaments 
are one of the major component of the intermediate filament network present in 
neuronal cells, which is composed by light (NF-L), medium (NF-M) and heavy (NF-H) 
subunits, and have important roles in maintaining cell shape and in setting the final 
axonal diameter (Lee and Cleveland, 1996). These filament networks are particularly 
important in large cells, such as MNs, with their characteristic large cell body and long 
axons. The aggregation of neurofilaments is a well-known pathological feature 
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appearing in many neurodegenerative disorders, including ALS (Hirano et al., 1984a). 
Similar aggregates were observed in one ALS animal model expressing the human 
mutated SOD1 enzyme, so called SOD1 transgenic mice (Gurney et al., 1994; Wong et 
al., 1995; Tu et al., 1996; Dal Canto and Gurney 1997; Zhang et al., 1997). Mutations 
in the so called KSP repeat region, (i.e. the repeat region of the gene encoding the 
neurofilament heavy protein, that is the major component of the neuronal 
cytoscheleton; Figlewicz DA et al., 1994; Tomkins J et al., 1998) of the NF-H gene are 
present in approximately 1% of sALS cases (Figlewicz et al., 1994; Tomkins et al., 
1998; Al-Chalabi et al., 1999). Impaired axonal transport, in both fast and slow 
components, has been reported in sALS and in fALS patients (Sasaki S, Iwata M 1996; 
Sasaki S, Maruyama S, 1992; Sasaki S et al., 1990), as well as in several ALS animal 
models (Dupuis et al., 1997; Sasaki et al 2004; Warita et al., 1999; Williamson TL, 
Cleveland DW 1999; Zhang et al., 1997). The involvement of neurofilament 
dysfunction as one of the primary events in ALS pathogenesis and progression was 
revealed in transgenic mouse model, in particular those displaying high over 
expression of the mutated gene (Collard and Julien, 1995). Neurofilament, those 
belonging to the principal intermediate filament formed by the co-assembly of three 
subunits (NF-L,NF-M and NF-H) and peripherin proteins, another intermediate 
filament that can self-assemble, are two types of intermediate filaments (IFs) and both 
were detected in the majority of axonal inclusion bodies, called spheroids, described in 
ALS patients MNs (Hirano et al., 1984; Corbo and Hays, 1992). To this we have to add 
the  finding that codon deletions or insertions in the KSP phosphorilation domain of the 
neurofilament NF-H gene are present in a subset if sALS (∼1% cases), (Figlewicz et 
al., 1994; Tomkins et al., 1998; Al-Chalabi et al., 1999) together with the description of 
mutations in the rod domain of the NF-L gene in a related disease, the Chacot-Marie-
Tooth disease type 2 (Mersiyanova et al., 2000; De Jonghe et al., 2001). These 
evidences further involve neurofilament processing in MND. Accumulation of 
mitochondria in cell bodies and proximal axons is a feature recently reported in ALS 
patients as well as in animal models, such as the SOD1 (see below, Sasaki. and Iwata 
1996; Sasaki and Iwata 2007). These authors have shown, that mitochondria and 
lysosomes accumulate in the proximal axons, located in the ventral horn (Sasaki. and 
Iwata 1996), suggesting a block of the axonal trafficking. The presence of 
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metabolically dysfunctional mitochondria (see previous paragraph) could also be due 
downstream to an impaired axonal transport (Magranè and Manfredi 2009). 
Abnormalities of axonal transport are also detected very early in the course of mutant 
SOD1-induced MNs degeneration (Williamson et al., 1998; Borchelt et al., 1998). The 
mechanisms leading to the progressive alteration in the axonal transport machinery are 
still elusive (Zhang et al., 1997; Wiliamson and Cleveland 1999). Such transport 
defects may also explain the presence of abnormal IF accumulation in human ALS 
cases with SOD1 mutation (Rouleau et al., 1996) and in the transgenic mice expressing 
SOD1 mutants (Gurney et al., 1994; Tu et al., 1996).  
 
NEUROTROPHIC FACTORS AND DYSFUNCTION 
 
Neurotrophic factors (NFs) are a group of neuropeptides that play an important role in 
regulating the growth, differentiation, and survival of neurones in the peripheral and in 
the CNS. In the spinal cord of ALS patients, the specific expression of NGF or of its 
corresponding high affinity receptor Trk A, were not detected and the motor cortex in 
ALS patients displays decreased levels of NGF, when compared to control brains 
(Anand et al., 1995). Recently, increased levels of NGF in post-mortem muscle tissue 
isolated from ALS patients was observed. Based on their survival-promoting effects on 
cultured MNs and in animal models, several NFs were proposed for human treatments 
and include insulin-like growth factor-1 (IGF-I) (Mitchell et al., 2002; Neff et al., 
1993; Bongioanni, et al., 2004), brain derived neurotrophic factor (BDNF) (Henderson 
CE et al., 1993), ciliary neurotrophic factor (CNTF) (Arakawa et al., 1990), glial cell-
line derived neurotrophic factor (GDNF) (Henderson et al., 1994), and vascular 
endhotelial growth factor (VEGF) (Lambrechts et al., 2003; Zheng et al., 2004). 
Unfortunately, several NFs (BDNF,CNTF, and GDNF) know to enhanced MNs 
survival in vitro and in vivo and that have undergone clinical trial as potential ALS 
treatments, were not effective in ALS patients (Miles et al., 2004; Miller et al., 2001; 
Miller et al., 1996).  The most recently tested was the IGF-1 (Myotrophin®), a NF 
considered to be essential for normal development of the nervous system. IGF-1 
(Myotrophin®) promotes motor neuron survival and nerve regeneration (Miller et al., 
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1996; Neff et al., 1993). Also in this case, clinical trials using IGF-1 in ALS patients in 
the US and Europe led to ambiguous and conflicting conclusions (Nilsson, et al., 1992; 
Nishimune et al., 2000). Ultimately, we do not have clear evidence indicating the 
primary deficiency of NFs in the origin and development of ALS. For this reason 
further in depth comprehension of the possible links between NFs and ALS is needed. 
The clarification of these mechanisms is highly relevant, in fact any step towards the 
development of drugs able to slow, or event to rescue, ALS damage and progression 
may rely on NFs properties.  
 
PROTEIN AGGREGATION 
 
Protein accumulation within cells or in the extracellular space of the peripheral nervous 
system or in the CNS has been documented in diverse neurodegenerative diseases and 
usually such accumulation is correlated to errors, due to several pathological 
mechanisms, occurring in the protein folding procedure (Uversky et al., 2003) . In this 
framework, ALS pathology is characterized by ubiquitin-immunoreactive inclusion 
(UBIRI) (Lowe et al., 1988; Piao et al., 2003 Maekawa et al., 2004), and usually these 
inclusions take various forms within spinal and brain stem MNs. Protein aggregates, 
immunoreactive to antibodies against ubiquitin (a protein tag the targets protein for 
proteolytic degradation) have been detected in virtually all ALS cases (Ince et al., 
1998, 2003; Piao et al, 2003). In addition, also SOD1 immunochemistry revealed 
protein aggregates in human fALS cases with SOD1 mutations and also in a proportion 
of sALS cases (Chou et al., 1996; Shibata et al., 1996a,b; Bruijn et al., 1998). In 
analogy, cytoplasmic protein aggregates have also been observed in mutant SOD1 
transgenic mouse models (Gurney et al., 1994, Dal Canto and Gurney, 1995, 1997; 
Bruijn et al., 1997b,1998) as well as in  cell culture models (Durham et al., 1997; Lee 
et al., 2002). The ubiquitinated SOD1 aggregates appeared as a component of the 
cytoplasmatic inclusion bodies in MNs and in some cases within the surrounding 
astrocytes in SOD1-mediated fALS transgenic mice and in the spinal cord of fALS 
patients (Bruijn et al., 1998; Bruijn et al., 1997). Interestingly, the mutant SOD1 
protein seems to be preferentially associated with brain and spinal cord mitochondria 
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isolated from post-mortem material and from SOD1 transgenic mice (Liu, et al., 2004). 
Why this SOD1 miss-localization occurs, and how it leads to cell death is still not 
known. The finding that mutant SOD1 binds the pro-apoptotic protein Bcl-2 both in 
human and mouse spinal cord, and that Bcl-2 bound to high molecular weight SOD1 
aggregates is detected only in spinal cord mitochondria, suggest a possible mechanism 
(Pasinelli, et al., 2004). In cultured spinal MNs, expression of mutant SOD1 resulted in 
abnormal cytoplasmatic aggregation of SOD1 and increased apoptosis, that was not 
seen in MNs expressing in wild-type SOD1 (Durham et al., 1997). Other proteins 
identified in SOD1-containig aggregates include ubiquitin, heat shock proteins 
involved in chaperone and proteasome function, the anti-apoptotic protein Bcl-2, the 
copper chaperone (CCS) for SOD1 CCS, GFAP, glutamate transporters and p38MAPK 
(Kato et al., 2001; Watanabe et al., 2001; Niwa et al., 2002; Bendotti et al., 2004; 
Pasinelli et al., 2004). Protein aggregation has been shown to inhibit the ubiquitin-
proteosome system (Bence et al., 2001) and inhibition of the proteosome may allow 
subsequent accumulation of damaged or miss-assembled proteins. In support of this 
hypothesis, reduced proteosome activity was been reported in mutant SOD1 transgenic 
mouse and cell cultures. In vitro, the metal-depleted mutant forms of SOD1 can acquire 
conformations of amyloid-like filaments and amyloid pores (Elam, et al., 2003). It was 
seen that modifying selectively in the microglia (Boille et al., 2006) or in the astrocytes 
(Lobsiger et al., 2007) the expression of mutant SOD1 in transgenic mice, slows the 
disease progression. Interestingly, lowering mutant SOD1 in muscle does not affect 
disease onset, progression, or survival (Boille´ et al., 2006). In conclusion, it has been 
shown that in patients with SOD1-associated fALS and in transgenic mouse models, 
MN cell death is preceded by the formation of cytoplasmic inclusions containing 
ubiquitin and aggregated mutant SOD1 protein. Inclusion bodies containing ubiquitin-
immunoreactive protein aggregates are also a feature of sALS.  
 
INFLAMMATION  
 
Increasing experimental evidence suggests that inflammatory pathways and microglia 
are activated in the pathogenesis of ALS (Sargsyan et al., 2005). A marked 
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inflammatory response in the pyramidal tracts has been described, indicated by the 
presence of numerous activated microglia and macrophages (Lampson et al., 1990; 
Kawamata et al., 1992; McGeer et al., 2002; Troost et al., 1990). In an animal model 
for the disease, the transgenic mice expressing the human mutated SOD1, (see below) 
several genes involved in mediating the inflammatory responses were found to be up-
regulated in the spinal cord already at pre-symptomatic stages (Yoshihara et al., 2002). 
As mentioned above, activated microglia and astrocytes were detected in the spinal 
cord of sALS patients and in that of the SOD1 animal model (Kawamata et al., 1992; 
Hall et al., 1998; Alexianu et al., 2001). Several inflammatory cytokines and enzymes, 
including various interleukin, tumor necrosis factor-α (TNFα), cyclooxigenase 2 
(COX2) and prostaglandin E2 (PGE2) have been shown to be up-regulated in the 
spinal cord of ALS patients (Almer et al., 2002; Henkel et al., 2004) and in mutant 
SOD1 mice (Elliott, 2001; Hensley et al., 2002; 2003; Yoshihara et al., 2002). 
Microglia is activated by these inflammatory cytochines and by ROS (Gonzales-
Scarano and Baltuch, 1999). Microglia isolated from pre-symptomatic SOD1 mice and 
maintained in vitro showed an increase in TNFα evoked release, when compared to 
wild type microglia (West et al., 2004). Accordingly, in this study, TNFα antagonists 
significantly increased the survival of the SOD1 mice (West et al., 2004).  
As already mentioned above, the CSF sampled from ALS patients was toxic to MNs in 
mixed spinal cord cultures and this toxicity could be, at least in part, prevented by 
inhibiting the microglial activation, using the minocycline drug (Tikka et al., 2002). It 
is relevant to note, that in ALS patients, a strong glial reaction typically surrounds the 
upper and lower motor neurons (Hirano 1996; Kushner et al., 1991; Nagy et al., 1994; 
O’Really et al., 1995). In fact, a widespread astrogliosis is commonly observed in ALS 
patients (Hirano, Neurology 1996; Schiffer et al., 1996). Several studies have 
extensively described the increased number of activated microglia and astrocytes in 
ALS patients, when compared to healthy tissue (Henkel et al., 2004; Kawamata et 
al.,1992). Marked microglia activation, IgG deposits, and lymphocytic infiltration have 
been demonstrated in the affected areas of tissue from ALS patients (Henkel et al., 
2004). Nevertheless, intensive investigations of inflammation in ALS (human and 
rodent models) have not provided a clear explanation for this strong inflammatory 
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response, several investigators suggested that the inflammatory process contributes 
significantly to MNs degeneration  (McGeer et al., 2002; Minghetti, 2004; Almer et al., 
2001). This hypothesis is supported by the observed increased survival of SOD1 ALS 
mice models in response to therapeutic agents known to suppress microglial activation 
(Zhu, et al., 2002; Van Den Bosch et al., 2002; Kriz et al., 2002), or to inhibit 
cyclooxygenase 2 activity, an agent highly involved in the inflammatory process 
(Drachman et al., 2002). 
 
 
APOPTOTIC PATHWAYS 
 
Apoptosis is a type of cell death where a cell actively pursues a pathway leading to its 
death showing a chromatin condensation, loss of mitochondrial membrane potential, 
plasma-membrane asymmetry, and detachment from the cellular matrix (Jerry Chipuk 
& Douglas Green 2005). A putative role of apoptosis in the onset and progression of 
ALS was suggested by early in vitro and in vivo experiments aimed at delineating a 
pathogenic role of the mutant SOD1 gene product (Nishitoh Hideki et al., 2008; Reyes 
et al., 2010;). 
Morphologic studies, detected the presence of apoptotic bodies within macrophages in 
the motor cortex, brain steam, and spinal cord in ALS patients (Troost, et al 1995). 
Other apoptotic markers including fractin, the LeY antigen and prostate apoptosis 
response-4 are highly expressed in spinal cords of ALS cases and in transgenic SOD1 
mice (Vukosavic et al., 2000; Yoshiyama, et al., 1994; Rangnekar et al., 1998; 
Pedersen et al., 2000; Guegan,  et al., 2001). Over expression of Bcl-2 (anti-apoptotic 
protein) in transgenic SOD1 mice has been shown to not only improve survival, but 
also to attenuate the degree of spinal cord degeneration (Kostic et al., 1997). 
Correlative studies, which have been conducted in humans ALS cases and in animal 
models of disease (namely the SOD1 mice, se below) have shown a marked decrease in 
the Bcl-2 mRNA expression, opposite to the higher levels of the Bax (pro-apoptotic 
protein) mRNA detected (Mu et al., 1996; Vukosavic et al., 1999). Additional studies 
investigated, in human ALS cases and in animal disease models (SOD1 mice), the role 
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in the pathogenesis of ALS of the caspase protein family. These studies showed the 
presence of caspases 1 and 3 activities in neurons isolated from the nervous system of 
the SOD1 mice model (Pasinelli et al., 2000) and similarly, the presence of caspases 1 
and 3 activity in spinal cord samples from ALS patients (Friedlander et al., 1997; Li et 
al., 2000). Additional investigations indicate that the caspase 9 is activated in the spinal 
cord of ALS patients (Inoue et al., 2003) as well as in SOD1 models (Figlewicz et al 
1994). Further support to the role of caspases and apoptotic pathways is provided by 
the finding that caspase inhibitors improve the survival and delay the disease 
progression in SOD1 mice, (Roy et al., 1998).  However, the molecular process 
involved in the selective degeneration of MNs in ALS pathology is very complex and 
although there are many assumptions about molecular pathways, this issue deserves 
further investigation.  
 
 
POTENTIAL ROLE IN ALS OF NON-NEURONAL CELLS 
 
Evidences for non-neuronal cell involvement in ALS have arisen directly from studies 
based on post-mortem tissue samples from sALS and fALS patients. Preliminary 
investigations observed the presence of significant glial fibrillary acidic protein 
(GFAP) immunoreactivity and cellular hypertrophy (Kamo et al., 1987; Murayama, et 
a., 1991). Further investigation extended these results, and reactive astrocytes were 
found widely distributed throughout subcortical white matter and cortical gray matter 
extending well into parietal, temporal, and, to a lesser extent, occipital areas in ALS 
patients (Nagy, et al., 1994; Kushner et al., 1991; Feigin, 1991). Reactive astrocytes 
have also been well documented in the ventral horn of ALS spinal cord sections in 
close proximity to degenerating cells in the ventral horn (O’Really et al., 1995; 
Schiffer, et al., 1996). One pathologic hallmark of SOD1 related fALS is the presence 
of ubiquitin and SOD1 positive cytosolic inclusions in neurons in the spinal cord, 
brainstem, and cortex (Kato et al., 1997) and similar cytoplasmic inclusions have been 
observed in astrocytes within the spinal cord, brainstem, and telencephalon in SOD1 
related fALS (Kato et al., 1997; Kato et al., 1999; Kato et al., 2000). Microglial cells 
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also undergo substantial pathological changes in ALS patients which are increased in 
the spinal cord  (Lampson et al., 1990) and this microgliosis usually extend to the 
motor cortex of ALS patients beyond MNs pools (McGeer et al., 2002). Important 
disease-driven interactions among neurons and non-neuronal cells may also occur via 
non-protein associated signalling mechanisms. For example, one important function of 
astrocytes is to remove the excitatory transmitters (mainly glutamate) from the 
extracellular space to prevent excitotoxicity (see the related previous paragraph) 
(Rothstein et al., 1996; Bergles and Jahr, 1997).  Since the neuron are bathed in 
extracellular fluid that has a high concentration of Na+ ions and low concentration of 
K+ ions and the relative concentration of this cations inside of cells are reversed, ionic 
balance and maintenance of homeostasis is important for normal neuronal function. 
The resting ion gradients across the cell membrane are crucial to the generation of 
essential neuronal signals, including the resting membrane potentials, the action 
potentials generation, activation and inactivation of voltage gated ion channels the 
efficacy of synaptic transmission and electrogenic transport of neurotransmitters.  
Astroglial cells are involve in the re-uptake and recycling of neurotransmitters (e.g., 
glutamate, glycine, ATP) which is important for maintaining normal extrasynaptic 
neurotramitter concentrations, in fact detailed structural and dynamic studies have 
reveled that astrocytes influence synaptic strength by releasing neurotransmitters like 
glutamate or glycine (Newman et al., 2003). The synapse therefore has recently been 
described as a tripartite structure that can modulate the synaptic strength (Araque et al., 
1999). Astrocytes are also involved in controlling the extracellular/perineuronal ionic 
homeostasis (K+, Cl-, Na+) and the impairment of one or more of these properties may 
directly influence the function and integrity of the surrounding neuronal networks. 
Glutamate toxicity could be a consequence of sustained neuronal activity or impaired 
glutamate clearance (Rothstein et al., 1996; Tanaka et al., 1997). Astrocytes can 
contribute to ALS pathogenesis by additional mechanisms. Astrocytes express a wide 
variety of functional receptors for many neurotransmitters, including glutamate, 
adenosine, norepinephrine, γ-Aminobutyric acid (GABA), histamine, adenosine5’-
triphosphate (ATP) and acetylcholine (Porter and McCarthy, 1997). The fact that the 
astrocytes Ca2+ signals may be triggered in glial cells by neurotransmitters released 
from synaptic terminals indicates the existence of functional neuron-to-astrocyte 
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communication, which represents a new form of intracellular signaling between 
neurons and astrocytes in the CNS (Araque et al., 1999; Araque et al., 2001). 
Astrocytes may release several gliotransmitters in a Ca2+-dependent manner (Volterra 
and Meldolesi, 2005) and the modulation of astrocytic Ca2+ signals that are evoked by 
glutamate and acetincholine (Ach) is finely regulated by the level of synaptic activity 
(Perea and Araque, 2005a). An increase in the network excitability, as suggested to 
occur during ALS progression, may cause alteration in Ca2+ homeostasis triggering the 
release of growth factors and gliotransmitters, ultimately leading to further 
neurodegeneration.  
 
This brief overview of the presumed mechanisms of disease involved in sALS and 
fALS, although far from being complete, was aimed at highlighting the complexity of 
progressive MN cell death and the large amount of co-factors potentially involved and 
currently investigated. There is convincing evidence of the importance of several 
distinct molecular mechanisms in the pathogenesis of this disease, and a multifactorial 
aetiology has been suggested (Cluskey and Ramsden, 2001). Thus ALS might emerge 
from a complex interplay between genetic factors, oxidative stress, glutamatergic 
excitotoxicity, damage to vital organelle and aberrant protein aggregation. 
  
SOD1 MUTATIONS IN ALS  
 
The core of my work was conducted using  the SOD1 mutant mice model, therefore 
such mutations and their implication in fALS are described, in more details, separately 
in the next paragraphs. 
 
 
SOD1 MUTATIONS IN ALS PATIENTS 
 
The discovery of mutations to the antioxidant enzyme copper, zinc superoxide 
dismutase (SOD1) in 1993 had given much hope, in that it allowed the development of 
molecular approaches to the study of ALS. After almost 20 years the mechanism(s) of 
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action triggered by the mutation in SOD1 enzyme are still unknown. Oxidative damage 
has been documented in degenerating ALS tissues, nonetheless a casual role of 
oxidation is difficult to prove (Wharton S et al., 2003). The first 13 mutations to the 
antioxidant enzyme, copper, zinc SOD1 were discovered in 1993 (Borchelt et al., 
1995) and today the list of SOD1 mutations has expanded to over 120 different ones 
(Hart et al., 2006; Winkler et al., 2009); (www.alsod.org), although the occurrence of 
these mutations in ALS is limited to about the 2% to 3% of all patients. In the majority 
of reports, ALS SOD1 mutations are missense point mutations on chromosome 21 and 
account for 20% of fALS usually inherited as autosomal dominant (Siddique et al., 
1991). Similar to mutation carriers in other diseases, not all SOD1 mutation carriers 
develop ALS, suggesting that other unknown factors must be contributing to the 
penetrance of the SOD1 mutation. Human ALS caused by SOD1 mutations display an 
age onset of 45±9 years and the symptoms occurrence is not biased by the gender 
(Juneja et al., 1997). The progression of the disease is variable, depending on the 
SOD1 mutation involved (Sorenson et al. 2002; Del Aguila et al., 2003). For example, 
the A4V mutation, present in approximately 50% of North American ALS families, has 
been consistently associated with a rapid (1± 0,4 years) disease course (Juneja, et al., 
1997). Other mutations confer significantly slower disease progression (10 years), such 
as the G37R (∼18±11 years), G41D (∼17± 6 years), H46R (∼17±6 years) and G93C 
(∼10±6 years) (Juneja, et al., 1997; Cudkowicz et al., 1997). Extensive variability in 
progression has been documented in patients displaying the I113T (∼2 - 20 years) 
(Orrell et al., 1997) and the G93R mutations (∼2 – 12 years) (Orrell et al., 1997). This 
variability suggests a complex interplay, in ALS development, of additional genetic 
and/or environmental influences. The mechanisms that lead from  SOD1 mutations to 
fALS are basically still unknown. The SOD1 enzymes are a group of three isoenzymes 
(SOD1, SOD2 and SOD3) all playing  key roles in reducing free-radical-induced 
cellular damage. These enzymes are crucial in scavenging the superoxide (O- 2) 
produced by oxidative respiration. SOD1 is primarily a cytosolic enzyme (Fridovich I. 
et al., 1975), but is also present in small amounts in the mitochondria (Okado-
Matsumoto, et al., 2002; Okado-Matsumoto et al 2001). SOD2 (Mn2+ SOD) is present 
in the mitochondria (Boukaftane Y, et al., 1998), whereas SOD3, that also contain Cu 
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and Zn, is located extracellularly (Boukaftane, et al., 1998). It is relevant to note that 
no mutations have been described in SOD2 or in SOD3 in fALS patients. One 
hypothesis about the mechanisms leading to ALS involves SOD1 aberrant catalysis. 
Peroxynitrite (-ONOO) is a toxic intermediate non-enzymatically generated via 
superoxide anions and nitric oxide interactions. Peroxynitrite subsequent catalysis by 
SOD1 can lead to the nitration of tyrosine residues within a large number of proteins 
(Beckman et al., 1993). In fact, high levels of nitrotyrosine in the spinal cord of mutant 
SOD1 transgenic mice (Bruijn et al., 1997a; Ferrante et al., 1997; Andrus et al., 1998) 
and in that of fALS patients (Beal et al., 1997; Tohgi et al., 1999) have been described. 
The discovery of SOD1 aggregates in the cytoplasm of MNs and astrocytes in mutant 
SOD1 transgenic mice and in some fALS patients (Shibata et al., 1996a; Bruijn et al., 
1997b) promoted also the idea that SOD1 aggregation in itself may be pathogenic. 
Aggregates in the MNs of ALS patients are immunoreactive to ubiquitin (Leigh et al., 
1991; Mather et al., 1993) and high-molecular weight forms of SOD1 have been 
detected in spinal cord tissue of ALS patient with G127X mutation (Jonsson et al., 
2004).  Spinal cord sections from SOD1-FALS patients have been examined by 
immunoistochemistry procedures and were found to contain aggregates that are 
reactive to anti SOD1 antibodies (Kato S, 2008) but see also (Matsumoto et al.,1996; 
Nilsson et al., 2007; Shibata et al., 1994).  
 
ALS ANIMAL MODELS: SIMILARITIES AND DIFFERENCES WITH THE 
HUMAN DISEASE 
 
The difficulty in diagnosing of the disease before the onset of symptoms makes 
virtually impossible its study at early stages. At the first onset of symptoms, the disease 
is already at an advanced stage, in which the MNs degeneration is already largely 
underway. Usually muscular weakness is the initial sign in the majority of the 
individuals with ALS (Gubbay  et al., 1985; Jokelainen, 1977; Li, 1990). The onset of 
muscle weakness indicates the degeneration of anterior horn cells in the spinal cord 
(Miller et al., 1999; Kent-Braun et al., 1998; Owen and Mulley 2002). Human 
pathologists, to confirm ALS diagnosis, are entirely dependent on human ALS autopsy 
samples in late stage of the disease progression, and the diagnosis of ALS is based on a 
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constellation of clinical and electrophysiological findings that are usually available in 
advanced stages of disease progression, or are confirmatory of the diagnosis only 
postmortem. These late stages of disease progression strongly limit any chance of 
analyzing and understanding the underlying mechanisms and therefore limit any 
improved understanding of ALS etiology and pathogenesis. Therefore, the emergent 
need has always been that of developing animal model of ALS; allowing a better 
investigation of factors involved in the disease onset and progression, and thus able to 
offer the opportunity to design future therapies. In practice, to address the early stage 
of the disease and to gain insights within the early mechanisms of disease, we need to 
investigate animal models. A breakthrough came in 1993 when Rosen et al (1993) 
identified the association of some fALS cases with SOD1 gene mutations. This 
discovery has led to an animal model in which the human mutations are brought to 
over−expression in mice (Gurney et al., 1994). 
Transgenic animals (mice and rats) are obtained by the microinjection of a cloned 
DNA construct into the pro nuclei of fertilized eggs. The generation of transgenic mice 
and rats based on the familial ALS SOD1 gene defects provided a real opportunity to 
unravel the biochemical/molecular steps responsible for MNs degeneration. A key 
question is whether results obtained in animal models are predictive of human 
outcomes. For example, a recent study showed that creatine administrated via drinking 
water had the ability to improve the survival of SOD1 mice (Klivenyi et al., 1999) 
unfortunately upon clinical trials creatine was shown to be ineffective in human ALS 
(Geert Jan Groeneveld et al., 2003). Similar conclusions were reached for the drug 
Celecoxib, an inhibitor of cycloxygenase 2 (COX-2) that significantly delayed the 
onset of weakness and weight loss and prolonged survival by 25% in mutant SOD1 
mice (Drachman et al., 2002) but in clinical trials showed no beneficial effects in ALS 
patients (Cudkowich et al., 2006). Thus, results obtained in drug tests performed in 
ALS animal models should be interpreted with caution. Notwithstanding these 
limitations, to date ALS animal models provide us with the only opportunity to 
investigate this neurodegenerative disease from the molecular level, and may help 
significantly in sheding light on many mechanisms that lead to MNs degeneration in 
ALS. 
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SOD1 ANIMAL MODELS  
 
SOD1 RAT MODELS 
 
In the last decade we experienced, an increasing developemtn of several genetic 
models of ALS, and a particular attention was given to transgenic mice and rats over-
expressing SOD1 human mutated gene. These animals develop progressively 
increasing neuromuscular symptoms suggestive of ongoing motor neuron disease. 
There are two types of human SOD1 mutations expressed in the in rat model able to 
induce ALS phenotypes (Nagai et al., 2001).  
 
 
 
nd: not described 
Table .2 (Turner and Talbot, 2008) 
 
The transgenic SOD1 H46R rats develop motor neuron deficits at approximately 145 
days of age, whereas G93A line-39 rats show clinical signs at around 125 days (Kato 
Shinsuke, 2008) In H46R spinal cords, the cell density in the ventral horn is not 
significantly decreased at 110 days, when compared with control animals. Conversely, 
at 135 days ventral horn neurons begin to disappear. At this age, cell inclusions appear, 
whereas at 160, 170 and> 180 days, the cells in the ventral horn are markedly 
decreased displaying several inclusions (Kato Shinsuke, 2008). On the other hand, rat 
expressing the G93A mutation, at 110 days, in the absence of a marked reduction in 
cell density, display a detectable cellular vacuolization generally associated with 
accumulation mSOD1 and indicative of neuron degeneration (Jaarasma et al., 2000). 
Only >130 days of age, a substantial loss of neurons in the ventral horn is apparent, 
along with the detection of inclusions and vacuolization pathology (Nagai et al., 2001). 
As the disease progresses, G93A rats loose body weight accompanied with an 
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increasing loss in physical performance and muscle weakness (Matsumoto et al., 
2006), as schematized below. 
 
Figure 5. Disease stage progression from the onset in SOD1(G93A) transgenic rats. (Turner 
and Talbot, 2008) 
 
Rat models are used for several ongoing biomedical researches and currently, represent 
the best “functionally” characterized mammalian animal model system. Despite this 
fact transgenic rat are less used when compared to transgenic mice in the field of 
human neurodegenerative disorders like ALS. This is due to the fact that the transgenic 
rat is more difficult to produce than the transgenic mice. Despite this limitation, 
transgenic rats have greatly expanded the range of potential experimental approaches. 
The advantage of rats compared to mice is partly related to the size, that may 
significantly facilitate some experimental procedures, such as serial sampling of the 
cerebrospinal fluid, in vivo nerve recording or neuroimaging procedures. On the other 
hand, mice models have allowed testing greater numbers of mutations identified in 
human ALS patients.  
 
SOD1 MOUSE MODELS 
 
In this section will described the different types of transgenic mice used as an animal 
model for ALS disease. The discovery of SOD1 mutations in FALS was promptly 
followed by the generation of a transgenic mouse ALS model, constitutively 
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expressing human mutated SOD1 genes (Gurney et al., 1994). In literature at least 12 
different human SOD1 mutations were described, which include 9 missense and 3 C-
terminally truncated variants (Turner and Talbot, 2008). The 12 different mutations are 
summarized in the table below: 
 
 
Table. 3 Transgenic mutant SOD1 mouse models (Turner and Talbot, 2008) nd: not described 
 
 
Almost all transgenic mice that express the human mutated SOD1 enzyme develop an 
ALS-like MN disease. In these animals the proposed mechanisms of MN degeneration 
are: 
- oxidative injury mainly via ROS production 
- cytoskeletal disorganization 
- glutamate excitotoxicity  
- disrupted calcium homeostasis 
- protein aggregation 
- apoptosis mechanisms 
- non neural cells involvement  
 
In the last 15 years, experimental research in MN disease has greatly benefited from 
the discovery of human SOD1 gene mutation and the development of new cell culture 
and animal models. Thanks to transgenic animals were discovered many pathological 
mechanisms involved in neurodegenerative process of ALS disease. The use of animal 
models has allowed us to study the different and progressive stages of the 
neurodegenerative process. The information extracted by the study of the animal 
models could be used to understand the general pathogenic picture of ALS and 
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translating these findings into new clinical relevant therapies will be one of the major 
challenges of the future. 
 
 
TRANSGENIC SOD1-G93A MOUSE MODELS 
 
The first report of transgenic mice expressing human mutant SOD1 was published by 
Gurney et al in 1994. This is the most well known ALS animal model and is used 
extensively by many researchers. Among these, the (G1) SOD1-G93A mice are the 
most widely studied (Yang Wendy W et al., 2011).  This line G1 differentiates in two 
other sub lines named G1H and G1L characterized different G93A-SOD1 transgene 
copy expression. GH1-SOD1-G93A mice express high number of transgene copies and 
G1L-SOD1-G93A express the low number of transgene copies. The line of mice GH1 
produced in the Jackson laboratory and coded as B6SJL-TgN(SOD1-G93A)1Gur (Chiu 
et al., 1995) carries 25 copies of transgene and is characterized by an early onset and a 
rapidly progressing disease. The G1L, coded as B6SJL-TgN(SOD1-G93A)1Gurdl 
(Gurney et al., 1997) expresses 8 predicted copies and develops latent and long 
duration disease with slow progression.   
The first clinical symptoms reported in G1H-G93A are the fine tremors in one or more 
limbs, which appear at approximately 90 to 100 days of age. From the limbic 
performance in almost all G1H SOD1-G93A mice, the appearance of the first muscle 
tremors occurs at about 100 days after bird, and finally the death occurs  approximately 
after 120 days.  Usually, in all GH1-G93A mice the neurological features,  that are 
limb muscle weakness and paresis followed by forelimbs paralysis towards the end 
stage with quadriplegia and death (Kato et al., 2005; Kato, 2008), are associated to 
profound degeneration of ventral root (VR), dorsal root (DR) and dorsal funiculus 
(DF). Furthermore, the number of ventral horn MNs  is usually decreased by 61,8%, 
when compared with non transgenic littermates (Guo Yan-Su et al., 2009). The 
neuromuscular junction shows the sign of degeneration around postnatal  day 47 (P47) 
(Pun et al., 2006) and proximal axonal loss is prominent by P80 in coincidence with the 
motor impairments observed in vivo. The neural degeneration seem to propagate in a 
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retrograde fashion, this means that proceeds from the proximal part of the 
neuromuscolar junction and proceeds towards the proximal axon, leading to the 
proposal that ALS may be a distal axonopathy, at least for lumbar MNs. Whereas the 
degeneration in VR, DR and DF are visible around 60 days (Guo Yan-Su et al., 2009). 
Traditionally, the hallmark of spinal MNs pathology  are mitochondrial vacuolization 
(Dal Canto and Gurney 1995), Golgi apparatus fragmentation (Mourelatos et al., 1996), 
neurofilament-positive inclusions (Tu et al.,1996) and cytoplasmic SOD1- 
immunoreactive aggregates. Spinal cord is also characterized by substantial 
astrocytosis and microgliosis around the time of disease onset (Hall et al., 1998) and 
the extensive microglia and astrocytes reaction usually proceed in a caudal to cranial 
direction (Leichsenring et al., 2006). The essential features of transgenic SOD1-G93A 
mice are summarized in Figure. 5  
 
Figure 6. Time course of clinical and neurophatological events in transgenic G1H-G93A mice. 
Symptoms onset occur at about 90 days of age, preceded by distal synaptic and axonal degeneration at 
the cellular level. Paralysis occurs 1 month later concomitantly to massive neuron  loss and reactive 
gliosis. At molecular level, mutant SOD1 aggregates into insoluble protein complexes (IPC) and 
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inclusion bodies modified by the ubiquitin-proteasome system (UPS), in parallel with a general 
subcellular degeneration within MNs (from Turner and Talbot, 2008). 
 
 
 
Table 4. (Turner and Talbot, 2008) 
 
Clinical onset in mice carrying lower numbers of genes copies ( i.e. G1L-G93A mice-
B6SJL-TgN(SOD1-G93A)1 Gur-dl) occurs at about P185 and death occurs after P250. 
This type of mice (G1L-G93A) examined at 90, 100, 120 and 250 days of age show 
only vacuolization pathology without significant neuronal loss or inclusion pathology. 
At P180 they show a slight decrease in the number of neurons, and at the terminal 
stage, there is a significant loss of anterior horn cells, with both inclusions and 
vacuolization pathologies (Kato S et al., 2005). Other anatomical studies have reported 
also axonal loss from ventral roots at 47 days of age and denervation of hind limb 
muscles (Frey et al., 2000) within the 90-day pre- symptomatic period. Higher numbers 
in the expression of transgene copies lead to a more aggressive pathogenic process. 
The most reasonable hypothesis is that the transgene copies which express the mSOD1 
enzyme cause a toxic effect on neuronal cells and when the number of transgene copies 
is higher the toxic effects on neuronal cells is amplified. 
 
 
ELECTROPHYSIOLOGICAL STUDIES  
 
The focus of my work is  the characterization of developing spinal networks in vitro 
(see below), with particular emphasis on the impact of SOD1 mutation on neuronal 
signaling during motor spinal network formation, before the ALS SOD1-related onset 
of MNs  degeneration. Ultimately, I have been interested in the impact of SOD1 
mutations in the maturation of spinal ventral circuits in general and in unmasking 
potential synaptic rearrangements which may contribute to the early-stage of SOD1 
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disease. The core of my work has been devoted to the electrophysiological 
characterization of synaptic networks located in the ventral spinal cord in vitro. 
Therefore I will summarize in the following paragraphs what we know on this issue 
from previous electrophysiological characterizations of spinal circuits in G93A SOD1 
models. These electrophysiological studies have been performed using different culture 
models, or acute preparations, isolated from ALS animal models. It is widely accepted 
that electrophysiological experiments are ideal tools to pursue further understanding of 
the interactions between the different cell types involved in this neurodegenerative 
disease and spinal network functions.  As stated before, a complex interplay of cellular 
pathologies accompanies the degeneration of spinal neurons in ALS, including 
glutamate toxicity, ROS production, mitochondrial dysfunction, deregulation of Ca2+ 
homeostasis and induction of pro-apoptotic pathways (Cluskey and Ramsden, 2001). 
Recent studies of G93A-SOD1 mice and rats suggest that oxidative damage is part of 
an unmitigated neuroinflammatory reaction, possibly arising in combination from 
mitochondrial dysfunction plus pathophysiologic activation of both astrocytes and 
microglia (Hensley et al, 2006). The integration of these processes creates a milieu 
inconsistent with healthy neural function. Although the involvement of these factors 
has been well established, their temporal and spatial interplay remains elusive. 
Distinguishing the primary from the secondary effects, or identifying any 
compensatory mechanisms, is of crucial importance to gain insights into adult-onset 
ALS. Disturbance of glutamate neurotransmission with glutamate-triggered Ca2+ entry 
appears an important initial step in neuronal degeneration. Spinal MNs receive strong 
and convergent glutamatergic inputs, they express Ca2+-permeable -AMPA receptors 
and have a low Ca2+ buffering capacity (Grosskrutz et al 2010). These characteristics 
are most likely crucial for leading MNs, functionally normal under physiological 
conditions, towards neurodegeneration under pathological conditions. Excitotoxicity 
occurs when the balance between release and reuptake of glutamate is disturbed, 
resulting in increased synaptic glutamate concentrations and excessive stimulation of 
glutamate receptors, which leads to increased intracellular free calcium concentrations, 
neuronal injury, and death (Heath and Shaw, 2002). MNs are extremely vulnerable to 
AMPA receptor-mediated excitotoxicity (recently reviewed by Bogaert et al. 2010) and 
we have shown that such a property is exacerbated in neurons from G93A-SOD1 mice 
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even at pre-symptomatic stages (Avossa et al. 2006). Exposure to ROS is sufficient to 
reduce uptake of glutamate through glutamate transporters on both glial and neuronal 
cells. Increased intracellular calcium levels have been measured in motor nerve 
terminals in ALS patients (Barber and Shaw, 2010) and mutant SOD1 mice (Siklos et 
al 1998). Increased calcium uptake into MNs mitochondria occurrs after exposure to 
AMPA or kainate and triggers an increased ROS generation (Carriedo et al.2000). 
AMPA/kainate-treated MNs releas ROS into the extracellular milieu at concentrations 
sufficient to induce oxidation and to disrupt glutamate uptake in neighboring 
astrocytes, thus creating a vicious cycle of increasing oxidative stress and 
excitotoxicity that ultimately leads to MNs degeneration (Grosskreutz et al, 2010). 
One of the most striking characteristics of ALS is the selectivity of the disease process 
for MNs. This selectivity is also illustrated by the fact that mostly MNs degenerate in 
mutant SOD1-associated fALS despite the over-expression of the mutant protein in 
every cell. Intrinsic or network related properties of MNs could explain this high 
sensitivity to excessive stimulation of glutamate receptors. Besides alteration in the 
glutamatergic signaling, development of MNs degeneration in ALS could be preceded 
by a period of excitatory disturbance in local spinal circuits. Patch-clamp recordings 
from neurons in acute G93A mice brainstem slice preparations recently unmasked the 
presence of membrane hyperexcitability, increased sodium currents and enhanced 
frequency of synaptic transmission in both MNs and interneurons (van Zundert et al 
2008). Intriguingly, these functional changes in neuronal activity are present in 
neonatal mice before MNs degeneration or appearance of symptoms. Similar results 
have been obtained in neonatal organotypic spinal cord slice cultures and in embryonic 
primary spinal cord cell cultures (Kuo et al, 2003), indicating that increased membrane 
excitability is an intrinsic property of G93A neurons and not the result of cell culturing. 
In this paragraph I will overview what is known about the SOD1 G93A mouse model 
from an  electrophysiological point of. For the sake of simplicity, I will describe the 
experiments based on the in vitro model adopted: primary dissociated cultures, spinal 
slices and entire spinal cord preparations because the interpretation of the different data 
obtained may be subjected to differences depending on the model used.  
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In a series of experiments using  in vitro brainsteam/spinal cord isolated from postnatal 
SODG85R mice, Amendola et al. (2004) observed, much earlier than previously 
recognized, that is large before the appearance of ALS symptoms, the impairment of 
the lumbar spinal motor system. In these studies, co-application of NMDA and 
serotonin (5-HT), at concentrations that in WT mice induce alternate rhythmic motor 
outputs (named fictive locomotion), were not effective in inducing fictive locomotion 
in transgenic isolated lumbar tracts. These authors showed that lumbar roots only rarely 
displayed transient burst activity, being in most cases silent. On the contrary the sacral 
network activation (S1-S3) induced by NMDA and 5-HT showed similar rhythmic 
activities in all sacral roots recorded from WT and SOD1G93A mice. These results 
shows that the early abnormalities may localize in lumbar segment (L3-L6) where 
MNs degenerate massively during the disease. It was demonstrated in the pre-
symptomatic mice SOD1G93A a progressive loss of a glial potassium channels 
(KCNJ10) members of the inward rectifier-family. The loss of the KCNJ10 channel in 
glial cells may lead to an increased extra cellular potassium concentration which could 
contribute to the increased excitability and thus contributing to the excitotoxic cascade. 
Other studies revealed, via single cell recordings, the expression of early 
hyperexcitability in SOD1G93A spinal MNs mainteined in dissociated or in 
organotypic cultures isolated from embryonic spinal cords (Pieri et al., 2003a; Kuo et 
al., 2004, 2005). In these experiment un up-regulation of persistent inward currents 
(PIC) emerged. Persistent inward current has been suggested to play a crucial role in 
the phatogenesis of ALS presumably at early stages of embryonic and post natal 
development. This current is composed of PCNa and L-type Ca2+ currents and could 
affect neuronal firing profile (Lee and Heckman, 1998; Heckman et al., 2003). Data 
from these studies suggested that mutant SOD1 cells were characterized by enhanced 
intrinsic excitability leading to a marked increase in slope of the F-I relationship and 
lower initial and final spike threshold on the ascending and descending phases of a 
current ramp protocol.  Figure 6. 
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Figure 7. Increase in slope of the F-I relationship and lower initial and final spike threshold 
(black dots G93A and white dots WT) on the ascending and descending phases of a current 
ramp protocol in transgenic SOD1G93A cultures (Kuo et al., 2000) 
 
However, despite the increase in neuronal excitability, the author could not document 
any evidence suggesting ongoing changes in MN passive properties like input 
resistance, resting membrane potential and capacitance. In a further investigation, Zona 
et al., (2006) reported a faster recovery from inactivation of voltage-gated Na+ current 
in organotypic cultured MNs of 15 days old SOD1G93A embryos when compared to 
control WT ones. The faster recovery from the inactivated states (Figure 7) allows to 
MNs to generate a higher number of action potentials (AP) (Figure 7), and since Na+ 
current regulates MN responses, such as firing activity during persistent stimuli, a 
faster recovery from inactivation allows MN to sustain higher firing frequencies, 
contributing to the several pathological pathways, based on neuronal hyper excitability, 
proposed in MNs degeneration (Cleveland and Rothstein 2001; Hand and Rouleau 
2002; Wong et al., 2002). 
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Figure 8. A: Higher firing APs frequency in G93A organotypic cultures following current 
injection  B: visible even from plot. C: The faster recovery from the inactivated states allow 
the generation of higher number of action potentials therefore higher APs frequency (Pieri et 
al., 2009) 
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The hyper-excitability showed by Zona et al are in accordance with the results found 
previously by Pieri et al., (2003). In fact, these authors showed that MNs isolated from 
SOD1G93A (E15) have an unusual increase in excitability that could be caused by a 
reduction of action potential (AP) duration (Fig 8) 
 
 
 
Figure 9. Higher frequency in G93A MNs when compared to hSOD1 not mutated cultures 
(top) which could be due to a shorter APs duration in G93A MNs (bottom) following faster 
recovery from inactivated states (Figure 7 C) (Pieri et al., 2003) 
 
However, additional studies performed by Bories et al. (2007) showed conflicting 
results with those conducted by Zona et al. (2006). Boris et al. found that, in 
SOD1G85R lumbar MN (postnatal 6-10 days), the F-I slope was steeper in control 
WT, rather than in SOD1 mice In fact, the G85R MN showed hypo-excitability 
characterized by a lower firing frequency in G85R MN when compared to WT MNs 
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(see Figure 8B)  and displayed a mean input resistence significantly lower. 
 
Figure 10.  Contrary other studies showed lower excitability in G85R MNs following current 
injection A: WT and B: G85R. C: Is necessary higher current for generation of the firing 
frequency, D: shows the difference in excitability of spinal neurones compared to MNs in WT 
and G85R cultures. (Cyril et al., 2007) 
 
This result could be indicative of morphological changes, e.g. larger soma or larger 
dendritic extension, and the decrease in input resistance could simply emerge from 
higher leak channel density. This difference seems to be MN specific, since it was not 
detected in spinal interneurons, recorded from the same preparation (Boris et al., 2007). 
However, in this case no differences were found in shape and duration of AP in  
contrast to previous (Zona et al. 2006; Pieri et al., 2003). Great attention was also paid 
to the glutamatergic AMPA –type, glutamate ionotropic receptors. A recent work from 
Spalloni et al. (2004) indicated that, in the SOD1G93A mouse model, the mutation 
may affect the subunit composition of the AMPA receptors expressed in cultured MNs. 
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Spalloni et al. (2004) have shown that in primary dissociated cultures derived from 
transgenic mouse (E15) MNs showed an increased vulnerability to kainic acid and 
AMPA-induced excitotoxicity, at concentrations as low as 25 µM and 10 µM, 
respectively.  Spalloni et al. (2004) reported the presence of more flip subunit isoform 
(Fi)  in AMPA receptors expressed in cultured G93A MN and such isoform are 
characterized by a slower desensitization and consequently have been associated with 
more current entry then the flop subunit isoform (Fo) (Sommer et al., 1990; Mosbacher 
et al., 1994; Lambolez et al., 1996). In an additional study (Pieri et al., 2003b), AMPA 
receptor permeability to a specific ion species like Na+ and K+, together with the 
membrane conductance of G93A MNs, displayed larger values than WT ones. 
Permeability to single species, after comparing activation of AMPA receptors in G93A 
MNs to controls, displayed significant reduction for Ca2+, whereas kainic acid-
activated membrane permeability to monovalent ionic species, such as Na+ and K+, in 
G93A cells was significantly higher.  In addition, miniature excitatory post-synaptic 
current (mEPSC) recorded in G93A MNs were found to be markedly slower than those 
recorded from WT cells, both in rise time and in decay phase (Pieri et al., 2003b). In 
accordance with these and other data (Spalloni et al., 2004; Kawahara et al., 2006; 
Boillèe et al., 2006), the MN degeneration is not a direct consequence of the high 
permeability of AMPA receptors to Ca2+ ions caused by the loss of GluR2 subunit 
(which determine the loss of Ca2+permeability of the AMPA receptors) or due to 
GluR2editing , rather, it may result from an increase in the activation of voltage-gated 
Ca2+ channels following the grater depolarizing current brought about by activation of 
these receptors. An increased Na+ influx trough AMPA receptors could also activate 
the Na+-Ca2+ exchanger, leading to further rising of Ca2+ within MNs.  More recently, 
much attention has been given to the inhibitory component. In fact, many authors have 
postulated the hypothesis  of a morphological and/or physiological synaptic 
rearrangement between excitatory and inhibitory transmission in spinal circuits 
involved in ALS desease (Plaitakis, 1990; Zanette et al., 2002; Schutz, 2005). It is very 
important to investigate both inhibitory and excitatory synaptic transmissions to 
understand better the circuits operation and therefore to understand how the SOD1 
mutation may cause the MN degeneration in ALS disease. We recently explored this 
intriguing aspect in Avossa et al. (2006). The core idea was that in the immature spinal 
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cord, genetically predisposed to cell death, the expression of the mutated SOD1 might 
impact the proper development of ventral circuits in a subtle fashion, posing the 
functional bases for compromising, in the long term, motoneuron viability. In Avossa 
et al (2006) we used the organotypic co-cultures developed from SOD1G93A 
embryonic mice (E12.5). Using transmission electron microscopy (TEM) we analysed 
the synaptic morphology in transgenic mice and WT. The TEM analysis were restricted 
to the ventral horn area. Within this area, we investigated the morphology and 
organization of the intracellular structures that have been shown to develop 
abnormalities in pre-symptomatic stage. 
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Figure 10.  Ultrastructural analysis of G93A cultures show a higher ration 
Inhybitory(simetric)/excitatory(assimetric) synapses when compared to WT (Avossa et al., 
2006) 
 
In Avossa et al. (2006) we reported a significantly increased ratio between inhibitory 
and excitatory synapses, together with a significant enlargement in the size of 
excitatory synapses (Figure 10). In the same preparations, we did notdetect the 
presence in SOD1G93A cultures, of cytoplasmatic vacuolization or of electrondense 
precipitates, or signs of mitochondrial swelling and enlargements, and MNs density 
was comparable to that of WT spinal slices (Figure 11.) indicating that the synaptic 
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rearrangement seen on TEM may represent the very first sign of network de-
arrangement observed in SOD1G93A tissue so far. 
 
 
Figure 11. Comparison of number, morphology and distribution of MNsin G93A ans WT.  No 
difference was shown between WT and G93A during on vitro growing at 8, 14 and 21DIV 
(Avossa et al., 2006) 
 
In a recently work Carunchio et al. (2008) analysed the physiological properties of 
GABAA receptors. These receptors presented higher affinity to the agonist together 
with a lower desensitization rate supported even by the immunoistochemical finding of 
a higher α1 subunits expression, when compared with control MNs (Carunchio et al., 
2008). The higher Cl- influx trough these GABAA receptors may play a role in the 
processes leading to MN injury. An increase in both inhibitory and excitatory 
spontaneous synaptic transmission was reported in hypoglossal MNs and superior 
cuniculus interneurons, in a study recently conducted on acute slices isolated from wild 
type and hSOD1G93A mice (van Zundert et al., 2008). These results have been 
interpreted as an attainment of a homeostatic balance in opposing synaptic activities to 
actively compensate for generalized neuronal hyperexcitability. These findings further 
strengthen our results. In Avossa et al. (2006) we showed that MNs from G93A 
cultures display an increased vulnerability to AMPA-mediated excitotoxicity when 
compared to WT cultures. This increased sensitivity to excitotoxic stimulis may 
indicate that the observed synaptic rearrangement  is linked to an improved 
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predisposition excitotoxic vulnerability in transgenic cultures when compared to WT 
ones.  
 
In conclusion, due to the complexity of ALS pathophysiology to understand the impact 
of SOD1 mutation to motor circuit development and synaptic balance in the spinal cord 
might be extremely relevant. Therefore new clues need to be provided to precisely 
rebuild the sequence of early events which occur within MNs and non-neuronal cells 
during early stages of circuit formation in ALS genetic models. Given the wide parade 
of mechanisms potentially involved, the experimental advantages of studying 
dissociated cultures may be limited by oversimplification of the system. In fact, quite 
often, dissociated neuronal cultures used in ALS research comprise pure MN and/or 
glial co-cultures, depending on which cell types are isolated and then maintained in 
opportune growth conditions. Co-cultures, in which MNs are growth on a glial feeder 
layer, can be considered an intermediate solution between monoculture, in which 
isolated MN grow, and the entire slices of explanted tissue.  
Organotypic cultures are substantially different from other cultures (mono and co-
cultures), in fact they consist of whole slices of tissue explanted and maintained in long 
term in vitro conditions. In such cultures the MNs are maintained in their normal 
environment condition, so retaining the cytoarchitecture and the dynamism of the 
explanted tissue, hence the name “organotypic“ (Gähwiler et al., 1997). 
 
ORGANOTYPIC SLICE CULTURES AS A TOOLS FOR INVESTIGATION OF 
SPINAL NETWORK OPERATION 
 
Organotypic slice cultures developed from CNS represent a very important tool for 
studying physiological and pharmacological properties of neuronal circuits, since they 
provide high experimental access to individual neurons, with the preserved original  
cytoarchitecture of the explanted tissue (Braschler et al., 1989). Moreover, they offer 
the advantage of being long-term in vitro preparations, in respect of acutely prepared 
slices, and this feature is relevant to perform experiments that involve observing the  
development of neuronal connectivity, chronic applications of drugs, chronic 
interference  with normal developmental cues or alterations in gene expression by viral 
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vectors, all  instances requiring long-term survival (Gähwiler et al., 1997). For these 
peculiar features organotypic cultures have become an essential tool for the work of 
many researchers. Animals at different ages are chosen in accordance to the CNS 
specific area from which organotypic cultures are developed. In general, neuron 
survival is longer when embryos or neonates are employed instead of more aged 
animals, whose slices suffer more  frequently of necrotic events; however, the best 
choice for each tissue is often empirically determined. Cultures can be maintained in 
dynamic or static conditions. The Maximov culture and interface culture (Stoppini et 
al., 1991) techniques, in which slices are incubated stationary, yield organized tissue 
cultures which remain many cell-layer thick, even after prolonged time of incubation 
(Gähwiler, 1984), while  the roller-tube technique (Gähwiler, 1981) is a suitable 
method to obtain remarkable  spreading and flattening of slices after few weeks in 
vitro, in fact individual neurons are  often arranged in a monolayer, so that they can be 
visually recognized by their  morphology. The flattening is a requirement for favoring 
electrophysiological experiments, besides immunohistochemical or microscopy 
studies. In addition to this, rotation allows a continuous alternation of nutrient medium 
and air above the slices, guaranteeing in this way the right oxygenation of the tissues 
(Gähwiler et al., 1997).  Overall, the roller-tube technique permits to the organotypic 
cultures to survive for 4  weeks or even more, while slices statically cultured have to be 
used within few days after  their preparation (Gähwiler et al., 1997). Organotypic slice 
cultures may be prepared from different region of the CNS. Hippocampus, thalamus, 
cerebellum, cerebral cortex, retina and spinal cord slice cultures are those better 
characterized. 
 
 
ORANOTYPIC SLICE CULTURES DEVELOPED FROM THE EMBRYONIC 
MOUSE SPINAL CORD 
 
Organotypic slice cultures allow direct experimental access to spinal microcircuits. 
This  preparation has been used in neuroscience research for a long time (Crain & 
Peterson,1963; Braschler et al., 1989; Streit et al., 1991; Gähwiler et al., 1997; 
Ballerini & Galante,1998; Galante et al., 2000) and represents a useful model for 
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studying the dynamics of intra-segmental maturation processes relying on 
propriospinal neurons and circuits (Avossa et al., 2003; Rosato-Siri et al., 2004; Furlan 
et al., 2005; Fabbro et al., 2006;  Furlan et al., 2007). In fact, despite the absence of 
afferent and supraspinal inputs, which are important for the development of spinal 
circuits (Harris-Warrick and Marder, 1991; Nusbaum et al., 2001; Branchereau et al., 
2002), in this preparation the ontogeny and functional development of classes of 
interneurons, such as the GABAergic ones, observed in vivo (Antal et al., 1994; 
Barbeau et al., 1999; Gao et al., 2001; Tran et al., 2003) is maintained (Avossa et al., 
2003; Furlan et al., 2005; Furlan et al., 2007). In these cultures many spinal cord cell 
types are present, and spontaneous neuronal activity  develops in a manner reminiscent 
to that observed in vivo (Avossa et al., 2003; Rosato-  Siri et al., 2004; Furlan et al., 
2007). The organotypic spinal slices basic cytoarchitectural organization, synaptic 
connections and the dorsal-ventral orientation of the original explanted tissue have 
been reported (Ballerini & Galante, 1998; Ballerini et al., 1999; Galante et al., 2000; 
Avossa et al., 2003; Rosato-Siri et al., 2004; Furlan et al., 2005, 2007).  In the mouse 
spinal cord, network activity is known to undergo several changes during circuit 
maturation (Branchereau et al., 2002; Hanson and Landmesser, 2003; Whelan, 2003). 
One peculiar feature of developing spinal circuits is the transient generation of 
spontaneous activity, typically organized into synchronous bursts or episodes, 
characterized by simultaneous activation at different spinal levels, separated by 
quiescent periods (Kudo et al., 1991; O’Donovan, 1997, 1998). This spontaneous 
synchronous activity tends to be lost upon maturation of embryonic spinal networks. 
These changes have also been shown to occur in co-cultured organotypic spinal cord 
and muscle explants (Rosato-Siri et al., 2004).   
Rosato-Siri et al. (2004) reported that at early stages of development in vitro (1 week 
of in vitro growth, 1 WIV), ventral interneurons generated spontaneous bursting 
activity well correlated with muscle contractions, while at later stages of motor 
network maturation (2 and 3 WIV) this activity disappeared in most of the recorded 
neurons and, when still present (i.e. 20-30% of recordings), bursts displayed shorter 
duration with high frequency firing and, more importantly, they were no longer 
correlated with muscular contractions (Rosato-Siri et al., 2004). This activity and its 
evolution in older cultures (at 2 and 3 WIV; corresponding to maturational phases 
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before and immediately after birth), was similar in terms of frequency, duration and 
dependence on glutamatergic synaptic transmission, to spontaneous bursting activity 
described in the entire mouse spinal cord preparation at similar embryonic and 
postnatal ages (Branchereau et al., 2002; Hanson and Landmesser, 2003; Whelan, 
2003).  Another important feature expressed during spinal circuit development is the 
role played by GABA-releasing interneurons that control wiring and network 
excitability within a restricted spatiotemporal window preceding birth (Caserta and 
Barker, 1994; Somogyi et al., 1995; Nishimaru et al., 1996; Gao et al., 2001; 
Nakayama et al., 2002; Allain et al., 2004, 2006). In fact, the action of GABA during 
development is often excitatory until shortly before birth. At this stage of prenatal 
development, GABA-mediated excitation is replaced by synaptic inhibition mediated 
by glycine and/or GABA itself (Barbeau et al., 1999; Gao et al., 2001; Branchereau et 
al., 2002; Hanson and Landmesser, 2003), with  surviving GABAergic neurons 
predominantly located in the dorsal horn (Phelps et al., 1999; Tran et al., 2003). In this 
context, Rosato-Siri et al. (2004) reported that at 1 WIV, the pharmacological and 
reversible block of both GABA and glycine receptors mediated currents by applying 
bicuculline and strychnine, did not appear to limit either burst duration or frequency, 
while at more developed stages (2 and 3 WIV), GABA and glycine receptor activity 
appear to have an inhibitory role, as their pharmacological block invariably induced 
synchronous bursting in preparations that did not burst spontaneously and prolonged 
the duration of spontaneous burst in the minority of preparations where bursting was 
still present (Rosato-Siri et al., 2004), as it was reported to occur in the entire spinal 
cord preparations (Wu et al., 1992; Gao et al., 2001). These results are supported by 
Avossa et al. (2003), who reported an appropriate spatiotemporal pattern of expression 
of the (GABA synthesizing enzyme) glutamic acid decarboxylase (GAD) positive 
interneurons, in organotypic cultures from embryonic mouse spinal cord. These authors 
observed a progressive decrease in GAD expressing cells from earlier stages of 
development (8 DIV, days in vitro) to older cultures (14 and 21 DIV). This temporal 
pattern was associated with a differential spatial distribution of GAD-labeled neurons, 
with positive neurons becoming increasingly restricted to the dorsal horn regions 
during the following 2 and 3 WIV, as it was reported to happen in vivo. Five different 
types of ventral interneurons in organotypic slices can be identified on the basis of their 
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discharge patterns (Prescott and Koninck, 2002; Szucs et al., 2003; Theiss and 
Heckman, 2005; Lu et al., 2006; Furlan et al., 2007): a) ‘tonic’ cells, that fired APs 
without apparent accommodation; b) ‘adapting’ cells, that discharged an early burst of 
APs followed by adaptation; c) ‘delay’ cells, that generated APs after a lag; d) 
‘irregular’ cells without discernible discharge patterns; e) ‘transient’ cells, that 
generated a single AP only. Interestingly, the distribution of the five neuronal classes is 
maturation-dependent, in particular, the firing properties of the majority of ventral 
recorded cells changed from ‘adapting’ at early embryonic ages to ‘tonic’ later in 
development (Furlan et al., 2007). Such changes occurred in coincidence with the 
critical transformation of spontaneous activity from bursting to sporadic discharges 
(Rosato-Siri et al., 2004; for review Whelan, 2003). Furlan et al (2007) 
electrophysiological and immunocytochemical results strongly suggest that the 
‘adapting’ cell type at early embryonic stages of development could be mainly 
identified as the GABAergic phenotype.   
The ontogeny of inhibitory transmission in the spinal tissue is intriguing because of the 
temporal delay before the appearance of GABAergic and glycinergic inhibition (Antal 
et al., 1994; Barbeau et al., 1999; Gao et al., 2001; Tran et al., 2003; Nabekura et al., 
2004; Allain et al., 2006). In the embryonic spinal cord, glycine progressively becomes 
the dominant force in driving more mature patterns of activity, such as co-ordinated 
locomotor-like bursts (Bonnot et al., 1998; Whelan et al., 2000). GABAergic 
interneurons appear to control the occurrence of spontaneous activity which, although 
not locomotor in nature, is seemingly necessary for normal motor network 
development (Barbeau et al., 1999; Gao et al., 2001; Moody and Bosma, 2005). It is 
likely that evolving changes in GABAergic transmission require fine-tuning in GABA 
release, probably via certain intrinsic mechanisms regulating GABAergic neuron 
excitability at different embryonic stages. Furlan et al., (2007) examined the role of the 
ERG current [IK(ERG)], a potassium conductance expressed by developing, GABA-
immunoreactive spinal neurons (Furlan et al., 2005). In organotypic cultures, only 
ventral interneurons with fast adaptation and GABA-immunoreactivity, and only after 
one week in culture, were transformed into high frequency bursters by E4031, a 
selective inhibitor of IK(ERG), that also prolonged and made more regular 
spontaneous bursts. In the isolated foetal spinal cord in which GABA- 
 75 
immunoreactivity and m-erg mRNA were co-localized in interneurons, ventral root 
rhythms evoked by NMDA plus 5-HT were stabilized and synchronized by E4031 
(Furlan et al., 2007). All these effects were lost after two weeks in culture or before 
birth in coincidence with decreased m-erg expression. These data suggest that E4031 
facilitated firing of certain GABAergic interneurons to recruit network neurons in a 
more coherent pattern. Lack of discharge alternation, however, indicated that neither 
before nor after applying E4031, there was electrophysiological evidence for synaptic 
inhibition mediated by GABA (Whelan, 2003; Kiehn, 2006). Accordingly, the time-
dependent expression of ERG channels would be down-regulated once GABA 
becomes inhibitory (Furlan et al., 2007). These studies, although largely limited to in 
vitro model systems, are the first correlating GABAergic expression profile with its 
discharge patterns and with global spinal segment activity during embryonic stages of 
development.  
  
Hence, the key features of organotypic slice cultures developed from embryonic mouse 
spinal cord, as inferred from reported data, can be resumed as follow:  
1) the circuit in the explants undergoes appropriate maturational processes during 
the first 3 WIV, the normal presence and distribution of anatomically distinct 
classes of neurons and glial cells being preserved (Avossa et al., 2003; Furlan et 
al., 2005; Furlan et al., 2007);   
 
2) the minimal circuit preserved in this type of preparation has been shown to 
replicate some of the basic patterns of activity generated by the entire spinal cord 
in vitro (Rosato-Siri et al., 2004);  
 
3) cultured explants contain clusters of MNs which develop functional muscular 
junctions with cocultured muscle tissue (Avossa et al., 2003; Rosato-Siri et al., 
2004).   
 
From these considerations clearly emerged that organotypic spinal cultures are indeed a 
valid in vitro model to investigate the dynamics of spinal circuits during maturation, 
besides phenomena like the mechanisms of neurogenesis, glial differentiation, 
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myelination, muscle formation and synaptogenesis.  
 
AIMS 
 
 
ALS may emerge from a complex interplay between genetic factors, oxidative stress, 
glutamatergic excitotoxicity, damage to vital organelle and aberrant protein 
aggregation. Yet, due to the widespread expression of the SOD1 gene (Crapo et al., 
1992), it is unclear why a SOD1 abnormality should selectively affect MNs. If we want 
to understand the timing and selectivity for MNs  killing, it is relevant, also in terms of 
future therapeutic strategies, to identify the initiating processes. This may be achieved 
by combining experimental strategies such as the development of in vivo disease 
models and in vitro cell culture. Spinal tissue cultures, where complex communication 
systems and physiological cell−to−cell interactions are preserved are particularly 
useful to unmask early functional aberration in a pre−symptomatic phase. In the last 
years, we successfully developed organotypic slice cultures from embryonic spinal 
cord isolated from wild type and from the G93A SOD1 transgenic mouse model of 
ALS (Avossa et al., 2006). Using this culture system we have shown that constitutive 
properties of G93A motor neurons are not responsible for facilitated death of these 
cells under control culture conditions (Avossa et al., 2006). In the same report we 
showed that in organotypic G93A spinal cultures, at a time point where there are no 
signs of ongoing MNs degeneration, it is possible to unmask an increased MNs 
susceptibility to excitotoxic stimuli. This suggests the presence of environmentally 
determined triggers activating cell death in transgenic tissue. 
Interestingly, we also reported, by TEM, the presence of a significant synaptic 
rearrangement expressed by G93A cultured spinal cord, which may emerge in G93A 
spinal networks from altered synaptic function (Avossa et al., 2006). 
In my project I exploited the newly developed fALS in vitro model system to 
investigate relevant spinal network properties of control WT tissue with those of 
mutant mouse organotypic cultures. The successful development of long-term cultures 
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from a genetic model of MN disease is a key requirement to investigate chronic 
interference with normal protective cues and long term effect of toxic treatments. Our 
model system is ideally suited to assess synaptic transmission or neuronal activity. The 
novel aspect of this model is represented by the possibility to test on healthy spinal 
MNs, genetically predisposed to cell death, the interplay among stress conditions and 
motor circuits’ activity in an in vitro system integrated by glial cells. Synaptic 
rearrangements such as the described unbalanced expression of symmetric vs 
asymmetric synapses in G93A cultured tissue (Avossa et al., 2006), may indicate that 
functional changes in synaptic transmission predate morphological alterations in vitro. 
Notably, organotypic slice cultures allow direct experimental access to spinal 
microcircuits. This preparation has been used in neuroscience research for a long time 
(Crain & Peterson, 1963; Braschler et al., 1989; Streit et al., 1991; Gähwiler et al., 
1997; Ballerini & Galante, 1998; Galante et al., 2000) and represents a useful model 
for studying the dynamics of intra-segmental neuronal maturation (Avossa et al., 2003; 
Rosato-Siri et al., 2004; Furlan et al., 2005; Fabbro et al., 2007; Furlan et al., 2007; 
Sibilla et al., 2009). In fact, despite the absence of afferent and supraspinal inputs, 
which are important for the development of spinal circuits, in this preparation the 
ontogeny and functional development of classes of interneurons, such as the 
GABAergic ones, observed in vivo is maintained (Avossa et al., 2003; Furlan et al., 
2005; Furlan et al., 2007). Several lines of experimental evidence support that 
functional evolution in vitro may proceed in accordance with the conditions expected 
to occur in vivo. First, discharge patterns in cultured ventral neurons evolve like those 
found in acute spinal slices taken at different postnatal ages (compare Furlan et al., 
2007 to Szucs et al., 2003 and to Theiss & Heckman, 2005). Second, ERG channel 
expression by GABAergic interneurons in culture is very similar to the one of the 
embryonic spinal cord (Furlan et al., 2005; 2007). Third, the changes in synaptic 
properties occurring in the spinal cord isolated at different embryonic ages are also 
found in cultured organotypic slices (Rosato-Siri et al., 2004; Furlan et al., 2007) as 
well as in the entire cultured spinal cord (Branchereau et al., 2002). 
The development of motor networks in the spinal ventral horn into functional circuits is 
a complex process comprising genetic and epigenetic mechanisms 
 78 
cooperating for the maturation of motor control (Kiehn, 2006). In the immature spinal 
cord, genetically predisposed to cell death, the expression of the mutated SOD1 might 
impact the proper development of ventral circuits in a subtle fashion, posing the 
functional bases for compromising, in the long term, MNs viability. 
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Experimental procedures 
 
 
PREPARATION OF THE ORGANOTYPIC SPINAL CULTURES 
 
In the present thesis work I have employed the organotypic cultures developed from 
slices of the spinal cord and dorsal root ganglia (DRG)isolated from SOD1G93A and WT 
embryonic mice. Spinal slice cultures were maintained with the dynamic technique 
(Gähwiler, 1981) where cultures are incubated in continuous rotation in a roller-tube. 
This dynamic modality allows a progressive spreading and flattening of the tissue, and 
it was reported first by Gähwiler (1981). The following short paragraphs describe in 
details the main steps of the culturing procedure. 
 
MOUSE LINES AND BREEDING STRATEGY 
 
Transgenic mice expressing a high copy number of the glycine 93 to alanine mutation 
of the hSOD1 gene (B6SJL-TgN(SOD1-G93A)1Gur; Gurney et al., 1994) and non-
transgenic females (B6SJLF1) were purchased from the Jackson Laboratories (Bar 
Harbor, ME, USA). Hemizygous carriers male were bred to F1 hybrid females 
(C57BI6XSJL) and offsprings were identified by polymerase chain reaction (PCR). 
The non transgenic G93A littermates (WT) were used as negative control for the 
genetic background. 
 
GENOTYPING 
 
For PCR analysis, genomic DNA was isolated from tails or from heads (adult and 
embryos, respectively) by adding 0.5 mL of proteinase K diluted in tail buffer (0.6 
mg/mL) and then incubating for at least 2 h in a termomixer set at 55° C and 1200 rpm. 
This procedure assures digestion of the tissues. The further addition of 500 µl of 
phenole while centrifuging at 12000 rpm for 10 min, allows the extraction of DNA. 
Then 200 µL of this solution containing DNA, was transferred to another eppendorf 
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and after add of absolute ethanole (EtOH, 400 µL), centrifuged for 5 min at 12000 rpm, 
to allow precipitation of the nucleic acid. After a wash in 600 µL of EtOH 70%, the 
samples were newly centrifuged at 12000 rpm for 5 min, then EtOH was removed and 
DNA samples were solved in 200 µL of sterile water. The following primer pairs for 
PCR were used: 5’-CAT CAG CCC TAA TC ATC TGA-3’ and 5’-CGC GAC TAA 
CAA TCA AAG TGA-3’, which amplifies a 236 bp product from exon 4 of the SOD1 
gene within the transgene construct; 5’-CTA GGC CAC AGA ATT GAA AGA TCT-
3’ and 5’-GTA GGT GGA AAT TCT AGC ATC ATC C-3’, which amplifies a 324 bp 
product of the endogenous interleukin 2 gene, used as positive control for DNA 
amplification using the PCR. 
 
PCR GENE AMPLIFICATION 
 
MIX Solution for each sample: 
 
11,6 µL - H2O 
2 µL - 10x RedTaq PCR Reaction Buffer (SIGMA cod. B5926) 
0,4 µL - Deoxynucleotide Mix (dNTPs) stock (10mM) (SIGMA cod. D7295) 
1 µL per each primers (see above for primers sequence) (SIGMA)* 
1 µL – RedTaq DNA Polymerase (SIGMA cod. D4309) 
1 µL – DNA extracted 
 
*The primers stock solution is at 100 µM (stored at -20 C°) and were diluited 1:10 in 
deionized H2O before using 
The total MIX solution for each PCR eppendorf are 20 µL 
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Electrophoresis 
Agarose gel (1%): 
1,5 gr - Agarose (SIGMA cod. A9539) 
150 mL - of TBE solution 0,5 N 
5 µL – Ethidium bromide   
Power supply calibrated at 120 V for 40-50 min 
 
 
 
PCR program (cycle 3x): 
 
1 94 C° (5 min) 
2 94 C° (1 min) 
3 65 C° (1 min) 
4 72 C° (1 min) 
5 29 C° times to 2 
6 72 C° (8 min) 
7 4 C°  
8 end 
 
 
EXPLANTATION 
 
The organotypic slice cultures of spinal cord and DRGs were prepared from mouse 
embryos at E12-13 of gestation. The pregnant mouse was anesthetized and afterwards 
sacrificed by cervical dislocation. This procedure is in accordance with the regulation 
of the Italian Animal Welfare Act, with the relevant EU legislation and guidelines on 
ethical use of animals and is approved by the local Authority Veterinary Service. We 
considered the first embryonic day (named E1) day one after mating. The embryos 
were extracted by caesarean section and left in their amniotic sacs, in a Petri dish 
containing Gey’s balanced salt solution (GBSS, in mM; CaCl2 (2H2O) 1,49; KCl 4,97; 
KH2PO4 0,22; MgCl2 (6H2O) 1; MgSO4 (7H2O) 0,28; NaCl 137,87; NaHCO3 2,7; 
Na2HPO4 0,84; glucose 5,55. The pH is 7.40 and the osmolarity 296 mOsm).   
From this point on the dissection was performed under the laminar flow hood in 
sterile conditions and under microscope (Olympus SZ40) control. The fetuses were 
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freed from their amniotic sac and put into a new Petri dish with fresh GBSS at 4C°. 
They were decapitated and their legs, tails and abdomen removed (Figure 1). The 
isolated backs of the embryos were cut into 275 µm thick transverse slices with a tissue 
chopper (McIlwain) (Figure 2 at 0 DIV) and put into a Petri dish with GBSS. Slices 
were chosen from the low thoracic and high lumbar level (Figure 1). They were 
cleaned from the rest of the tissues to leave only the spinal cord with the two DRG 
attached and then transferred into a new Petri dish with GBSS and maintained at +4°C 
for 1 hour.  
 
 
 
EMBEDDING AND INCUBATION 
 
After 1 hour, single slices were placed into a drop (20 µL) of reconstituted chicken 
plasma (CHINE PLASMA on a glass coverslip. Plasma was then coagulated by 
addition of a drop (30 µL) of thrombin (Sigma) to keep the slices in place. After 30-45 
min, to allow stabilization of the coagulum, the coverslips were placed into plastic 
tubes (Nunc) filled with 1 mL of fresh medium and immediately put in a roller drum, 
which rotates at approximately 120 rph, contained in an incubator. Rotation is essential 
for feeding, aeration and flattening of the cultures. In fact, slices are submerged in 
medium during half a turn and covered with a film medium for the other half. Cultures 
were kept at 36,5°C in the presence of humidified atmosphere, with a concentration of 
5.2% CO2. In this conditions organotypic cultures can be maintained for 4 weeks or 
more. Experiments were performed on WT and G93A sister cultures during the first 3 
Figure 1.The figure shows an example of an 
embryo at 12-13 days of gestation (E12-13).  The 
three dashed lines shows the area where the cut is 
applied to isolate the low thoracic and high lumbar 
region of spinal cord from the rest of embryo. 
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weeks of culturing. Lyophilized thrombin (Sigma-Aldrich) is diluted in distilled water 
(200 u/mL). Prior to use glass coverslips (12x24 mm, thickness 1,2 mm, Vitromed) are 
treated as follows: inserted into a teflon holder, submerged in hydrochloric acid 0.5 N 
for 24 h, then repetitively washed with distilled water and leaved in absolute alcohol 
for 30 min. Then coverslips are dried and sterilized at +120°C in an oven over night. 
 
 
 
MEDIUM AND MEDIUM CHANGE 
 
 
The standard medium consists of: 67% Dulbecco’s modified Eagle’s medium 
(Invitrogen, Italy), 25% fetal bovine serum (FBS, Invitrogen), 8% sterile water for 
tissue culture (Invitrogen), 5 ng/mL nerve growth factor (NGF, Almone, Israel) diluted 
in Hanks and BSA (1 mg/mL). The pH is 7,35 and osmolarity 300 mOsm. Hank’s 
solution contains (mM): CaCl2 2H2O 1,26; KCl 5,37; KH2PO4 0,44; MgCl2 6H2O 0,49; 
MgSO4 7H2O 0,4; NaCl 148,85; Na2HPO4 0,34; glucose 5,55. The pH is 7.4 and the 
osmolarity 296 mOsm. During the first six days in vitro (DIV) the medium contains a 
higher concentration of NGF (15 ng/mL), which is needed for a good development of 
cells and culture. After this period the old medium is replaced by a fresh standard one, 
with the addition of a mixture of antimitotics (Cytosine arabinoside, Fluoro-
deoxyuridine, uridine, Sigma), which allows to prevent the exaggerated growth of non-
neuronal cells. After 24h this antimitotics-enriched medium is replaced by a fresh 
standard one, which is then replaced weekly. We used Medium B (see Table 1) at the 
day of dissection and, after 6 days, we replaced it by Medium C (1 mL in every tube), 
which contains also a blend of Antimytotic, such as 1% 5-Fluoro-2-deoxyuridine, 1% 
Cytosyne Arabinoside (ARA-C) and 1% Uridine. After 24 h Medium C is replaced by 
Medium A, which had to be changed every 7 days. In all the experiments reported in 
this thesis we used organotypic cultures developed from embryonic mouse spinal cord 
and maintained in vitro from 1 to 3 weeks (from 8 to 23 Days in vitro - DIV). The 
compositions of the three types of medium are shown in the following (Table1). 
Components Medium A Medium B Medium C 
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D-MEM 67 mL 67 mL 67 mL 
FBS 25 mL 25 mL 25 mL 
Distilled Water 8 mL 8 mL 8 mL 
NGF 5 ng/mL 20 ng/mL 5 ng/mL 
Antibiotic-Antimicotic 
Solution 100X 
1 mL 1 mL 1 mL 
Antimicotics / / 10 µM 
Table 1. Shows the quantity of single components for 100 mL of final cultures medium 
 
 
 
ORGANOTYPIC CULTURES GROWING IN VITRO 
 
While growing in vitro, slices become spread and flattened, features which are 
essential for visualization of single neurons. The spreading degree depends on many 
factors like the rotation speed, the origin of the explanted tissue and the initial 
thickness of the slices. In fact, soon after the dissection, slices are too thick to allow the 
visualization of single cells. A fast rotation of the tubes allows the plasma coagulum 
and the damaged cells on top of the slices to be gradually washed, with a better access 
to individual neurons for electrophysiological recordings. The roller-tube technique 
assures the preservation of the organotypic organization of the tissue while facilitating 
the identification of single class of cells. Moreover, for being long-term preparations, 
the tissue can complete recover from the dissection trauma and easily adapt to the new 
in vitro development. For all these reasons, the roller-tube technique is widely used to 
obtain organotypic slice cultures. These cultures are suitable model for 
electrophysiological recordings and also for other technical approaches, like imaging. 
Neuronal cells progressively differentiate and began to produce electrical activity, 
which is correlated to the features of the single neuronal phenotype and to the features 
of the specific synaptic network impinging on this cell, detected as post synaptic 
currents, both excitatory and inhibitory, during intracellular recordings (Rosato-Siri et 
al., 2004; Furlan et al., 2007)  
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MORPHOLOGY OF THE SPINAL SLICES 
 
 
The original structure of the spinal cord is preserved in organotypic spinal slices. After 
one, two or three weeks in culture (named, 7,14 and 21  DIV) the slices appear as 
depicted in Figure 2. The dorsal-ventral orientation of the spinal cord is clearly visible 
for the presence of the dorsal root fibres and by the presence of the central fissure 
(Figure 3). Within organotypic spinal cultures different neuronal phenotypes develop. 
This heterogeneity allowed the employment of this preparation to monitor the 
development of MNs, interneurons, muscular fibres and DRGs (Avossa et al., 2003; 
Rosato-Siri et al., 2004). MNs are generally identified from their localization and 
morphology. In order to localize them, organotypic spinal cultures are stained using the 
choline acetyltransferase (ChAT) immunocytochemical technique (Avossa et al., 
2003). Positive neurons are often localized on both sides of the ventral fissure and they 
are characterized by large, triangle-shaped soma (>20 µm) and multipolar dentritic 
prolongations. MNs have been demonstrated to display both excitatory and inhibitory 
post-synaptic potentials, which may be suppressed by application of inhibitors of the 
synaptic transmission (Streit et al., 1991). Mono and polysynaptic connections have 
been described between DRG and MNs (Streit et al., 1991; Galante e al., 2000).  
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Figure 2. The different stage during the preparation of organotypic cultures from embryonic 
mouse spinal cord. A) Isolation of spinal cord from mouse fectuses; B) Slice are cut on tissue 
chopper; C) Dissection of spinal cord slices after cut. DRGs still remain attached to the slices; 
D) and E) The spinal slice (with DRG) are fixed on glass coverslip, which are then inserted 
into plastic tubes, with the cultures medium in F) and G); H) the tubes were kept in a roller 
drum. In figure below is visible an example of the organotypic spinal culture at 0, 7, and 14 
DIV where is visible the progressive flattening at different stage of development. Blue 
rectangles define ventral regions.  
 
 
Ventral pre-motor interneurons represent a particularly important class of neurons in 
the spinal cord, since they are considered to belong to the pre-motor networks, 
responsible for the generation of motor patterns (Ballerini and Galante, 1998; Ballerini 
et al., 1999; Galante et al., 2000; Galante et al., 2001; Rosato-Siri et al., 2002). In 
organotypic spinal slices interneurons are visually identified on the basis of specific 
morphological criteria. First, they are located in ventral horns, which are identified by 
the ventral fissure (Figure 3). Second, they have an oval cell body with a diameter < 20 
µm. Finally, they are monopolar or bipolar cells, characterized by a widespread 
dendritic arborisation (Ballerini and Galante, 1998; Ballerini et al., 1999; Avossa et al., 
2003; Furlan et al., 2005; Furlan et al., 2007). As emerged from intracellular 
electrophysiological recordings, in organotypic spinal cultures ventral interneurons 
usually display spontaneous synaptic activity, often characterized by distinctive 
synchronous temporal patterns (Ballerini and Galante, 1998; Ballerini et al., 1999; 
Rosato-Siri et al., 2004; Furlan et al., 2007: Sibilla et al., 2009). DRG cells are 
characterized by a large (40-50 µm) polygonal cell body (Avossa et al., 2003) and they 
do not display spontaneous synaptic activity. In fact, patch-clamp recordings show that, 
conversely from MNs and interneurons, they occasionally give rise to single action 
potentials which are not evoked by synaptic potentials. To test functional connections 
between DRG and spinal neurons, DRG cells may be ex
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bipolar focal electrode and evoked synaptic currents can be recorded from ventral 
interneurons, patch-clamped in whole-cell configuration and held at different 
membrane holding potentials (Galante et al., 2000). 
 
 
Figure 3. The magnification of the organotypic slice visible in Figure 2.  Ventral horn (VH); 
dorsal horn (DH); dorsal root ganglia (DRG) and the ventral fissure (). 
 
 ELECTROPHISIOLOGICAL RECORDINGS 
 
 
The experiments were performed on cultured slices after 7, 14 and 21 DIV. A coverslip 
with a colture was placed in a Perspex chamber mounted on the table of an inverted 
microscope (Nikon TE200). The slice was constantly superfused with standard Krebs 
(see solutions) and the flow was 5 ml/min. Drugs were applied by external superfusion. 
All experiments were carried out at room temperature (22 ± 2°C). Patch micropipettes 
were filled with intracellular solutions (see solutions) and put on the pre-amplifier box 
or ‘head-stage’. An Ag/AgCl electrode connected the head-stage with the intracellular 
solution. The electrical signal converged on the pipette-holder, then it was pre-
amplified and sent to the principal amplifier (EPC-7; List, Germany). The holder was 
fixed on manual control macro-manipulators, which allowed a gradual and progressive 
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approach to the cell and on piezo-electrical control micromanipulators which allowed 
micrometer movements on the cellular membrane (Physic Instruments, Germany; 
Luigs & Neumann, Germany). 
 
 
PATCH-CLAMP TECHNIQUES 
 
In this thesis,  all recordings were done in the whole-cell patch clamp configuration 
(Sackmann and Neher, 1986). The first step consists in establishing a tight adhesion 
between the glass micropipette and the cellular membrane, to form the high resistance 
‘seal’, which is considered good only for resistance values included between 1 and 4 
GΩ (see Figure 5). 
 
GLASS PIPETTES AND VOLTAGE CLAMP 
 
 
For voltage clamp recordings were used the borosilicate capillaries (Hilgenberg) with 
internal filament. The capillaries measure is: Length 100 mm, outside diameter 1,5 mm 
and wall thickness 0,225 mm. For outside-out recording were used the same capillaries 
but with wall thickness of 0,315 mm. All the capillaries were cleaned before use with 
ethanol 100% for 30 minutes, washed with de-ionized H2O and then maintained over 
night at 120 C°.  
Micropipettes were pulled from thin-wall (for voltage clamp) and thick-wall (for 
outside-out) borosilicate glass capillaries (Clark, UK) by a two steps puller (List-
Medical, NARISHIGE model PC-10 Germany or Japan). Two symmetrical pipettes 
were obtained from each capillary, which had the right resistance and shape to reduce 
artifacts, like series resistance and capacitive transients. Moreover, the presence of 
electrical noise and the formation of a good seal, depend upon the quality of the 
capillaries and the dimensions of the pipette’s tips, which corresponded to 
approximately 1-2 µm (Figure 4.). 
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Figure 4. Example of the pipette’s tips for patch clamp recordings  
 
The pipette-holder ensures: a) the electrical connection between the intracellular 
solution and the amplifier; b) the opportunity to apply, by a proper T-shaped 
connection, a pressure variation on the cell membrane just under the pipette, so to 
allow the seal formation by applying the right negative pressure. Pipette is leaned on 
the membrane of the cell to investigate. Then a slight negative pressure, normally 
obtained by suction, is applied to the internal of the pipette, so that the patch membrane 
gently inflects. At this point, measured resistance sharply goes up (from 4-7 MΩ to 1-4 
GΩ) and the electrical noise is reduced. This is the so-called cell-attached 
configuration, in which the cell is attached to the micropipette, but the cell membrane 
is intact. We performed our experiments in the whole-cell configuration, which can be 
obtained from the cell-attached configuration if a further suction is applied to cause the 
rupture of the patch of cell membrane (Figure 5). In this configuration the intracellular 
space is in continuity with the internal of the pipette, while the seal is maintained and 
the activity of the whole cell can be recorded. After the membrane patch is broken the 
resistance (250- 400 MΩ) corresponds to that of the entire neuron, varying in 
according to the cell size. During the experiments, electrophysiological responses were 
acquired with an amplifier (EPC7), digitized at 10 KHz using an A/D converter 
(Digidata 1200A, Axon Instruments) for voltage clamp recordings, and for outside-out 
recording the signal were digitized at 20 KHz using an A/D converter (Digidata 
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1440A) and stored (pCLAMP software, version 10.2, Axon Instrument) for further 
analysis.  
 
VOLTAGE CLAMP RECORDINGS 
 
 
Voltage clamp technique allows measuring the ionic currents across the membrane 
while holding (‘clamping’) the membrane voltage at a set level. During experiments, 
individual ventrally located inter-neurons were patch clamped with micropipettes 
whose tip resistance was 4-6 MΩ when filled with the intracellular solution. To record 
currents an EPC7 amplifier was used allowing clamp of the membrane potential at 
constant values. Usually the membrane potential was held at – 56 mV, a value close to 
their resting membrane potential (-58 ± 7 mV) measured in current clamp conditions 
with zero current injection. Membrane potential values weren’t corrected. After the 
formation of a 1-4 GΩ seal, the fast capacitance transient, due to the  pipette was 
cancelled. After breaking through the membrane the capacitance was usually 60±30.5 
pF and no series resistance compensation was adopted, since its value was usually <15 
MΩ (12 ± 4 MΩ) and no distortion in synaptic events was observed. Cell input 
resistance was assessed after the establishment of whole-cell configuration and during 
the experiment by pClamp software and varied depending on the cell.   
 
Figure 5. Approaching the cell A) the current response is lower; B) applying the suction is visible 
the giga-seal during the which the pipette resistance rise 1-4 MΩ; C) applying short shots of 
vacuum the membrane breaks and the whole cell is formed 
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OUTSIDE-OUT RECORDINGS 
 
 
Outside-out single channel recording techniques allows to measure the ionic currents 
across the one or few channel located on a small piece of membrane attached on the tip 
of the glass electrodes. During these experiments, individual ventrally located inter-
neurons were patch clamped with micropipettes whose tip resistance was 9-10 MΩ and 
thick wall when filled with the intracellular solution used also for voltage clamp 
recording. The outside-out patch is obtained by simply pulling away the patch pipette 
from a whole-cell configuration (see voltage clamp) (Figure 6). By using outside-out 
patch clamp techniques is possible to characterize the subunits composition of 
glycinergic receptors expressed in ventral horn neurons based on the different 
conductance of α1β heteromeric and α2 homomeric glycinergic receptors (reference). 
To record the single channel currents in the outside out configuration we used a 
Multiclamp700B amplifier, signals were digitized at 20 KHz and the holding potentials 
were maintained in the range between -75 and -100 mV. 
 
 
Figure 6. The current response to a test pulse in whole cell configuration A) and resealing 
when the pipette is pulled from a cell in outside-out configuration B). 
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TRACE FILTERING 
 
 
All the voltage clamp recorded traces were filtered with Lowpass Gaussian filter at 
1KHz  while the outside-out recorded trace were filtered with Lowpass filter Bassel 
filtering at 300 Hz. 
 
 
SOLUTION 
 
EXTRACELLULAR SOLUTION (Krebs solution) 
 
 
While recording, cultures were continuously superfused with the standard Krebs 
extracellular solution containing (mM): 152 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 
10HEPES, 10 glucose. The pH was adjusted to the value 7,40 with NaOH and the 
osmolarity was 310 mOsm. 
 
 
INTRACELLULAR SOLUTION 
 
 
Micropipettes were filled with an intracellular solution, whose composition was (mM): 
120 K-gluconat, 20 KCl, 10 HEPES, 10 EGTA, 2 MgCl2 and 2 Na2ATP. The pH was 
7,35 (adjusted with KOH) and osmolarity 295 mOsm. 
 
DRUGS 
 
 
Drugs were bath applied through the perfusion solution. Stock solution were made 
usually at concentration 100 higher than the final ones and stored at -20 °C. The final 
concentration was obtained adding an amount of the stock solution to standard Krebs. 
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The effects of drugs started to be detectable after about 30 s from the application, 
however hey were measured at steady state (5 min). 
The following drugs were used:  
- 6-Cyano-7nitroquiloxaline-2,3-dione disodium salt (CNQX) 10 µM for whole 
cell recording and 5 µM for outside-out recording (SIGMA, Italy), the 
antagonist of AMPA/kainate-type glutamate ionotropic receptors (outside-out 
and voltage clamp); 
- Strychnine nitrate 1 µM for voltage clamp and 2 µM in outside-out recordings 
(Sigma) is a glycinergic receptors antagonist; 
- SR-95531 (gabazine), 10 µM (SIGMA), which acts as an antagonist at   GABAA 
receptors (outside-out and voltage clamp); 
- Tetrodotoxin (TTX, 1 µM) (Latoxan, France), to block Na+ channels (outside-ot 
and voltage clamp) 
- Ethanaminium bromide (QX-314) (SIGMA) 5 µM to block voltage activated 
Na+ channel (outside-out) 
- 2-Amino-5-phosphonovaleric acid (APV) 20 µM (SIGMA) to block NMDA 
receptors 
- Glycine perfused (15-50 µM) for single channel receptors activation during the 
outside-out recordins 
 
 
DATA ANALYSIS 
 
Experiments were obtained from 91 different culture series and the result are presented 
as mean ± SD, with n=number of neurons unless stated otherwise. 
The analysis of spontaneous synaptic currents and miniature post-synaptic 
currents (PSCs and mPSCs, respectively) was performed using the Clampfit 10.2 
program (Axon Instruments, Foster City, CA, USA).  
The event detection was performed trough the detection algorithm based on template 
event detection. The templates are created by extracting and averaging the spontaneous 
event meaning at least 10-15 PSCs visually identified or by making the template trough 
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the template function setting the rise time, decay time and peak amplitude with 
AxoGraphX OS. 
The detection criterion is calculated from the template scaling factor and how closely 
the scaled template fits the data. Events are then progressively detected and the 
program allows accepting an event as valid or rejecting it, as in the case of summated 
responses or superimposed events, while the search is in progress. Events were so 
captured and aligned at their onset. On average 300 single PSCs and 100 mPSCs were 
analyzed from each cell to obtain mean kinetic and amplitude parameters. Usually, 
from each average synaptic event, peak amplitude, rise time (from 10% to 90% peak 
amplitude) and decay time (expressed as τ), by fitting a mono exponential function, 
were calculated. 
 Statistical significance (p-values in the text and in the figure legends) was 
evaluated by one-way ANOVA and by the two-tailed Student’s t-test, for paired 
values. Statistical significance of percentage values was evaluated with Fisher’s exact 
test of independence, which allows to compare two attribute variables, each with to 
possible values and is more accurate than the chi-squared test, when the expected 
numbers are small. Statistical differences were considered significant at p < 0.05.  
Rhythmic activity was characterized by inter burst period (cycle period) and 
burst duration. The cycle period is defined as the time between two consecutive bursts, 
set at onset, while the duration is the time from the burst onset and 80-90% of its 
baseline recovery (Figure 7). 
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Figure 7. Example of voltage clamp recorded trace which show the features of the measure of 
the cycle period and burst duration  
 
 
Rhythm regularity of spontaneous and induced bursting activity was quantified by the 
coefficient of variation of cycle period (CVIB) and the coefficient of variation of burst 
duration (CVd). The coefficient of variation is defined as the ratio between the standard 
deviation and the mean. It was calculated for cycle period and durations of each cell, 
mediated on a sample of cells and expressed as percentage. 
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RESULTS 
 
 
SPONTANEOUS NETWORK ACTIVITY DURING THE FIRST, SECOND 
AND THIRD WEEK OF IN VITRO DEVELOPMENT IN WT AND G93A 
SLICE CULTURES 
 
Spontaneous synaptic activity was routinely recorded from ventral interneurons 
identified by morphological criteria. In Figure 1 it is shown an example of a spinal 
slice culture. Progressive higher magnification of the ventral horn area (Figure 1 A and 
B) illustrates a ventral interneuron (Figure 1 C) from which the patch clamp recordings 
were performed. Neurons were empirically termed interneurons when their cell body 
diameter was between 10 and 20 µm, thus making them clearly distinguishable from 
either larger (35–60 µm diameter) multi-polar cells morphologically resembling MNs 
and DRG neurons, that possess a large cell body (> 40 µm diameter) with just one or 
two large processes emanating from it (Avossa et al., 2003; 2006). 
 
 
 
Figure 1. A: An example of of organotipyc spinal cultures at 14DIV. Expanded field shows 
the progressive higher magnification of the ventral horn area in B, localised by ventral fissure 
(arrow). In C: the arrow indicate an example of ventral neuron from which where performed 
the patch clamp recordings. 
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The term “interneuron” does not exclude, however, the possibility of including 
projection or propriospinal neurons within the tested cell population, although the 
restricted size of the network and its very thin layer structure would have 
predominantly comprised local neurons (Sibilla et al., 2009).  Figure 2 A, B and C, 
corresponding to recordings of interneurons sampled at the first, second and third week 
of in vitro growth (respectively), show example of spontaneous activity recorded under 
voltage clamp mode at -56 mV Vh. At this potential value, synaptic currents mediated 
by glutamate, GABAA and by glycine receptors activation were, in our experimental 
conditions (see methods) all detected as inward currents. Spontaneous activity emerges 
as early as at 8 DIV, and we followed up any spontaneous network activity (SNA) 
changes over the three different stages of development, that is  at one, two and three 
weeks of in vitro growth (named from now on 8, 14 and 21 DIV, respectively) in both 
types of cultures, WT (i.e. control) and transgenic (G93A) with the intent to identify 
any difference in circuitry development. In standard Krebs solution at 8 DIV 52.9% 
(n=32 slices; quantified in histograms in Figure 3 A) of the recorded WT ventral 
interneurons displayed a typical SNA consisting of irregular slow bursts (sample 
tracings are shown in Figure 2 A). Such events  lack a regular burst cycle period 
(28.8±24.9 s; n=13 slices, plot in Figure 3 B) and displayed a variable burst duration 
(2.6±2.5 s n=12 slices, plot in Figure 3 C). When analysing the activity between bursts, 
we could detect a background of spontaneous postsynaptic currents (PSCs) 
characterized by variable amplitude values and variable decay time course (expanded 
traces in Figure 2 A1; events with different decay are exemplified by mean tracings 
shown in Figure 3 E). These synaptic events are made up by a mixed population of 
inhibitory and excitatory PSCs. On average, the total frequency of these mixed PSCs, 
detected during the interburst intervals in WT at 8 DIV, was 7.42±5.1 Hz (n=21 cells; 
plot in Figure 3 D). The application of 1µM TTX always suppressed spontaneous 
bursts, suggesting that they were mediated by network activity and spike propagation. 
Sparse miniature postsynaptic currents (mPSCs) were unmasked by TTX (not shown). 
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Figure 2. A: (8DIV), B: (14DIV) and C: (21DIV) are three representative traces of 
spontaneous network activity recorded from ventral interneuron from WT in standard Krebs 
solution, characteristic for the three different stages of in vitro development. 
 
When exploring network activity in WT cultures at 14 DIV, we observed a drastic 
reduction in the appearance of spontaneous bursting , that was detected in only 28.5% 
of recorded ventral interneurons (n=77; plot in Figure 3 A) bursting activity was 
suppressed by TTX in a manner similar to that at 8 DIV. Differently from 8 DIV 
neurons, the majority (71.5%) of recorded cells displayed high frequency PSCs 
(sample tracings in Figure 2 B expanded in B1).  Bursting in WT at 14 DIV was 
characterized by a reduced mean cycle period (15.3±9.9 s; plot in Figure 3 B, n=22) 
when compared to that measured at 8 DIV, with a similar burst duration (2.8±3.9 s; 
Figure 3 C). The total PSCs frequency (at 14 DIV frequency values detected between 
bursts in bursting slices were pooled together with those measured in non-bursting 
neurons, that were the large majority of the recorded cells at this age)  was significantly 
(p<0.05; n=45) boosted to 17.59±2.3 Hz, when compared to WT at 8 DIV (plot in 
Figure 3 D). This reduction in bursting slices was transient, since at 21 DIV 85.7% of 
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recorded WT ventral interneurons showed bursting activity (see histograms in Figure 
3A, n=15). The appearance of the synchronous events (see sample tracings in Figure 2 
B), that is their kinetic features, at 21 DIV strongly differed from that at 8 or 14 DIV, 
in fact during the third week of in vitro development the cycle period  shortened to 
1.44±0.64 s and burst duration mean value was as fast as 0.52±0.18 s (see histograms 
Figure 3 B and C). In 21 DIV neurons, also the frequency of mixed spontaneous PSCs 
(dected between bursts) was increased to 35.45±2.4 Hz  (plot in Figure 3 D; n=8). 
 
 
 
Figure 3. A: The histogram shows the percentage of bursting slices during the three weeks of 
in vitro development 52%, 28% and 82% for 8, 14 and 21 DIV. The bursting activities in 
terms of B: cycle period  and C: burst duration show a progressive shortening over the 
developmental period. D: During the developmental period the total PSCs frequency increase 
significantly from 8 to 21 DIV. E: Shows 2 examples of PSCs identified by their different 
decay times.  
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In the previous section we have shown that during the first three weeks of in vitro 
development the WT cultured spinal networks generate a typical spontaneous synaptic 
bursting activity that was routinely recorded by patch clamp techniques.  Similar 
recordings were performed from sister slice cultures developed from G93A embryos 
(Figure 4 A, A1, B and B1 compare tracings from WT and G93A, respectively, at 
similar age in culture). Despite the similar bursting activity, a significantly higher 
amount (83%; p<0.05; n=29; tested by the Fisher’s exact test; plot in Figure 5 A) of 
G93A interneurons at 8 DIV  displayed spontaneous bursting activity consisting of 
large events (sample tracings in Figure 4 and in Figure 6), that, similarly to WT ones, 
displayed an irregular cycle period  (20.8±14 s) and variable burst duration (5±7.7 s; 
see histograms in Figure 4 C and D; pooled data from n=20 and n=18 cells, in WT and 
G93A, respectively). Spontaneous PSCs frequency in G93A interneurons was 
measured during the intervals between bursts (sample expanded tracings in Figure 4 
B1). The PSCs frequency was 8.78±11.4 Hz (n=9; summarized in Figure 5 C) and TTX 
application during this developmental period always suppressed spontaneous bursts 
and unmasked sparse mPSCs (not shown). The extremely low probability of detecting 
mPSCs at 8 DIV (both in WT and in G93A interneurons), did not allow for a proper 
statistics. Interestingly, the detected higher probability of generating spontaneous 
synchronous bursts is in accordance with the reported intrinsic hyper excitability of 
G93A spinal networks (van Zundert et al., 2008). Although we are not providing direct 
evidence of increased excitability, our observation of a transient increase in network 
synchronization brought about by SOD1 mutation (see plot in Figure 5 A), is the first 
reported at this early stage of development. 
 
To simplify the results description, SNA at 14 and at 21 DIV in G93A is described and 
compared to WT one together with the PSCs analysis (page 120). 
 
 
PROPERTIES OF SPONTANEOUS PSCs DURING THE FIRST WEEK 
OF IN VITRO DEVELOPMENT IN WT AND G93A SLICE CULTURES 
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In a second set of experiments we focused our attention on the properties of the 
spontaneous PSCs isolated from recordings obtained from n=22 WT interneurons and 
n=25 G93A ones, recorded from 13 different culture series at 8 DIV. The principal aim 
of this set of experiments was to investigate the presence of any difference in synaptic 
transmission between WT and G93A, regardless the increased bursting activity 
detected in G93A slices at 8 DIV (see previous paragraph). An example of ongoing 
spontaneous activity in standard Krebs solution was given in Figure 4 A, A1 and B, B1 
were  the  representative traces are shown, recorded from WT and G93A  neurons. At 8 
DIV, in this set of recordings, PSCs frequency was on average 8.78±11.4 Hz in WT 
and 9.53±10.3 Hz in G93A (summarized in Figure 5 C). When visually inspecting the 
detected events, we were able to distinguish at least two broad categories of PSCs, 
based on their fast or slow decay time. To quantify this differences, we separated these 
events (see methods) and we measured the PSCs fast decay time constant and the PSCs 
slow decay time constant (expressed as τ values, obtained by mono-exponential fitting 
procedures as described in the methods). On a sample of WT (n=21) and G93A (n=25) 
interneurons, the average τ value of fast events was 6±1.4 ms  in WT recordings and 
5.2±1 ms  in G93A ones, while the average τ value for slow PSCs was 35.8±7.3 in WT 
and 32.8±7.9  in transgenic G93A cultures. We verified the absence of any correlation 
between the rise time and decay time values of the measured fast and slow PSCs, thus 
excluding the possibility that the different decay values be due to electronic filtering. 
Thus, in both culture groups at 8 DIV, spontaneous PSCs display similar categories of 
events, with similar τ values, and similar relative frequencies (4.8±3.7 Hz and 5.1±4 
Hz fast PSCs and 2.3±1.5 Hz and 2.7±2.8 Hz slow PSCs, WT and G93A respectively; 
n=6 and n=7). 
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Figure 4. A: and B: Representative traces of spontaneous ventral interneuron bursting activity 
during at 8 DIV recorded in WT (top trace) and G93A (bottom trace). A1: and B1: Shows the 
details of the events selected between the bursts activity that were used for PSCs isolation and 
further statistical analysis. The plots (bottom) show in C: burst duration and in D: cycle period  
in WT and G93A.  
 
When measured, the mean amplitudes of fast and slow PSCs were comparable between 
the two groups of 8 DIV cultures, WT and G93A. In fact, the mean amplitude of fast 
PSCs was 37.6±19.2 pA (n=10 WT neurons) and 33.4±16.5 pA (n=18 G93A neurons) 
and, similarly, the slow PSCs displayed mean amplitudes of 43.5±35.9 pA and 
43.7±30.6 pA, WT and G93A neurons, respectively. In Figure 3 E, an example of fast 
(top) and slow (bottom) PSCs recorded in Krebs solution were shown.   
Therefore, despite the diverse incidence of bursting, we could not detect significant 
differences in the frequency, amplitude, τ, and ratio of slow and fast synaptic events in 
WT and G93A spinal networks in culture at 8 DIV. Fast and slow PSCs were further 
 103 
characterized by their pharmacological properties and these results are reported in the 
next paragraph. 
 
 
Figure 5. A: Plot showing the percentage of bursting slices, which is higher for G93A 
(p<0.05) than for WT ones. B: Burst amplitude and  C: PSCs frequency, note that there are no 
differences between WT and G93A cultures.  
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PHARMACOLOGICAL CHARACTERIZATION OF PSCs DURING THE 
FIRST WEEK OF IN VITRO DEVELOPMENT IN WT AND G93A SLICE 
CULTURES 
 
Fast PSCs events were readily blocked by application of the selective antagonist for 
AMPA/Kainate glutamate receptor subtypes CNQX (10 µM) (compare Figure 6 A3 
and B3 to C1 and D1), thus confirming the glutamatergic nature of fast PSCs (Galante 
et al., 2000). When CNQX was applied to bursting neurons at 8 DIV (WT n=12; G93A 
n=14) spontaneous synchronized activity was promptly abolished (Figure 6 C and D), 
thus indicating the major contribution of AMPA mediated synaptic transmission to this 
activity in both culture groups at this age of development in vitro.  
 105 
 
Figure 6. A: and B: Two representative traces of spontaneous bursting activity recorded from 
ventral interneurons. A1: and B1: expanded tracings, note the different scale bare and note the 
similar shape of the bursts. C: and D: Show the progressive bolck of bursting activity 
following application of CNQX 10 µM. A3: and B3: expanded tracings before and C1: and 
D2: after CNQX application. 
 
 
In these recordings, to better visualize the Cl- mediated synaptic component, remaining 
after CNQX application, we kept the Vh at more negative values (i.e. – 70 mV) to 
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increase anion driving force and therefore to obtain larger GABA and glycine receptor-
mediated event amplitudes. After the block of the AMPA/kainate mediated fast PSCs, 
the residual post-synaptic activity consisted of PSCs of variable amplitude and variable 
decay time constant for both WT and transgenic G93A (Figure 7 A) spinal cultures. In 
this experimental condition, both GABAergic and glycinergic receptor mediated 
currents displayed a slower, when compared to AMPA-mediated PSCs, decay time 
during this early period of development, that is further slowed down by the presence of 
22 mM intracellular Cl ions (Pitt et al.,2008), therefore we were not able, on the simple 
basis of their τ to dissect GABAA-PSCs from glycine-PSCs, in the absence of GABA 
or Glycine receptors’ specific blockers. Under this experimental conditions, the mean 
frequency of all mixed IPSCs  was 1.1±0.43 Hz and 0.9±0.35 Hz for WT and G93A 
samples, respectively. Such values were not significantly different (n=30 and n=23, 
WT and G93A, respectively) and the mean decay time constant, pooling all events 
together, was of 30.9±6.5 ms in WT and 40.3±3.6 ms in G93A, same sample of cells. 
The IPSCs mean amplitude values, again without dissecting GABA mediated from 
glycine mediated events,  were 16.1±2.9 pA in WT cultures and 12.2±3.1 pA in 
transgenic G93A cultures. Under this recording condition, that is in the absence of 
specific GABA or glycine receptor antagonists, we were able, in only a small sample 
of recorded WT (n=3) and G93A (n=3) neurons, to separate three different categories 
of events, identified by their decay time constant (τ<10ms; 10ms<τ>18ms and τ>18ms; 
Figure 7 B and C). Hence, no differences emerged, in fact the two groups of cultures 
have an equal distribution of the three classes of PSCs recorded in the presence of 
CNQX . 
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Figure 7. A: Two examples of recorded traces in WT and G93A shows PSCs with different 
amplitude and decay time constant (τ) during application of CNQX 10 µM. The red line 
indicates the monoexponential fitting for measuring the decay time constant  (τ). B: The 
histogram shows the distribution of PSCs event with different τ values. C: WT average 
sample traces are scaled and superimposed to illustrate the different decays. 
 
Further treatment by co-application of 10 µM CNQX and 10 µM SR95531 (gabazine; a 
specific and selective GABAA receptor antagonist) was performed on n=3 WT and n=4 
G93A interneurons at 8 DIV. Under these experimental conditions slow GABA events 
disappeared (Galante et al., 2000) and we were able to unmask a group of PSCs 
(2.5±1.8 Hz in WT and 1.4±0.5 Hz in G93A) characterized by similar peak amplitude 
values (20.9±0.9 pA and 16.9±5.9 pA in WT and G93A, respectively) displaying a 
decay time course of 14.4±4.4 ms  in WT and 14.7±4.3 ms in G93A. Further 
application of 1 µM of strychnine, a selective blocker for glycinergic receptors, 
completely removed these events (data not shown). In addition, when we analysed their 
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voltage dependence, CNQX and SR95531 resistant PSCs reverted polarity at Vh -36 
mV in accordance to the estimated Nerst potential value for Cl- in our experimental 
conditions (see methods).  
These events were therefore identified as glycinergic spontaneous PSCs, and were 
similar, in all measured parameters, in both culture groups, WT and G93A at 8 DIV.  
 
INDUCED DISINHIBITED BURSTING DURING THE FIRST WEEK OF 
IN VITRO DEVELOPMENT IN WT AND G93A SLICE CULTURES 
 
In the isolated spinal cord from neonatal mouse and rat, the block of glycine and 
GABAA receptors with strychnine and bicuculline induces spontaneous rhythmic 
bursting (disinhibited bursting) in the entire spinal cord, monitored from MNs (Bracci 
et al., 1996a). These rhythmic bursts are highly regular and are characterized by several 
repetitive intra burst oscillations and bursts are also synchronous among left and right 
ventral roots (Bracci et al., 1996a). Intrinsic membrane properties of MNs seem not to 
be involved in the generation of this rhythmic pattern that relies entirely on the 
activation of pre-motoneuronal spinal networks (Tscherter et al 2001 and Streit et al., 
1001). It has been also shown that bursting in the presence of strychnine and 
bicuculline requires the activation of spinal networks contained in a single ventral horn 
spanning over few lumbar segments (Bacci et al., 1996b). Interestingly, organotypic 
spinal cultures preserve the segmental spinal circuits sufficient to generate this 
disinhibited rhythm (Ballerini and Galante, 1998; Ballerini et al., 1999). This property 
has allowed a detailed characterization of disinhibited rhythm at the level of pre-motor 
circuits during development in vitro.  Being such rhythmogenic activity a 
characterizing feature of spinal networks, we decided to assess whether the block of the 
inhibitory components of the spinal network could highlight any difference in the 
excitatory glutamatergic transmission and bursting properties of early G93A circuits 
when compared to WT ones.  We applied 1 µM strychnine and 10 µM  SR95531 
(gabazine) in 8 DIV WT (n=18) and G93A slices (n=24) and in all recorded 
interneurons this treatment lead to the build up of a regular and slow pattern of 
spontaneous activity that consisted of regular, long episodes (or bursts) of 
synchronized network activity followed by silent intervals. Such a rhythm was always 
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preceded by an initial phase where irregular summation of bursts occurred, lasting 
several tens of seconds to minutes after the application of the drugs (see Figure 8 A). 
After this very initial phase the rhythm stabilised and persisted with a regular pace as 
long as the drugs were applied. All this features have been previously reported in 
organotypic spinal cultures. Once stabilized, bursting activity displayed  a regular burst 
duration and burst cycle period (Figure 8 B and C), that was on average 12.2±9.3 s 
(WT) and 8.1±4.2 s (G93A) and 34±20.1 s (WT, n=10) and 34.3±10 (G93A, n=11) 
duration and cycle, respectively (summarized in Figure 8 D and E). The regularity of 
the rhythm was also confirmed by the measured coefficient of variation, CVCycle period = 
24±6% and 34±11% for WT and G93A cultures, respectively. For burst duration, the  
CVd = was 17±4% in WT and 16±5% in G93A. Our results indicate that at 8 DIV, that 
is in spinal circuits during late embryonic period, no apparent alterations in rhythmic 
activity based on glutamatergic transmission  are expressed in G93A spinal explants. 
Such activity was promptly removed by TTX application in both culture groups. The 
similar appearance of disinhibited bursting features, suggested that the AMPA 
mediated component alone of the spinal networks was not responsible for the increased 
probability of spontaneous bursting detected in G93A slices at 8 DIV. Other 
mechanisms, still to be elucidated, seem to be involved. In fact, also the absence of 
differences in GABA and glycine synaptic events, suggested the presence of subtle 
changes in G93A circuits, not directly linked to synaptic re-arrangements. This notion 
is strengthened by the analysis of the kinetics properties of the AMPA-PSCs recorded 
during co-application of Strychnine and SR95531 and selected between the bursts, this 
analysis did not shown any difference between WT and G93A cultures (τ=5.26±1.72 
ms and peak amplitude 39.52±22,86 pA for WT, n=9;  τ=5.63±1.35 ms and peak 
amplitude 38.86±24.89 pA for G93A, n=13).  
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Figure 8. A:  Example of SNA in Krebs solution (top trace) and after co-application of 
strychnine 1 µM and SR95531 10 µM shows the induction of spontaneous network driven 
rhythmicity. B: and C: two examples of recorded traces during drugs perfusion shows the 
similarities of dishinibited bursting activities between WT and G93A cultures. The histograms 
D: cycle period and C: burst duration, note that no differences were detected between WT and 
G93A.      
 
 
 
 
The regular dishinibited bursts were abolished on 27% of cases in WT (n=11) and 33% 
of cases in G93A (n=9) by application of CNQX 10µM.  The residual activity was 
characterised by bursts characterized by a slower pace (59.85±19.5 s and 32.96±15.24 
s cycle period, WT and G93A) and a shorter burst duration (6.92±1.61 s and 4.81±0.93 
s, WT and G93A). Further application of APV 10µM (selective blocker of the 
glutamate NMDA subtype ionotropic receptors) all bursting activity disappears, 
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suggesting the presence of a strong NMDA mediated component in such activities 
(Figure 9 C). 
 
 
 
Figure 9. A: and B: Pharmacology of the residual disinhibited bursting activity  in CNQX and 
in C:  Sample tracings of disinhibited rhythm blocked by CNQX.  D: 27 % in WT and 33% in 
G93A slices are completely suppressed by CNQX E: and F: Disinhibited cycle period and 
burst duration in WT and G93A.   
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PROPERTIES OF SNA DURING THE SECOND AND THIRD WEEK OF 
IN VITRO DEVELOPMENT IN WT AND G93A SLICE CULTURES 
 
At 14 and 21 DIV, G93A cultured spinal circuits (n=10) displayed similar probability 
of bursting when compared with WT (n=12; see histograms in Figure 10 E), and 
kinetic features were also similar at the corresponding ages as shown in plots in  Figure 
10 F and G. In Figure 10 A, A1 and B, B1, sample tracings of bursting activity at 14 
DIV in WT and G93A are shown; in the same Figure traces in C,C1 and in D, D1 
display sample of bursting activity at 21 DIV in WT and G93A. In G93A the cycle 
period at 14 DIV was 15±7.4 s and at 21 DIV was 2.3±0.34 s with corresponding burst 
duration of 1.45±1.3 s and of 0.53±0.12 s (n=8, each; histograms in Figure 10 F and 
G).  
As performed similarly for 8 DIV WT and G93A cultures, we analysed the PSCs 
frequencies at 14 and 21 DIV, regardless of decay categories. The mixed population of 
PSCs detected between bursts was pooled together with that detected in non bursting 
neurons, both at 14 and at 21 DIV. In G93A, similar to WT, total mixed PSC frequency 
significantly increased along with in vitro age (in G93A at 14 DIV 16.5±4.5 Hz and at 
21 DIV 37±3.3 Hz). Such results are summarized by tracings in Figure 11 A, A1 (14 
DIV) and in B, B1 (21 DIV) and the plot in Figure 11 C.  
It is interesting to note that, when spontaneous rhythmogenesis reappeared at 21 DIV, 
the probability of bursting is higher in WT than in G93A, in contrast to what is 
reported at 8 DIV (see Figure 5 A for 8 DIV and Figure 10 E for 21 DIV). 
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Figure 10. A: and B: (14 DIV) shows two examples of recorded traces from WT and G93A 
during spontaneous bursting activities in Krebs solution A1: and B1: higher magnification of 
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bursts. C: and D:  (21 DIV) the same type of recordings with C1: and D1:  higher 
magnification. E: percentage of bursting slices during the second and third week of in vitro 
development, note the absence of significant differences between WT and G93A cultures. F: 
and G: histograms summarize the mean cycle period and burst duration. No significant 
differences were detected.  
 
 
PHARMACOLOGICAL CHARACTERIZATION OF PSCs DURING THE 
SECOND AND THIRD WEEK OF IN VITRO DEVELOPMENT IN WT 
AND G93A SLICE CULTURES 
 
During the maturation of the spinal cord in vitro several functional changes occur 
within the spinal circuit such as the lower probability of expressing synchronous 
bursting activity during the second week, where bursts were replaced by high 
frequency PSCs (see first paragraph), or the later occurrence of fast oscillating activity 
during the third week, on a background of intense spontaneous synaptic activity. These 
changes are suggested to depend, at least in part, on the progressive maturation of 
spinal circuits, even in culture, leading to shifts in Cl- intracellular concentration 
(Rosato-Siri et al., 2004; Furlan et al., 2007). The switch from the excitatory to the 
inhibitory effects of GABA/glycine occurs in the whole CNS including the spinal cord, 
in which we can identify three stages representing precise ontogenetic landmarks: (i) 
GABA and glycine act as strict excitatory neurotransmitters (E13.5, in the mouse, 
Branchereau et al., 2002; between E13–E14 in the rat, see Nishimaru et al., 1996), (ii) 
GABA and glycine start acting as inhibitory neurotransmitters (in the mouse after 
E14.5, Branchereau et al., 2002; but see Delpy et al., 2008; in the rat from E14.5–
E15.5,Nishimaru et al., 1996) and (iii) GABA and glycine act as inhibitory 
neurotransmitters in the majority of neurons (in the mouse E17.5, Branchereau et al., 
2002; similarly in the rat at E17– E19, see Wu et al., 1992). The mechanisms 
underlying these changes have been mainly related to the regulation of intracellular Cl- 
concentration, responsible for the switch of the GABA-glycinergic transmission from 
excitatory to inhibitory (Owens et al., 1996), and to GABA-glycine induced large 
decreases in input resistance, that shunt the membrane to incoming excitatory 
potentials (Marchetti et al., 2002; Wu et al., 1992). Thus, at 14 DIV in standard Krebs 
solution, the majority of the recorded WT and G93A interneurons  (Vh -56 mV; see 
 115 
first paragraph) displayed an intense spontaneous synaptic activity (like those visible in 
Figure 2 B).  We investigated, similarly to what we have done at 8 DIV, PSCs by 
isolating pharmacologically AMPA, GABA and glycine mediated events in WT and 
G93A slices.  
At 14 DIV the spontaneous PSCs were represented by inward currents 
characterized by high frequency and variable amplitude. As previously showed for 
PSCs at 8 DIV, the inward currents recorded from ventral interneurons in standard 
Krebs solution could be dissected in fast and slow events on the basis of their decay 
time. Interestingly, in a small group of recordings, displaying lower PSCs frequencies 
(total PSC frequencies 8.78±11.4 Hz in WT n=4 and 9.53±10.3 Hz in G93A, n=3) 
when compared to the average 14 DIV values (see plot in Figure 11 C), we were even 
able, differently from the immature 8 DIV, in the absence of pharmacological blockers, 
to separate PSCs with a fast (around 5 ms), intermediate (around 13 ms) and slow 
(around 35 ms) τ. These three categories are different from those detected at 8 DIV 
upon removal of AMPA/Kainate receptor mediated activity by CNQX applications. In 
the large majority of 14 DIV neurons (WT and G93A), in the absence of 
pharmacological block of specific receptors, it was difficult to distinguish exactly the 
three components in any recordings, due to the occurrence of superimposed events, or 
summated ones, related to the intense spontaneous synaptic activity. Notwithstanding 
these difficulties, it is tempting to speculate that the fast PSCs (frequency values 
6.34±5.4  Hz and 7.8±6 Hz in WT and G93A, respectively, n=4 and n=3), displaying 
mean τ values of 5.36±1,7 ms  (35.44±20.31 pA, mean peak amplitude, WT) 5.1±1.6 
ms (34±21.20 pA, G93A) represented AMPA receptor-mediated glutamatergic 
currents. On the contrary, slow PSCs (frequency values 1.1±2.43 Hz and 0.9±1.93 Hz 
in WT and G93A, respectively), displaying mean τ values of 32±5.1 ms (47.3±13.2 pA 
WT) and 25.4±4.6 ms (45.2±3.7 pA G93A) might represent GABAA mediated PSCs. 
Medium PSCs (frequency values 1.9±2.4 Hz and 1±3.5 Hz in WT and G93A) 
displayed mean τ of 14.23±2.9 ms and 12±3.4 ms with 36±12.3 pA and 43±14.21 pA, 
WT and G93A, respectively) and were suggested to represent mixed glycine/GABA 
mediated events (Russier et al., 2002). In fact, when we analysed PSC voltage 
dependence, by changing the Vh within the -70/+20 mV range, fast PSCs reversed 
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polarity at 0 mV and became outward at +20 mV, while the medium and slow PSCs 
disappeared at -40 mV and were outward at -10 mV (data not shown). Regardless the 
described difficulties, we were able, for this set of recordings, to calculate the ratio 
between these three PSCs components in WT and G93A. No differences in frequencies 
and amplitudes emerged between transgenic neurons and control ones, between the two 
groups (WT and G93A) at the relative ages. 
 
Figure 11. A: (G93A) and A1: (WT) at 14 DIV spontaneous activities recorded in Krebs 
solution and B: and B1: at 21 DIV.  C: The plot shows the increasing of PSCs frequency 
during the in vitro development from 14 to 21 DIV.  
 
 We proceeded, in the next set of experiments, with the pharmacological dissection of 
the PSCs recorded at 14 and 21 DIV in WT and G93A slices. 
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We were particularly interested in dissecting out the inhibitory, GABA and glycine, 
mediated components, that were more difficult to isolate by means of τ detection. 
Therefore, we blocked by CNQX application all AMPA/kainate receptor mediated 
PSCs (sample tracings in Figure 12 B and C). In the presence of CNQX, we analysed 
n=35 and n= 52 interneurons (at 14 and at 21 DIV, WT and G93A, respectively). As 
previously described (Galante et al., 2000), the PSCs displaying the fastest τ were 
blocked and the residual activity was characterized by PSCs of variable amplitude and 
decay time course, representing a mixed population of GABAA and glycine mediated 
PSCs, where we could identify, on the basis of different decay time distributions (see 
example in Figure 12 D), as done at 8 DIV in CNQX, three categories of IPSCs. It is 
interesting to note that during the three weeks of development in vitro the organotypic 
cultures express a different percentage in the detected three categories of events, 
identified, as was the case for 8 DIV, by the variable decay times (τ<10ms; 
10ms<τ>18ms and τ>18ms; Figure 12 D, E and F). The gradual increasing in the 
τ<10ms PSCs during 14 and 21 DIV may depend on spinal cultures maturation. 
However, no differences were found between WT and G93A cultures.  
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Figure 12. A: Representative traces of spontaneous activity in CNQX at different ages in 
culture B and B1: at 14 DIV and C and C1: at 21 DIV. D: representative distribution of τ 
values for a 21 DIV recorded neuron in CNQX (21 DIV WT). E: and F: shows the 
distribution of the three different event categories detected in CNQX, no significant difference 
emerged between WT and G93A for any given age.  
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We next focused our attention, as we did for the 8 DIV circuits, on the glycinergic 
component, that was more difficult to isolate without blockage of GABAA mediated 
slow events. Therefore, we performed a set of experiments where we co-applied 
CNQX 10 µM and  SR95531 (gabazine) 10 µM (Figure 13).  Application of SR95531 
usually increased the event frequency from 7.1± 4.6 Hz and 7.7± 5.3 Hz (WT and 
G93A respectively) to 12.2± 5 Hz and 13.7± 8.3 Hz in WT and G93A (plot in Figure 
13 C, 14 DIV). This increase in glycinergic PSCs frequency after pharmacological 
removal of GABAA receptor activity may indicate an inhibitory effect of GABAA 
receptors on glycinergic transmission. Further application of strychnine completely 
remove the PSCs ensuring the glycinergic nature of residual PSCs following 
application of CNQX and SR95531 (Figure 13 B2). We analysed such 
pharmacologically isolated glycinergic PSCs in n=34 WT and in n=27 G93A ventral 
interneurons (at 14 and 21 DIV), and we decided to analyse and compare all recordings 
obtained from  8, 14 and 21 DIV. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. A: Example of recorded trace at 14 DIV in CNQX B: after coapplication of 
SR95531. A1: and B1: expanded traces from A and B. C: plot where is showed the increasing 
of PSCs frequency following application of SR95531 D: The reversal potentials show the 
point of inversion of Cl- current in accordance with Nerst equation. E: the plot shows the 
distribution of glycinergic peak amplitude over the developmental period in WT and G93A. In 
no case was found any difference between WT and G93A cultures.  
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Glycinergic PSCs undergo a progressive increase in terms of mean frequency 
and amplitude, and such progressions are reported, from 8 to 21 DIV, in the plot in 
Figure 13 E and in Figure 14 C, also summarized (for glycinergic PSC amplitude 
values) in Table 1, indicating the overall absence of significant differences between 
WT and G93A slices. Number of cells analysed are reported in the table, relative to 
each developmental age in vitro analysed. Although all in all similar, it is interesting to 
note that the mean peak amplitude values were usually larger (Table 1), although not 
significantly, in G93A slices from 15 DIV on, when compared to WT ones. 
 
  
DIV WT (pA) ±SD G93A (pA) ±SD 
8-10 20,9 0,8 20,7 12,5 
12-14 35,7 24,7 20,9 14,5 
15-16 47 44,8 49,7 24 
17-18 37 25,3 69 90,2 
Table 1. (n=74 WT and n=50 G93A) 
 
Analysing the reversal potential of glycinergic PSCs in WT and G93A neurons from 14 
to 21 DIV, revealed that, although we forced the intracellular Cl-concentration in all 
experiments, the measured values of PSCs recorded in the presence of CNQX and 
SR95531 became more negative, from -35 mV at 8 DIV to -40 mV at 14 DIV (see plot 
in Figure 13 D) and then to -45 mV at 21 DIV. However no differences were seen 
between WT and G93A cultures. 
What mostly attracted our attention was the observed, in both WT and G93A slices, 
progressive changes in glycineric PSC τ.  Glycinergic event decay time is known the 
undergo typical changes during normal physiological maturation in the spinal cord 
(Takahashi et al., 1992). In fact, glycinergic receptors (GlyRs) are composed of α and 
β subunits. Four α subunit isoforms (α1 to α4)  and only one β subunit isoform have 
been described (Betz and Kneussel, 2000; Legendre et al., 2001; Aguayo et al., 2004). 
It was shown that the expression of these subunits in rat spinal cord neurons in vivo 
was developmentally regulated (Malosio et al., 1991; Watanabe, H.  and Akagi, 1995). 
Thus, while the α1 subunit is expressed at low levels in embryonic and newborn rat 
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spinal cords, its expression increases during development, reaching high levels after 
postnatal day 15. The α2 subunit, on the contrary, is abundantly expressed in 
embryonic (E14), but not in newborn or postnatal mouse spinal cord. Studies in spinal 
cord and brainstem slices have revealed that the decay time constant of IPSC and 
mIPSC shortens during development, mainly due to the change in expression of GlyRs 
subunits (Takahashi et al., 1992). Although  α subunits efficiently form homomeric 
GlyRs in recombinant expression systems, homomeric α1, α3 and α4 GlyRs are 
weakly expressed in adult neurons (Lynch, 2009). In contrast, α2 homomeric GlyRs 
are abundantly expressed in embryonic neurons, although their numbers decline 
sharply by adulthood. Numerous lines of biochemical, biophysical, pharmacological 
and genetic evidence (Lynch, 2009) indicate that in the majority of cases, in the adult 
spinal cord, glycinergic neurotransmission is mediated by heteromeric α1β GlyRs, and 
this changes the overall glycinergic IPSC decay time. For example, the decay time 
constant of evoked IPSCs was reported to be 27 ms in embryonic and 6 ms in postnatal 
spinal neurons (Aguayo et al., 2004). Similar changes were reported when spontaneous 
mIPSCs were recorded in slices from rat spinal cord and medullary neurons (Gao et al., 
1998; Gao et al., 2001; Singer et al., 1998). These modifications in the time course of 
synaptic currents have been associated with the developmentally regulated switch 
between immature α2 to adult α1 subunits, with the latter exhibiting short mean open 
times (Krupp et al., 1994; Singer et al., 1998; Aguayo et al., 2004).  
In this thesis, we have found similar changes in the decay phase of pharmacologically 
isolated glycinergic PSCs in mouse cultured spinal slices during the developmental 
period from 8 DIV to 22 DIV. The decay time of glycinergic PSCs in cultured neurons, 
both in WT and G93A, became progressively shorter, presumably due to a progressive 
maturation of GlyRs leading to the switch from α2 to α1 subunits.  
We observed  that the τ values of isolated glycinergic PSCs was 15.4±4.4 ms (n=6 
WT) at 8 DIV and became significantly shorter, 8.5±2.4 ms (n=5 WT) at 21 DIV, (see 
plot in Figure 14 D). In a similar fashion, glycinergic PSCs in G93A display a 
progressive shortening as well, but, as reported in the plot in Figure 14 D, while at 8 
DIV the mean τ values were similar between G93A (n=7) and WT glycinergic PSCs 
(Figure 14 D and F for representative traces), at 14 DIV these values start to diverge 
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and became significantly shorter at 21 DIV in G93A (G93A τ 6.2±1.9 and WT τ 
8.5±2.4; n=13 and n=11 respectively, p<0.05). These changes are exemplified by the 
superimposed averaged glycinergic PSCs (WT and G93A, black and red traces, 
respectively)  scaled and superimposed in Figure 14 F. 
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Figure 14. A: (14DIV) and B: (21DIV) Example of recorded traces from WT and G93A 
following application of CNQX and SR95531. C: the plot shows the distribution of PSCs 
frequency which increases over the developmental period (from 8 DIV to 21 DIV). D: The 
plot shows the progressive fastening of the decay time values over the three weeks of in vitro 
maturation. In G93A the τ values are significantly smaller when compared with WT at 21 
DIV. E: The plot shows the absence of linear relationships between PSCs τ values and rise 
time ones. F: Shows two examples of glycinergic scaled events at 8 DIV (black WT and red 
G93A) and at 21 DIV. Note the difference in scaled events during the third week of 
development.  
 
These results hold the potential to suggest the novel idea that spinal neurons, and in 
particular MNs, in G93A might undergo chronic stress as a result of  a dis-regulation in 
inhibitory glycinergic innervation (recently suggested by Chang and Martin., 2011), 
already emerging during early development, that may be secondary to glycinergic 
dysfunction (Chang and Martin, 2009). We decided therefore to investigate whether 
such differences in the rate of shortening of glycinergic PSCs may be related to a 
diverse modulation in G93A of GlyRs subunit expression during development in vitro. 
To unravel this issue, we decided to analyse the decay time constant of 
pharmacologically isolated glycinergic mPSCs at 21DIV in WT and G93A and to 
proceed with a set of experiments in the patch clamp out side out configuration, 
enabling a direct evaluation of GlyRs subunit expression. 
 
 
GLYCINERGIC mPSCs IN WT AND G93A SPINAL SLICE CULTURES 
AT 21 DIV 
 
Glycinergic mPSCs (0.14±0.18 Hz and 0.09±0.06 Hz, n=15 WT and n=11 G93A, 
respectively) recorded in the presence of CNQX 10 µM, SR95531 10 µM and TTX 1 
µM were readily blocked by strychnine, therefore represented minies of glycinergic 
nature, both in WT and in G93A slice cultures. Under these experimental conditions τ 
values were on average  8.1±3 ms (n=12 WT) and 7.9±3.1 ms (n=12 G93A), 
displaying similar mean peak amplitude of 7±4 pA (WT) and 8±48 pA (G93A). 
These results suggest that the significant shortening detected in G93A glycinergic 
PSCs at 21 DIV is not related to changes in the developmental expression of GlyRs 
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subunits. We further address this issue with two additional set of experiments, 
described in the next paragraphs. 
 
GLYCINE SINGLE CHANNELS DETECTION IN OUTSIDE OUT 
RECORDINGS IN WT AND G93A SLICE CULTURES: THE α SUBUNIT 
SWITCH  
 
In order to characterize the glycinergic receptor maturation, we decided to perform the 
outside-out patch clamp recording. Our recordings show that in both WT and 
transgenic G93A slices, at this stage of maturation (21 DIV) the developmental switch 
from α2 to α1 subunit has already occurred, in fact the percentage (summarized in plots 
of Figure 15) of α1β heteromeric glycinergic receptors is the 77% in WT slices (n=13 
patches) and the 89% in transgenic G93A ones (n=10 patches). 
The Figure 16 shows two examples of traces, obtained from WT and transgenic G93A 
slices respectively, where the administration of 50 µM glycine through the perfusion 
system induces the opening of channels. Since the recording holding potential was -75 
mV and the amplitude of currents was ~ 3.5 pA, we could calculate the value of 
conductance (40-50 pS), corresponding to that of  α1β heteromeric receptors.  
In our results, we detected a slight increase (12%) in the percentage of glycinergic α1β 
heteromeric receptors in transgenic G93A slices in comparison with WT ones.  At the 
same time, we studied the maturation process of glycinergic receptor during an earlier 
stage of differentiation. In this set of experiments, outside-out patch clamp experiments 
found that at 14 DIV, while WT slices displayed α1β heteromeric receptors in the 
majority of the analyzed patches (80% n=40), transgenic G93A cultures were showing 
the presence of the immature isoform of the glycinergic receptor in almost half of the 
cases (α2 homomeric receptors 48% and α1β heteromeric receptors: 52%, n=42).  
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Figure 15 In the plot is shown the percentage of α1β heteromeric receptors expression in 
SOD1G93A and WT during the 2 week of in vitro development (corresponding to 14-15 DIV) 
(p<0.05)  and 3 week (18-23 DIV) 
 
The Figure 16 displays two examples of outside-out recordings at -80 mV holding 
potential. In the case of WT slice, the administration of 15 µM glycine induces the 
opening of channels, whose conductance is ~40 pS, typical of α1β heteromeric 
receptors;  Conversely, in transgenic G93A slice, the majority of current amplitudes 
flowing through the channels are larger and allow to calculate the conductance as ~100 
pS, which is indicative of the α2 homomeric type, although it is possible to distinguish 
the co-existence of smaller sub-conductance levels into the trace. 
 
α1β 
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Figure 16. in the figure are shown two representative traces (A: WT and B: G93A) recorded 
in outside-out patch clamp at 14-15 DIV in which is possible to see the higher bursting 
amplitude in G93A cultures due to a higher percentage of α2 homomeric receptors 
 
 
INDUCED DISINHIBITED BURSTING DURING THE SECOND WEEK 
OF IN VITRO DEVELOPMENT IN WT AND G93A SLICE CULTURES 
 
In organotypic slice cultures, the pattern of spontaneous bursting following application 
of strychnine and bicuculline was shown to display developmentally regulated 
differences in terms of frequency and duration of the regular bursting episodes, 
between distinct stages (8 and 14 DIV) of in vitro spinal maturation (Ballerini and 
Galante, 1998). Thus we decided to study the profile of such disinhibited bursting 
when induced in WT and G93A slice cultures at 14 DIV. In WT (n=20) and G93A 
(n=25) slices co-application of 1 strychnine together with SR95531 (gabazine) always 
successfully induced the build up of regular and rhythmic bursting. Figure 17 shows an 
example of such induced rhythmic activity for both WT and G93A. As already 
reported (Ballerini and Galante, 1998) at this later stage of development in vitro, both 
cycle period and duration were shorter when compared to the one measured at 8 DIV in 
WT and G93A (cycle period were 14.7±7.9 s and 20.1±10 s in WT and in G93A, 
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respectively; and burst duration 5.2±3.5 s in WT and 8.1±4.2 s in G93A See summary 
in plots of Figure 18 A and B)  
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Figure 17. A: and B: the dishinibited busting activity following application of strychnine 
1µM and SR95531 10 µM were analysed during second  and C: and D: third week of in 
vitro development.  
 
Disinhibited bursting was blocked by TTX, as was the case for 8 DIV 
cultures.
  
Figure 18 A: the plot shows the burst duration at 14 DIV and at 21 DIV and B: Cycle period 
at 14 and 21 DIV. No differences were detected between WT and G93A cultures.  
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Figure 18 Pharmacology of disinhibited rhythm A, A1 and A2: WT and  B. B1 and B2 G93A. 
D: 33 % in WT (n=6) and 27% in G93A (n=11) disinhibited burst is completely suppressed by 
CNQX 10 µM. E: and F: disinhibited bursting cycle period and burst duration in WT and 
G93A cultures.   
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Further application of CNQX 10µM completely blocked dishinibited bursting activity 
in 33% (n= 6, WT) and 27% (n=11; G93A) slices at 14 DIV. In the remaining cases the 
bursting activities persisted (Figure 18 A and B, WT and G93A respectively) and was 
is completely removed by application of APV (Figure 18 A2 and B2 WT and G93A 
respectively). Analysis of cycle period (16.92±5.26 s and 16.58±8.25 s; WT and G93A 
respectively)  and  burst duration (4.81± 1.44 s n=4 and 4.07±0.90 s; WT and G93A) 
did not show any differences between the two groups of cultures.  At 21 DIV the 
percentage of slices in which the bursting activity was removed by  CNQX 10 µM was 
14% (n= 7) in WT and 28% (n= 7) in G93A cultures (Figure 20 C)  the cycle period 
(7.17±0.44 WT n=6;  10.85±3.33 G93A n=5) and burst duration  (4.43±1.41 WT n=6; 
4.07±0.90 G93A n=5) displayed no differences between the two groups (Figure 20 D 
and E).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 A: and B: Even in this case the disinibited bursting activity following application of 
strychnine + SR95531 usthe PSCs activity disappear after application of CNQX 10 µM and 
appearing of bursting activities which A2: and B2: are suppressed by coapplication of APV 10 
µM C:  The disinibited bursting activity following application of strychnine + SR95531 in D: 
14 % in WT (n=7) and 28% in G93A (n=7) slices are completely suppressed by simply 
addiction of CNQX 10 µM. E: and F: No difference were found between WT and G93A 
cultures. 
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CONCLUSIVE REMARKS 
 
Organotypic coculturs of mice spinal cord and DRG represent a suitable tool for the 
study of rhytmogenesis, development and patho-physiology of spinal circuits. Recently 
the organotypic slice cultures, developed from embryonic mice spinal cord, have been 
extensively used to investigate various aspects of circuit development and were shown 
to retain the presence and proper distribution of anatomically distinct classes of 
neurons and glial cells usually accompanying the growth of spinal cord in vitro 
(Avossa et al., 2003; Rosato-Siri et al., 2004; Furlan et al., 2005; Furlan et al., 2007; 
Sibilla et al., 2009). For this reason this preparation represents a useful in vitro model 
for the study of spinal physiology, in that the circuits in embryonic explant undergoes a 
certain degree of maturation while growing in vitro (Ballerini and Galante, 1998; 
Avossa et al., 2003; Furlan et al., 2005; Furlan et al., 2007; Sibilla et al., 2009) and 
replicates some of the basic pattern activity observed in the entire spinal cord in vitro. 
Spinal circuits, preserved in organotypic slices, are able to express rhythmic events and 
spontaneous network activity in different pharmacological conditions and using diverse 
neurotransmitter systems which enabled us to investigate different aspects of synaptic 
transmission. For this reason the overexpression of the mutated hSOD1 G93A tissues, 
that is maintained in organotypic spinal cultures (Avossa et al., 2006) represent an ideal 
tool to investigate in details synaptic transmission and pre-motor circuit operation. In 
particular, we wondered whether SOD1 mutation induced subtle changes in motor 
network physiology, before the appearance of clear degeneration, ultimately 
contributing to the MN specific damage. Our preliminary work on G93A slice cultures 
(Avossa et al., 2006) described an increase susceptibility of MNs to excitotoxic stimuli, 
in addition we documented by TEM microscopy a discrete synaptic rearrangement in 
the ventral horns, detecting in G93A a higher ratio  between the symmetric (inhibitory) 
and asymmetric (excitatory) synapses (Avossa et al., 2006). Importantly, despite the 
fact that MNs growing in G93A spinal organotipic cultures were less able to 
compensate experimentally-induced excitotoxic stress, when compared with WT 
cultures in the absence of excitotoxic-treatment, we never observed any morphological 
feature indicating ongoing neurodegenerative process at early stages of development.  
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Based on these preliminary results, we decided to characterize and compare between 
WT and G93A, spinal network premotor activity, via electrophysiological recordings, 
at several time points of in vitro growth.  
 
 
The principal finding of the present study is the novel description of altered glycinergic 
receptors maturational processes, potentially leading to ongoing subtle dysfunction of 
inhibitory systems in the G93A spinal circuit. 
  
Upon CNQX applying we unmasked different classes of IPSCs, grossly divided into 
three classes of IPSC with different ranges of τ values, usually difficult to unravel only 
on the base of their decay time constant as pure glycinergic PSCs. The easier 
identifiable class was that of slower IPSCs, characterised by a slow decay time 
constant (40-50ms) with a reversal potential that corresponds to the calculated chloride 
reversal potential (-35mV) in our recording condition, suggested to be the GABAergic 
PSCs.  Slower events disappeared in fact upon SR95531 application. Interestingly in 
both WT and G93A, the proportion of slow events progressively reduced along with 
development in vitro, in both WT and G93A.  
When pharmacologically isolating glycinergic PSCs by SR95531 removal of all 
GABAA mediated activity, it was possible to note an increase in frequency of the 
residual PSCs. This increase may indicate an ongoing inhibitory role of gabaergic 
activity on the network, or on glycine neurons directly, although further experiments 
are needed to clarify this issue. It is interesting to note that such an effect was already 
present, although with minor impact, at 8 DIV, thus indicating the development of an 
already inhibitory role of gabaergic transmission in cultured late embryonic or early 
postnatal spinal circuits. 
The frequency of glycinergic PSCs progressively increase along with development in 
vitro, and such increased was similarly detected in WT and G93A slices, indicating an 
overall equal progressive maturation of glycinergic innervation. Accordingly, the peak 
amplitude of these events progressively increased in both culture groups.  
The novel results in this thesis, came from the analysis of the glycinergic decay time 
constant (τ). First we have shown that, in organotypic cultures a progressive decrease 
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in τ values resembling physiological process of maturation in the intact animal, occurs 
(Gao et al., 1998, 2001; Singer et al., 1998; Takahashi et al., 1992). This modification 
on the time course of synaptic currents have been associated with the developmentally 
regulated switch from immature and early postnatal homomeric GlyR composed of α2 
subunits (Becker et al., 1988) to the hetero-olygomeric GlyRs composed of three β and 
two α1 subunits, with the latter exhibiting short mean open times (Ali et al., 2000; 
Krupp et al., 1994; Singer et al., 1998). During intermediate developmental stages, 
glycinergic synapses probably express a variable proportion of slow (α2) and fast (α1) 
GlyRs, which results in IPSCs of intermediate duration (Ali et al., 2000).   
Interestingly, the mean t value reached by the transgenic 68 sample during the third 
week in vitro (∼6 ms), was exceptionally fast in relation with the imposed intracellular 
Cl- concentration. In fact, it has been recently shown that different intracellular Cl-
concentrations affect the time course of decay of glycinergic synaptic currents, 
according to the following relationship: the higher is the concentration of intracellular 
Cl-, the slower is the decay of glycinergic currents (Pitt et al., 2008). For native α1β 
GlyRs, the mature form of GlyRs, it has been shown that, when intracellular chloride is 
increased from 10 to 30 mM, a slowdown from ~ 7 ms to ~ 11 ms was observed and in 
131 mM of Cl- (the so-called “symmetrical” concentrations) currents become even 
three time slower (~ 20 ms; Pitt et al., 2008). At concentration as low as 22 mM, close 
to that imposed during our recordings, we should have observed, in the presence of 
mature GlyRs, a ~ 9 ms time constant, which is close to the mean decay time course 
reported for control cultures (∼8 ms), but does not correspond to the values detected in 
G93A glycinergic PSCs at 21 DIV (∼6 ms). As already mentioned in this thesis, 
intracellular Cl- concentration within neurons is finely tuned during development and 
represents a key factor for the switch of GABA and glycine receptor activation 
responses from depolarizing to hyperpolarizing (Owens et al., 1996). However, 
changes in intracellular Cl- buffering during gabaergic and glycinergic activity in 
G93A is ruled out by the similar reversal potentials of glycinergic PSCs detected.  
Certainly, the progressive shift towards more negative values of the Cl- reversal during 
maturation in vitro (in WT and G93A) indicates that the intracellular concentration 
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brought about by the pipette is unequally distributed in sub-cellular compartments, or 
more efficiently buffered, during later stages of development. 
Our outside out results suggested that the progressive maturation of glycinergic 
receptors in G93A  spinal circuits display a slightly different profile when compared to 
controls, in particular at 14 DIV. During the second week of development in vitro the 
transgenic G93A displayed a lower percentage of α1β heteromeric receptors when 
compared to WT. This difference completely recovered during the third week. These 
results are particularly interesting, however cannot account for the different decay time 
of glycinergic PSCs detected at 21 DIV.  
Alternatively, a higher occurrence in G93A synapses of GABA co-release together 
with glycine might be responsible of a displacement of glycine from the receptors and 
thus terminate glycinergic responses, hene τ values (Lu et al., 2008). This is further 
supported by the absence of obvious changes in τ in glycinergic mPSCs at 21 DIV 
between WT and G93A. Early evidence that fast inhibitory synapses use multiple 
neurotransmitters came from immunohistochemical and electron microscopy studies, 
which showed the presence of clear co-localization of specific GABA and glycine 
markers in the spinal cord, auditory brainstem, dorsal cochlear nucleus, and 
oculomotor nucleus, among others (Triller et al., 1987; Ottersen et al., 1988; Todd and 
Sullivan 1990; Helfer et al., 1992; Kolston et al., 1992; Wentzel et al., 1993; Juiz et al., 
1996). In addition, several works describe the occurrence of GABA and glycine co-
accumulation in synaptic vesicles, via a common vesicular transporter (Burger et al., 
1991; Gasnier, 2000). The co-release of both neurotransmitters seems to be involved in 
the functional inhibition of MNs, and was observed during the early development of 
spinal neurons (Gao et al., 2001). The higher co-localization and co-release of GABA 
and glycine at G93A spinal presynaptic terminals may lead to direct interaction of 
GABA on the glycine-binding subunits of GlyRs. Thus, co-released of GABA and 
glycine may accelerates glycinergic transmission by acting directly on glycine 
receptors, narrowing the time window for effective inhibition (Lu et al., 2008) and this 
mechanism can potentially be responsible for the observed faster PSCs in G93A.  
Although further experiments are needed to clarify this issue, it is tempting to speculate 
that the mechanisms of disease in SOD1 models might be engaged early during circuit 
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formation and the disease could be much more protracted than generally appreciated 
(Chang and Martin, 2011).  
This thesis support the novel idea that motoneurons in ALS might undergo chronic 
stress as a result of inhibitory dysfunction. In particular, it has recently been suggested 
that this inhibitory insufficiency could be secondary to glycinergic interneuron disease 
or dysfunction (Chang and Martin, 2009; 2011) involving Renshaw cells and neural 
networks.  Our results add additional evidence and more complexity to this emerging 
hypothesis. 
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